[{"text":"We're supporting World Veterinary Day tomorrow: http://t.co/breMiKH6","id":"195901352377982976","created_at":"2012-04-27T15:44:56.000Z","entities":{"urls":[{"start":48,"end":68,"url":"http://t.co/breMiKH6","expanded_url":"http://bit.ly/JrlDl5","display_url":"bit.ly/JrlDl5"}],"annotations":[{"start":17,"end":36,"probability":0.6294,"type":"Other","normalized_text":"World Veterinary Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195901352377982976","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We are closed on Tuesday 1 May: http://t.co/iVb9iVTa","id":"195895168841424898","created_at":"2012-04-27T15:20:22.000Z","entities":{"urls":[{"start":32,"end":52,"url":"http://t.co/iVb9iVTa","expanded_url":"http://bit.ly/JrjXba","display_url":"bit.ly/JrjXba"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195895168841424898","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've updated the vocabularies used to comply with Art. 57 (2) requirements on submission of information on medicines \nhttp://t.co/LI9twTlF","id":"195874035735855104","created_at":"2012-04-27T13:56:23.000Z","entities":{"urls":[{"start":119,"end":139,"url":"http://t.co/LI9twTlF","expanded_url":"http://bit.ly/JK8l5s","display_url":"bit.ly/JK8l5s"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195874035735855104","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've approved 100th herbal community monograph \nhttp://t.co/66L2xpfz","id":"195873543244881922","created_at":"2012-04-27T13:54:26.000Z","entities":{"urls":[{"start":49,"end":69,"url":"http://t.co/66L2xpfz","expanded_url":"http://bit.ly/JK85DJ","display_url":"bit.ly/JK85DJ"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195873543244881922","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @colitiscrohn: #EMA: The European Medicines Agency launched its new Scientific Coordination Board \nhttp://t.co/DUb9toz2 #health #medicine","id":"195771379180781568","created_at":"2012-04-27T07:08:28.000Z","entities":{"urls":[{"start":102,"end":122,"url":"http://t.co/DUb9toz2","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/04/news_detail_001503.jsp&mid=WC0b01ac058004d5c1&jsenabled=true","display_url":"ema.europa.eu/ema/index.jsp?…"}],"annotations":[{"start":28,"end":52,"probability":0.4401,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":[{"start":3,"end":16,"username":"colitiscrohn","id":"70621626"}],"hashtags":[{"start":18,"end":22,"tag":"EMA"},{"start":123,"end":130,"tag":"health"},{"start":131,"end":140,"tag":"medicine"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195771379180781568","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195727601715781632"}]},{"text":"RT @eurordis: ECRD 23 -25/05 '12. Bruselas, Bélgica  http://t.co/vM5SvB3K  la conferencia sobre #EnfermedadesRaras más importante del año!","id":"195771340446384128","created_at":"2012-04-27T07:08:19.000Z","entities":{"urls":[{"start":53,"end":73,"url":"http://t.co/vM5SvB3K","expanded_url":"http://bit.ly/JBqCRq","display_url":"bit.ly/JBqCRq"}],"annotations":[{"start":34,"end":41,"probability":0.7783,"type":"Place","normalized_text":"Bruselas"},{"start":44,"end":50,"probability":0.9289,"type":"Place","normalized_text":"Bélgica"}],"mentions":[{"start":3,"end":12,"username":"eurordis","id":"26993786"}],"hashtags":[{"start":96,"end":114,"tag":"EnfermedadesRaras"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195771340446384128","source":"TweetDeck","lang":"es","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195754159943860225"}]},{"text":"RT @eurordis: ECRD 23. -25/05 '12 Brüssel, Belgien http://t.co/8AvNsN4x  Nehmen Sie an der wichtigsten Konferenz des Jahres für seltene# ...","id":"195573462394347520","created_at":"2012-04-26T18:02:01.000Z","entities":{"urls":[{"start":51,"end":71,"url":"http://t.co/8AvNsN4x","expanded_url":"http://bit.ly/JBqiCn","display_url":"bit.ly/JBqiCn"}],"annotations":{},"mentions":[{"start":3,"end":12,"username":"eurordis","id":"26993786"}],"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195573462394347520","source":"TweetDeck","lang":"de","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195572977474088960"}]},{"text":"RT @asinfarma: Luego de mucho esperar, finalmente la EMA (European Medicines Agency) ha publicado la revisión de su Guideline sobre V…ht ...","id":"195544220336009217","created_at":"2012-04-26T16:05:49.000Z","entities":{"urls":{},"annotations":[{"start":53,"end":82,"probability":0.3485,"type":"Other","normalized_text":"EMA (European Medicines Agency"}],"mentions":[{"start":3,"end":13,"username":"asinfarma","id":"112455303"}],"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195544220336009217","source":"TweetDeck","lang":"es","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195543999224877056"}]},{"text":"RT @fernandotazon: La validacion de procesos en la EU: Luego de mucho esperar, finalmente la EMA (European Medicines Agency) ha pub... h ...","id":"195544035107147776","created_at":"2012-04-26T16:05:05.000Z","entities":{"urls":{},"annotations":[{"start":98,"end":122,"probability":0.391,"type":"Other","normalized_text":"European Medicines Agency"}],"mentions":[{"start":3,"end":17,"username":"fernandotazon","id":"102720653"}],"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195544035107147776","source":"TweetDeck","lang":"es","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195543061219115008"}]},{"text":"RT @WHO_Europe: Interested in #vaccine and #immunization issues? Follow WHO/Europe’s dedicated Twitter profile on immunization @WHO_Euro ...","id":"195528938531987456","created_at":"2012-04-26T15:05:06.000Z","entities":{"urls":{},"annotations":[{"start":76,"end":81,"probability":0.8562,"type":"Place","normalized_text":"Europe"},{"start":95,"end":101,"probability":0.5683,"type":"Organization","normalized_text":"Twitter"}],"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":30,"end":38,"tag":"vaccine"},{"start":43,"end":56,"tag":"immunization"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195528938531987456","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195528651255713794"}]},{"text":"Our pilot of electronic application forms will apply to all veterinary medicine applications as of next Wednesday: http://t.co/arHVwlTe","id":"195528377359278080","created_at":"2012-04-26T15:02:52.000Z","entities":{"urls":[{"start":115,"end":135,"url":"http://t.co/arHVwlTe","expanded_url":"http://bit.ly/IfO4mX","display_url":"bit.ly/IfO4mX"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195528377359278080","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've set up a group to coordinate the activity of our committees: http://t.co/MxpSOFoK","id":"195528194139500544","created_at":"2012-04-26T15:02:08.000Z","entities":{"urls":[{"start":67,"end":87,"url":"http://t.co/MxpSOFoK","expanded_url":"http://bit.ly/Ig5Dn6","display_url":"bit.ly/Ig5Dn6"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195528194139500544","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @TheInfoDaily: Announcement: European Medicines Agencys Scientific Coordination Board Starts Reflection On Best Cooperation... http: ...","id":"195513565485072384","created_at":"2012-04-26T14:04:01.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":16,"username":"TheInfoDaily","id":"589052221"}],"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195513565485072384","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195484391743561730"}]},{"text":"RT @jobsiniceland: Multilingual Secretary: Our client, The European Medicines Agency, based in Canary Wharf are looking for profess... h ...","id":"195513539643969537","created_at":"2012-04-26T14:03:54.000Z","entities":{"urls":{},"annotations":[{"start":55,"end":83,"probability":0.4784,"type":"Organization","normalized_text":"The European Medicines Agency"},{"start":95,"end":106,"probability":0.8372,"type":"Place","normalized_text":"Canary Wharf"}],"mentions":[{"start":3,"end":17,"username":"jobsiniceland","id":"26271308"}],"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195513539643969537","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195475942653693952"}]},{"text":"RT @WHO_Europe: Answering your questions today: Nedret Emiroglu, Robb Butler, Ajay Goel, Niyazi Cakmak, Dragan Jankovic, & Dina Pfeifer  ...","id":"195513386174382080","created_at":"2012-04-26T14:03:18.000Z","entities":{"urls":{},"annotations":[{"start":48,"end":62,"probability":0.9726,"type":"Person","normalized_text":"Nedret Emiroglu"},{"start":65,"end":75,"probability":0.9895,"type":"Person","normalized_text":"Robb Butler"},{"start":78,"end":86,"probability":0.9862,"type":"Person","normalized_text":"Ajay Goel"},{"start":89,"end":101,"probability":0.9935,"type":"Person","normalized_text":"Niyazi Cakmak"},{"start":104,"end":118,"probability":0.9672,"type":"Person","normalized_text":"Dragan Jankovic"},{"start":123,"end":134,"probability":0.9862,"type":"Person","normalized_text":"Dina Pfeifer"}],"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195513386174382080","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195513201339809794"}]},{"text":"RT @WHO_Europe: Welcome to today’s Twitter chat on #immunization. WHO experts will be here for the next hour to answer your questions #i ...","id":"195513362816319488","created_at":"2012-04-26T14:03:12.000Z","entities":{"urls":{},"annotations":[{"start":35,"end":41,"probability":0.623,"type":"Product","normalized_text":"Twitter"}],"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":51,"end":64,"tag":"immunization"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195513362816319488","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195512672123498498"}]},{"text":"We're extending our pilot of electronic application forms to all veterinary medicine applications next week: http://t.co/arHVwlTe","id":"195483857259200512","created_at":"2012-04-26T12:05:58.000Z","entities":{"urls":[{"start":109,"end":129,"url":"http://t.co/arHVwlTe","expanded_url":"http://bit.ly/IfO4mX","display_url":"bit.ly/IfO4mX"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195483857259200512","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @WHO_Europe: Any question about #vaccination? Ask the #experts – use #immunizeEurope – today, 16:00-17:00 (Paris time)! http://t.co/K ...","id":"195482245241376768","created_at":"2012-04-26T11:59:33.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":35,"end":47,"tag":"vaccination"},{"start":57,"end":65,"tag":"experts"},{"start":72,"end":87,"tag":"immunizeEurope"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195482245241376768","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195437517007355904"}]},{"text":"Guido #Rasi formalises new high-level group\n http://t.co/MxpSOFoK","id":"195423986811801600","created_at":"2012-04-26T08:08:03.000Z","entities":{"urls":[{"start":45,"end":65,"url":"http://t.co/MxpSOFoK","expanded_url":"http://bit.ly/Ig5Dn6","display_url":"bit.ly/Ig5Dn6"}],"annotations":[{"start":0,"end":4,"probability":0.9163,"type":"Person","normalized_text":"Guido"}],"mentions":{},"hashtags":[{"start":6,"end":11,"tag":"Rasi"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195423986811801600","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: New ECDC report suggests preventive actions for #malaria transmission at #EU level http://t.co/4f03RY9S","id":"195184943205330944","created_at":"2012-04-25T16:18:11.000Z","entities":{"urls":[{"start":96,"end":116,"url":"http://t.co/4f03RY9S","expanded_url":"http://bit.ly/Jq0TI3","display_url":"bit.ly/Jq0TI3"}],"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":61,"end":69,"tag":"malaria"},{"start":86,"end":89,"tag":"EU"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195184943205330944","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195184737273389056"}]},{"text":"Scientific Coordination Board reflects on coordination between committees\nhttp://t.co/MxpSOFoK","id":"195179276356685827","created_at":"2012-04-25T15:55:40.000Z","entities":{"urls":[{"start":74,"end":94,"url":"http://t.co/MxpSOFoK","expanded_url":"http://bit.ly/Ig5Dn6","display_url":"bit.ly/Ig5Dn6"}],"annotations":[{"start":0,"end":28,"probability":0.7246,"type":"Organization","normalized_text":"Scientific Coordination Board"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195179276356685827","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @WHO_Europe: @ECDC_EU Ask WHO experts about #immunization in our Twitter #chat.Tomorrow, 26.4., 16:00-17:00 CEST - #immunizeEurope -  ...","id":"195164938455617537","created_at":"2012-04-25T14:58:41.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"},{"start":16,"end":24,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":47,"end":60,"tag":"immunization"},{"start":76,"end":81,"tag":"chat"},{"start":118,"end":133,"tag":"immunizeEurope"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195164938455617537","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195164270697259010"}]},{"text":"On 2 May, we're extending our pilot of electronic application forms to all veterinary medicine applications: http://t.co/arHVwlTe","id":"195154209916719104","created_at":"2012-04-25T14:16:04.000Z","entities":{"urls":[{"start":109,"end":129,"url":"http://t.co/arHVwlTe","expanded_url":"http://bit.ly/IfO4mX","display_url":"bit.ly/IfO4mX"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195154209916719104","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: Public health organisations need to build trust to communicate effectively on immunisation. See report: http://t.co/o4zvroB ...","id":"195125850625146882","created_at":"2012-04-25T12:23:22.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":{}},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195125850625146882","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195124996593561600"}]},{"text":"RT @GeraldVanRoey: eSubmission Gateway now live for all applications for human medicines to the European Medicines Agency: http://t.co/k ...","id":"195096779501481984","created_at":"2012-04-25T10:27:51.000Z","entities":{"urls":{},"annotations":[{"start":96,"end":120,"probability":0.7333,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":[{"start":3,"end":17,"username":"GeraldVanRoey","id":"356720014"}],"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"195096779501481984","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"195067680309510144"}]},{"text":"Companies can now submit applications for human medicines via eSubmission Gateway http://t.co/AgIfLXMc","id":"194687670734172160","created_at":"2012-04-24T07:22:12.000Z","entities":{"urls":[{"start":82,"end":102,"url":"http://t.co/AgIfLXMc","expanded_url":"http://bit.ly/HZOQQg","display_url":"bit.ly/HZOQQg"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"194687670734172160","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"All types of applications for human medicines can now be submitted online http://t.co/AgIfLXMc","id":"194445182849134592","created_at":"2012-04-23T15:18:38.000Z","entities":{"urls":[{"start":74,"end":94,"url":"http://t.co/AgIfLXMc","expanded_url":"http://bit.ly/HZOQQg","display_url":"bit.ly/HZOQQg"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"194445182849134592","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"eSubmission Gateway now live for all applications for human medicines\nhttp://t.co/AgIfLXMc","id":"194359663343570944","created_at":"2012-04-23T09:38:49.000Z","entities":{"urls":[{"start":70,"end":90,"url":"http://t.co/AgIfLXMc","expanded_url":"http://bit.ly/HZOQQg","display_url":"bit.ly/HZOQQg"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":1,"like_count":0,"quote_count":0},"conversation_id":"194359663343570944","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: Seasonal #influenza is on the decline all across Europe. See ECDC weekly surveillance report: http://t.co/apQtPAiy","id":"193329915477753856","created_at":"2012-04-20T13:26:58.000Z","entities":{"urls":[{"start":107,"end":127,"url":"http://t.co/apQtPAiy","expanded_url":"http://bit.ly/IW1v66","display_url":"bit.ly/IW1v66"}],"annotations":[{"start":62,"end":67,"probability":0.9908,"type":"Place","normalized_text":"Europe"}],"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":22,"end":32,"tag":"influenza"}]},"public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193329915477753856","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"193329763107078144"}]},{"text":"#CHMP outcome from April 2012 meeting http://t.co/fRtcyDHs","id":"193328665046679553","created_at":"2012-04-20T13:22:00.000Z","entities":{"urls":[{"start":38,"end":58,"url":"http://t.co/fRtcyDHs","expanded_url":"http://bit.ly/IW0JWJ","display_url":"bit.ly/IW0JWJ"}],"annotations":{},"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"CHMP"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193328665046679553","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've recommended authorisation of #Forxiga, a novel treatment for type 2 #diabetes\nhttp://t.co/mabJONpb","id":"193328104725413889","created_at":"2012-04-20T13:19:46.000Z","entities":{"urls":[{"start":84,"end":104,"url":"http://t.co/mabJONpb","expanded_url":"http://bit.ly/JnO3cg","display_url":"bit.ly/JnO3cg"}],"annotations":{},"mentions":{},"hashtags":[{"start":35,"end":43,"tag":"Forxiga"},{"start":74,"end":83,"tag":"diabetes"}]},"public_metrics":{"retweet_count":8,"reply_count":1,"like_count":8,"quote_count":0},"conversation_id":"193328104725413889","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We maintain our past recommendation not to grant a marketing authorisation for #Glybera \nhttp://t.co/AWUcOuvu","id":"193327225649627138","created_at":"2012-04-20T13:16:17.000Z","entities":{"urls":[{"start":89,"end":109,"url":"http://t.co/AWUcOuvu","expanded_url":"http://bit.ly/HSwBvY","display_url":"bit.ly/HSwBvY"}],"annotations":{},"mentions":{},"hashtags":[{"start":79,"end":87,"tag":"Glybera"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193327225649627138","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: @ECDC_EU publishes reports assessing Europe’s capability of detecting #swine #influenza A(H3N2)v viruses http://t.co/TQJXLI4P","id":"193321370996846592","created_at":"2012-04-20T12:53:01.000Z","entities":{"urls":[{"start":118,"end":138,"url":"http://t.co/TQJXLI4P","expanded_url":"http://bit.ly/HXLGlK","display_url":"bit.ly/HXLGlK"}],"annotations":[{"start":50,"end":55,"probability":0.9735,"type":"Place","normalized_text":"Europe"}],"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":13,"end":21,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":83,"end":89,"tag":"swine"},{"start":90,"end":100,"tag":"influenza"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193321370996846592","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"193321277300285440"}]},{"text":"We have given new recommendation for #MS drug #Gilenya http://t.co/NjMxMLLr","id":"193316165446156289","created_at":"2012-04-20T12:32:20.000Z","entities":{"urls":[{"start":55,"end":75,"url":"http://t.co/NjMxMLLr","expanded_url":"http://bit.ly/HXv4uL","display_url":"bit.ly/HXv4uL"}],"annotations":{},"mentions":{},"hashtags":[{"start":37,"end":40,"tag":"MS"},{"start":46,"end":54,"tag":"Gilenya"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193316165446156289","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @agesnews: #Arzneimittelsicherheit - #BASG #AGES #Medizinmarktaufsicht informiert zu #Gilenya Wirkstoff: #Fingolimod @EMA_News http:/ ...","id":"193313323805184000","created_at":"2012-04-20T12:21:02.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":12,"username":"agesnews","id":"223456379"},{"start":120,"end":129,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":14,"end":37,"tag":"Arzneimittelsicherheit"},{"start":40,"end":45,"tag":"BASG"},{"start":46,"end":51,"tag":"AGES"},{"start":52,"end":73,"tag":"Medizinmarktaufsicht"},{"start":88,"end":96,"tag":"Gilenya"},{"start":108,"end":119,"tag":"Fingolimod"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193313323805184000","source":"TweetDeck","lang":"de","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"193313044858814464"}]},{"text":"RT @euparkinsons: Unmet needs in #Parkinson’s disease - survey report published: http://t.co/7pLWCcEx","id":"193293956501618689","created_at":"2012-04-20T11:04:05.000Z","entities":{"urls":[{"start":81,"end":101,"url":"http://t.co/7pLWCcEx","expanded_url":"http://bit.ly/JdIpdx","display_url":"bit.ly/JdIpdx"}],"annotations":{},"mentions":[{"start":3,"end":16,"username":"euparkinsons","id":"190227425"}],"hashtags":[{"start":33,"end":43,"tag":"Parkinson"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193293956501618689","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"193292946005704704"}]},{"text":"RT @NHSChoices: Breast cancer 'is 10 different diseases', study finds. What might this mean for treatment now & in future? http://t.co/k ...","id":"193274195617132544","created_at":"2012-04-20T09:45:33.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":15,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193274195617132544","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"193273157120045056"}]},{"text":"We give advice on how to better manage risk of adverse effects on the heart with #Gilenya\nhttp://t.co/NjMxMLLr","id":"193263828891471872","created_at":"2012-04-20T09:04:22.000Z","entities":{"urls":[{"start":90,"end":110,"url":"http://t.co/NjMxMLLr","expanded_url":"http://bit.ly/HXv4uL","display_url":"bit.ly/HXv4uL"}],"annotations":{},"mentions":{},"hashtags":[{"start":81,"end":89,"tag":"Gilenya"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193263828891471872","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ClinicalProfess: European Medicines Agency finalises guidance on third-country trial standards - http://t.co/FgyQf1cU #EMA #pharma","id":"193250500089614336","created_at":"2012-04-20T08:11:24.000Z","entities":{"urls":[{"start":101,"end":121,"url":"http://t.co/FgyQf1cU","expanded_url":"http://bit.ly/IWoPpA","display_url":"bit.ly/IWoPpA"}],"annotations":{},"mentions":{},"hashtags":[{"start":122,"end":126,"tag":"EMA"},{"start":127,"end":134,"tag":"pharma"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"193250500089614336","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"193250159449227265"}]},{"text":"RT @EFSA_EU: The importance of #bees: 80% of crops cultivated in EU depend on pollinator insects. How #EFSA helps to protect them: http: ...","id":"192931495940337664","created_at":"2012-04-19T11:03:47.000Z","entities":{"urls":{},"annotations":[{"start":65,"end":66,"probability":0.5669,"type":"Place","normalized_text":"EU"}],"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":[{"start":31,"end":36,"tag":"bees"},{"start":102,"end":107,"tag":"EFSA"}]},"public_metrics":{"retweet_count":10,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192931495940337664","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"186735747561299968"}]},{"text":"RT @ECDC_EU: #Influenza epidemics is on the decline all across #Europe: read ECDC weekly surveillance report http://t.co/HDdVEeAp","id":"192931447785533441","created_at":"2012-04-19T11:03:36.000Z","entities":{"urls":[{"start":109,"end":129,"url":"http://t.co/HDdVEeAp","expanded_url":"http://bit.ly/HHVQTc","display_url":"bit.ly/HHVQTc"}],"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":23,"tag":"Influenza"},{"start":63,"end":70,"tag":"Europe"}]},"public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192931447785533441","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"190782741393055744"}]},{"text":"RT @WDD: Do you want to know more about #IntDiabetesFed? Read the new Annual Report 2011! #diabetes http://t.co/yo3IMs4S","id":"192896256274735104","created_at":"2012-04-19T08:43:45.000Z","entities":{"urls":[{"start":100,"end":120,"url":"http://t.co/yo3IMs4S","expanded_url":"http://bit.ly/IUuw7t","display_url":"bit.ly/IUuw7t"}],"annotations":{},"mentions":[{"start":3,"end":7,"username":"WDD","id":"15179874"}],"hashtags":[{"start":40,"end":55,"tag":"IntDiabetesFed"},{"start":90,"end":99,"tag":"diabetes"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192896256274735104","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192896115295784960"}]},{"text":"RT @EUnetHTA: EUnetHTA WP1 and Executive Committee meeting, April 18-19, 2012, Rome Italy.\nGovernance and Management topics are being di ...","id":"192896046987354113","created_at":"2012-04-19T08:42:56.000Z","entities":{"urls":{},"annotations":[{"start":79,"end":88,"probability":0.4946,"type":"Place","normalized_text":"Rome Italy"}],"mentions":[{"start":3,"end":12,"username":"EUnetHTA","id":"56493220"}],"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192896046987354113","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192895543717011456"}]},{"text":"RT @joaocarapinha: The European Medicines Agency published a guide to assure ethical standards in the conduct of clinical trials. http:/ ...","id":"192665260900102144","created_at":"2012-04-18T17:25:52.000Z","entities":{"urls":{},"annotations":[{"start":23,"end":47,"probability":0.4242,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":[{"start":3,"end":17,"username":"joaocarapinha","id":"39525118"}],"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192665260900102144","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192664890811494405"}]},{"text":"RT @euparkinsons: #EMA press release- 2wards a robust global framework 4 conduct & oversight of clinical trials: http://t.co/2bpriPCL","id":"192603388922441728","created_at":"2012-04-18T13:20:00.000Z","entities":{"urls":[{"start":113,"end":133,"url":"http://t.co/2bpriPCL","expanded_url":"http://bit.ly/HS6nvM","display_url":"bit.ly/HS6nvM"}],"annotations":{},"mentions":[{"start":3,"end":16,"username":"euparkinsons","id":"190227425"}],"hashtags":[{"start":18,"end":22,"tag":"EMA"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192603388922441728","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192598387344932865"}]},{"text":"RT @L_9Revolution: The European Medicines Agency published a guide to assure ethical standards in ... http://t.co/nOjOjack","id":"192572700588380160","created_at":"2012-04-18T11:18:04.000Z","entities":{"urls":[{"start":102,"end":122,"url":"http://t.co/nOjOjack","expanded_url":"http://bit.ly/JfAyOA","display_url":"bit.ly/JfAyOA"}],"annotations":[{"start":23,"end":47,"probability":0.4831,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":[{"start":3,"end":17,"username":"L_9Revolution","id":"174488795"}],"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192572700588380160","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192572258563276800"}]},{"text":"RT @Searchline03: The European Medicines Agency and Conflict of Interest - http://t.co/f5rCEUzm","id":"192569170238517248","created_at":"2012-04-18T11:04:02.000Z","entities":{"urls":[{"start":75,"end":95,"url":"http://t.co/f5rCEUzm","expanded_url":"http://shar.es/rAEUi","display_url":"shar.es/rAEUi"}],"annotations":{},"mentions":[{"start":3,"end":16,"username":"Searchline03","id":"311511785"}],"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192569170238517248","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192546303966842880"}]},{"text":"RT @Euroalert: The European #Medicines Agency published a guide to assure ethical standards in the conduct of #clinical trials http://t. ...","id":"192569143025868800","created_at":"2012-04-18T11:03:56.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":13,"username":"Euroalert","id":"94132143"}],"hashtags":[{"start":28,"end":38,"tag":"Medicines"},{"start":110,"end":119,"tag":"clinical"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192569143025868800","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192543760704483328"}]},{"text":"RT @RegLinkNews: European Medicines Agency issues draft guidance on clinical testing of tissue engineered products: http://t.co/Jd1LyF4c","id":"192530162745749504","created_at":"2012-04-18T08:29:02.000Z","entities":{"urls":[{"start":116,"end":136,"url":"http://t.co/Jd1LyF4c","expanded_url":"http://bit.ly/HQScap","display_url":"bit.ly/HQScap"}],"annotations":{},"mentions":[{"start":3,"end":15,"username":"RegLinkNews","id":"297589805"}],"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192530162745749504","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192372361092272129"}]},{"text":"RT @IntDiabetesFed: World Diabetes Congress Dubai programme session webcasts available online! #WDC2011 #diabetes http://t.co/vz2ilU2A","id":"192263862630879232","created_at":"2012-04-17T14:50:51.000Z","entities":{"urls":[{"start":114,"end":134,"url":"http://t.co/vz2ilU2A","expanded_url":"http://bit.ly/AEDBE2","display_url":"bit.ly/AEDBE2"}],"annotations":[{"start":20,"end":48,"probability":0.5318,"type":"Other","normalized_text":"World Diabetes Congress Dubai"}],"mentions":[{"start":3,"end":18,"username":"IntDiabetesFed","id":"38393473"}],"hashtags":[{"start":95,"end":103,"tag":"WDC2011"},{"start":104,"end":113,"tag":"diabetes"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192263862630879232","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192263285662433280"}]},{"text":"Our Head of Human Medicines Special Areas is now a member of a #UN commission on #women and #children: http://t.co/2iSWIqiO","id":"192253627690262528","created_at":"2012-04-17T14:10:11.000Z","entities":{"urls":[{"start":103,"end":123,"url":"http://t.co/2iSWIqiO","expanded_url":"http://bit.ly/HLun1Z","display_url":"bit.ly/HLun1Z"}],"annotations":{},"mentions":{},"hashtags":[{"start":63,"end":66,"tag":"UN"},{"start":81,"end":87,"tag":"women"},{"start":92,"end":101,"tag":"children"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192253627690262528","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Please send us your comments on the guideline on periodic benefit-risk evaluation reports: http://t.co/pSqrbrDA","id":"192253302522642432","created_at":"2012-04-17T14:08:53.000Z","entities":{"urls":[{"start":91,"end":111,"url":"http://t.co/pSqrbrDA","expanded_url":"http://bit.ly/HZMwZ2","display_url":"bit.ly/HZMwZ2"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192253302522642432","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're working towards a global approach to good clinical practice in clinical trials conducted outside Europe: http://t.co/vLc54AMb","id":"192253060859432961","created_at":"2012-04-17T14:07:56.000Z","entities":{"urls":[{"start":111,"end":131,"url":"http://t.co/vLc54AMb","expanded_url":"http://bit.ly/HWXaUn","display_url":"bit.ly/HWXaUn"}],"annotations":[{"start":103,"end":108,"probability":0.9839,"type":"Place","normalized_text":"Europe"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192253060859432961","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"See the highlights from this month's meeting of our veterinary committee #CVMP: http://t.co/lWZl6XjC","id":"192252397446373376","created_at":"2012-04-17T14:05:18.000Z","entities":{"urls":[{"start":80,"end":100,"url":"http://t.co/lWZl6XjC","expanded_url":"http://bit.ly/HLYjPQ","display_url":"bit.ly/HLYjPQ"}],"annotations":{},"mentions":{},"hashtags":[{"start":73,"end":78,"tag":"CVMP"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192252397446373376","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @EUlondonrep: RT @europedirect: Please support our Human Library on 27 April: http://t.co/uAL7f7V7 http://t.co/tzQYLarw #eyaa12","id":"192247843606626304","created_at":"2012-04-17T13:47:12.000Z","entities":{"urls":[{"start":81,"end":101,"url":"http://t.co/uAL7f7V7","expanded_url":"http://europedirectleeds.org.uk/archives/4692","display_url":"europedirectleeds.org.uk/archives/4692"},{"start":102,"end":122,"url":"http://t.co/tzQYLarw","expanded_url":"http://fb.me/1i9Vs5hVb","display_url":"fb.me/1i9Vs5hVb"}],"annotations":{},"mentions":[{"start":20,"end":33,"username":"europedirect","id":"29224401"}],"hashtags":[{"start":123,"end":130,"tag":"eyaa12"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192247843606626304","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192247030393999360"}]},{"text":"RT @NCRI: Registration open for #Cancer Clinical Trials Units Annual Meeting on 22nd June in London http://t.co/P5Og2Qce","id":"192246887334690817","created_at":"2012-04-17T13:43:24.000Z","entities":{"urls":[{"start":100,"end":120,"url":"http://t.co/P5Og2Qce","expanded_url":"http://bit.ly/CancerCTU","display_url":"bit.ly/CancerCTU"}],"annotations":[{"start":93,"end":98,"probability":0.9926,"type":"Place","normalized_text":"London"}],"mentions":{},"hashtags":[{"start":32,"end":39,"tag":"Cancer"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192246887334690817","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192246140761149440"}]},{"text":"@tomHBK Please send your question to info@ema.europa.eu so that we can respond to you directly.","id":"192243970498236416","created_at":"2012-04-17T13:31:48.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":1,"like_count":0,"quote_count":0},"conversation_id":"192243266551427074","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"replied_to","id":"192243266551427074"}],"in_reply_to_user_id":"23872146"},{"text":"RT @makenzihammonds: http://t.co/Q3s2D0r4 The European Medicines Agency and Conflict of Interest - Policy ...","id":"192212320439631872","created_at":"2012-04-17T11:26:02.000Z","entities":{"urls":[{"start":21,"end":41,"url":"http://t.co/Q3s2D0r4","expanded_url":"http://bit.ly/HPHBOC","display_url":"bit.ly/HPHBOC"}],"annotations":{},"mentions":[{"start":3,"end":19,"username":"makenzihammonds","id":"320749303"}],"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192212320439631872","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192211954457247744"}]},{"text":"RT @policymed: The European Medicines Agency and Conflict of Interest http://t.co/ekW1estK","id":"192198503299153920","created_at":"2012-04-17T10:31:08.000Z","entities":{"urls":[{"start":70,"end":90,"url":"http://t.co/ekW1estK","expanded_url":"http://bit.ly/HPvDVc","display_url":"bit.ly/HPvDVc"}],"annotations":{},"mentions":[{"start":3,"end":13,"username":"policymed","id":"37907016"}],"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192198503299153920","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192185634230763520"}]},{"text":"Agnès Saint Raymond becomes a member of the #UN Commission on life-saving commodities for #women and #children: http://t.co/2iSWIqiO","id":"192169173756022784","created_at":"2012-04-17T08:34:36.000Z","entities":{"urls":[{"start":112,"end":132,"url":"http://t.co/2iSWIqiO","expanded_url":"http://bit.ly/HLun1Z","display_url":"bit.ly/HLun1Z"}],"annotations":[{"start":0,"end":18,"probability":0.9671,"type":"Person","normalized_text":"Agnès Saint Raymond"}],"mentions":{},"hashtags":[{"start":44,"end":47,"tag":"UN"},{"start":90,"end":96,"tag":"women"},{"start":101,"end":110,"tag":"children"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192169173756022784","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We invite you to comment on the guideline on periodic benefit-risk evaluation reports: http://t.co/pSqrbrDA","id":"192168769982959616","created_at":"2012-04-17T08:32:59.000Z","entities":{"urls":[{"start":87,"end":107,"url":"http://t.co/pSqrbrDA","expanded_url":"http://bit.ly/HZMwZ2","display_url":"bit.ly/HZMwZ2"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192168769982959616","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @EFPIA: #EFPIA DG: in order for #H2020 to succeed we should build on the successes of Innovative Medicines Initiative @IMI_JU  #innoh ...","id":"192168467598811137","created_at":"2012-04-17T08:31:47.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":9,"username":"EFPIA","id":"52084584"},{"start":121,"end":128,"username":"imi_ju","id":"1473203261469790214"}],"hashtags":[{"start":11,"end":17,"tag":"EFPIA"},{"start":35,"end":41,"tag":"H2020"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192168467598811137","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192168193115176961"}]},{"text":"Check out the latest #CVMP highlights http://t.co/lWZl6XjC","id":"192168129877647360","created_at":"2012-04-17T08:30:27.000Z","entities":{"urls":[{"start":38,"end":58,"url":"http://t.co/lWZl6XjC","expanded_url":"http://bit.ly/HLYjPQ","display_url":"bit.ly/HLYjPQ"}],"annotations":{},"mentions":{},"hashtags":[{"start":21,"end":26,"tag":"CVMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192168129877647360","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're taking steps towards global framework for conduct and oversight of clinical trials http://t.co/vLc54AMb","id":"192167571653533697","created_at":"2012-04-17T08:28:14.000Z","entities":{"urls":[{"start":89,"end":109,"url":"http://t.co/vLc54AMb","expanded_url":"http://bit.ly/HWXaUn","display_url":"bit.ly/HWXaUn"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192167571653533697","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @EFPIA: #EU announces #H2020 next framework prog for #research and #innovation with budget of €80bn #innohealth","id":"192165849803665408","created_at":"2012-04-17T08:21:23.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":9,"username":"EFPIA","id":"52084584"}],"hashtags":[{"start":11,"end":14,"tag":"EU"},{"start":25,"end":31,"tag":"H2020"},{"start":56,"end":65,"tag":"research"},{"start":70,"end":81,"tag":"innovation"},{"start":103,"end":114,"tag":"innohealth"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"192165849803665408","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"192165510341869569"}]},{"text":"Agnès Saint Raymond has been appointed to the #UN Commission on life-saving commodities for #women and #children: http://t.co/2iSWIqiO","id":"191935246877470720","created_at":"2012-04-16T17:05:03.000Z","entities":{"urls":[{"start":114,"end":134,"url":"http://t.co/2iSWIqiO","expanded_url":"http://bit.ly/HLun1Z","display_url":"bit.ly/HLun1Z"}],"annotations":[{"start":0,"end":18,"probability":0.9765,"type":"Person","normalized_text":"Agnès Saint Raymond"}],"mentions":{},"hashtags":[{"start":46,"end":49,"tag":"UN"},{"start":92,"end":98,"tag":"women"},{"start":103,"end":112,"tag":"children"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"191935246877470720","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're asking for feedback on the guideline on periodic benefit-risk evaluation reports: http://t.co/pSqrbrDA","id":"191930324693958657","created_at":"2012-04-16T16:45:29.000Z","entities":{"urls":[{"start":88,"end":108,"url":"http://t.co/pSqrbrDA","expanded_url":"http://bit.ly/HZMwZ2","display_url":"bit.ly/HZMwZ2"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"191930324693958657","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've published a reflection paper on the assurance of ethical and GCP standards in the conduct of clinical trials\nhttp://t.co/vLc54AMb","id":"191924532313985024","created_at":"2012-04-16T16:22:28.000Z","entities":{"urls":[{"start":115,"end":135,"url":"http://t.co/vLc54AMb","expanded_url":"http://bit.ly/HWXaUn","display_url":"bit.ly/HWXaUn"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"191924532313985024","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: RT @Parlimag: Investing in immunisation: A PM special supplement on #vaccines and #immunisation online now http://t.co/XvrCsG1H","id":"191904346189987841","created_at":"2012-04-16T15:02:16.000Z","entities":{"urls":[{"start":120,"end":140,"url":"http://t.co/XvrCsG1H","expanded_url":"http://bit.ly/IXNH0v","display_url":"bit.ly/IXNH0v"}],"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":16,"end":25,"username":"Parlimag","id":"21223877"}],"hashtags":[{"start":81,"end":90,"tag":"vaccines"},{"start":95,"end":108,"tag":"immunisation"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"191904346189987841","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"191903874632781824"}]},{"text":"We've published the #CVMP highlights for April 2012 http://t.co/lWZl6XjC","id":"191904309313675264","created_at":"2012-04-16T15:02:07.000Z","entities":{"urls":[{"start":52,"end":72,"url":"http://t.co/lWZl6XjC","expanded_url":"http://bit.ly/HLYjPQ","display_url":"bit.ly/HLYjPQ"}],"annotations":{},"mentions":{},"hashtags":[{"start":20,"end":25,"tag":"CVMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"191904309313675264","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We published yesterday a new procedural guidance on similar biological medicines http://t.co/IW8cwWvY","id":"190422710545940480","created_at":"2012-04-12T12:54:46.000Z","entities":{"urls":[{"start":81,"end":101,"url":"http://t.co/IW8cwWvY","expanded_url":"http://bit.ly/HrSxPI","display_url":"bit.ly/HrSxPI"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"190422710545940480","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Yesterday we published new regulatory procedural advice on similar biological medicines http://t.co/IW8cwWvY","id":"190364350727458816","created_at":"2012-04-12T09:02:52.000Z","entities":{"urls":[{"start":88,"end":108,"url":"http://t.co/IW8cwWvY","expanded_url":"http://bit.ly/HrSxPI","display_url":"bit.ly/HrSxPI"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"190364350727458816","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We published new document on regulatory procedural advice on similar biological medicines \nhttp://t.co/IW8cwWvY","id":"190099205438717952","created_at":"2012-04-11T15:29:17.000Z","entities":{"urls":[{"start":91,"end":111,"url":"http://t.co/IW8cwWvY","expanded_url":"http://bit.ly/HrSxPI","display_url":"bit.ly/HrSxPI"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"190099205438717952","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"@drug_czar The list is live now. Apologies for the delay! http://t.co/TjHPLKlf","id":"190079426137042945","created_at":"2012-04-11T14:10:41.000Z","entities":{"urls":[{"start":58,"end":78,"url":"http://t.co/TjHPLKlf","expanded_url":"http://bit.ly/IBFYAd","display_url":"bit.ly/IBFYAd"}],"annotations":{},"mentions":[{"start":0,"end":10,"username":"drug_czar","id":"267894360"}],"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189358563116855297","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"replied_to","id":"189358563116855297"}],"in_reply_to_user_id":"267894360"},{"text":"RT @EFPIA: PR: #EFPIA launches process for its European Medicines Verification System: http://t.co/lGIpdrPU #counterfeits #safety @PGEU  ...","id":"190077143449993218","created_at":"2012-04-11T14:01:37.000Z","entities":{"urls":[{"start":87,"end":107,"url":"http://t.co/lGIpdrPU","expanded_url":"http://bit.ly/HKFOWz","display_url":"bit.ly/HKFOWz"}],"annotations":{},"mentions":[{"start":3,"end":9,"username":"EFPIA","id":"52084584"},{"start":130,"end":135,"username":"PGEU","id":"459292439"}],"hashtags":[{"start":15,"end":21,"tag":"EFPIA"},{"start":108,"end":121,"tag":"counterfeits"},{"start":122,"end":129,"tag":"safety"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"190077143449993218","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"190076805682700291"}]},{"text":"Our vision for the way forward in providing open access to full clinical trial data on authorised medicines: http://t.co/oVLhdd6f","id":"190054795330064384","created_at":"2012-04-11T12:32:48.000Z","entities":{"urls":[{"start":109,"end":129,"url":"http://t.co/oVLhdd6f","expanded_url":"http://bit.ly/I1TDT7","display_url":"bit.ly/I1TDT7"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"190054795330064384","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @Hep_Alliance: What is #hepatitis? http://t.co/kLLaqTSJ","id":"190015200848650240","created_at":"2012-04-11T09:55:28.000Z","entities":{"urls":[{"start":38,"end":58,"url":"http://t.co/kLLaqTSJ","expanded_url":"http://bit.ly/nv2g4i","display_url":"bit.ly/nv2g4i"}],"annotations":{},"mentions":[{"start":3,"end":16,"username":"Hep_Alliance","id":"20170584"}],"hashtags":[{"start":26,"end":36,"tag":"hepatitis"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"190015200848650240","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"190014548445642752"}]},{"text":"Our Senior Medical Officer and Executive Director have responded to a call for open access to full data on medicines: http://t.co/oVLhdd6f","id":"190002167569063936","created_at":"2012-04-11T09:03:41.000Z","entities":{"urls":[{"start":118,"end":138,"url":"http://t.co/oVLhdd6f","expanded_url":"http://bit.ly/I1TDT7","display_url":"bit.ly/I1TDT7"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"190002167569063936","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've proposed a way forward for the publication of full data from clinical trials: http://t.co/oVLhdd6f","id":"189998505325113344","created_at":"2012-04-11T08:49:08.000Z","entities":{"urls":[{"start":84,"end":104,"url":"http://t.co/oVLhdd6f","expanded_url":"http://bit.ly/I1TDT7","display_url":"bit.ly/I1TDT7"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":8,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"189998505325113344","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @EFPIA: RT @IMI_JU: IMI 5th Call on European Lead Factory featured in @NatureMedicine http://t.co/kifvXKMP","id":"189715266215739392","created_at":"2012-04-10T14:03:38.000Z","entities":{"urls":[{"start":89,"end":109,"url":"http://t.co/kifvXKMP","expanded_url":"http://bit.ly/Ivt3jo","display_url":"bit.ly/Ivt3jo"}],"annotations":{},"mentions":[{"start":3,"end":9,"username":"EFPIA","id":"52084584"},{"start":14,"end":21,"username":"imi_ju","id":"1473203261469790214"},{"start":73,"end":88,"username":"NatureMedicine","id":"26832834"}],"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189715266215739392","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"189714514730680320"}]},{"text":"Last Wednesday Eric Abadie resigned as chair of the Committee for Medicinal Products for Human Use (CHMP): http://t.co/eOEhqeHx","id":"189707936266846208","created_at":"2012-04-10T13:34:31.000Z","entities":{"urls":[{"start":107,"end":127,"url":"http://t.co/eOEhqeHx","expanded_url":"http://bit.ly/HQFuac","display_url":"bit.ly/HQFuac"}],"annotations":[{"start":15,"end":25,"probability":0.9936,"type":"Person","normalized_text":"Eric Abadie"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189707936266846208","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Marketing-authorisation holders: feed back on our draft list of reference dates for periodic safety update reports: http://t.co/WrjotuWv","id":"189707723443671040","created_at":"2012-04-10T13:33:40.000Z","entities":{"urls":[{"start":116,"end":136,"url":"http://t.co/WrjotuWv","expanded_url":"http://bit.ly/HMmVY8","display_url":"bit.ly/HMmVY8"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189707723443671040","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We support World Health Day. This year the theme is ageing and health: http://t.co/sWdWkOiO","id":"189707371944226819","created_at":"2012-04-10T13:32:16.000Z","entities":{"urls":[{"start":71,"end":91,"url":"http://t.co/sWdWkOiO","expanded_url":"http://bit.ly/HekgqI","display_url":"bit.ly/HekgqI"}],"annotations":[{"start":11,"end":26,"probability":0.8785,"type":"Other","normalized_text":"World Health Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189707371944226819","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Eric Abadie has resigned as chair of the CHMP: http://t.co/eOEhqeHx","id":"189671793840238593","created_at":"2012-04-10T11:10:54.000Z","entities":{"urls":[{"start":47,"end":67,"url":"http://t.co/eOEhqeHx","expanded_url":"http://bit.ly/HQFuac","display_url":"bit.ly/HQFuac"}],"annotations":[{"start":0,"end":10,"probability":0.9984,"type":"Person","normalized_text":"Eric Abadie"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189671793840238593","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Please give us feedback on our draft list of reference dates for periodic safety update reports: http://t.co/WrjotuWv","id":"189671684029153280","created_at":"2012-04-10T11:10:28.000Z","entities":{"urls":[{"start":97,"end":117,"url":"http://t.co/WrjotuWv","expanded_url":"http://bit.ly/HMmVY8","display_url":"bit.ly/HMmVY8"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189671684029153280","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're supporting World Health Day: http://t.co/sWdWkOiO","id":"189671563761692673","created_at":"2012-04-10T11:09:59.000Z","entities":{"urls":[{"start":35,"end":55,"url":"http://t.co/sWdWkOiO","expanded_url":"http://bit.ly/HekgqI","display_url":"bit.ly/HekgqI"}],"annotations":[{"start":17,"end":32,"probability":0.8956,"type":"Other","normalized_text":"World Health Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"189671563761692673","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Eric Abadie resigns as chair of the CHMP: http://t.co/eOEhqeHx","id":"187604515309092865","created_at":"2012-04-04T18:16:16.000Z","entities":{"urls":[{"start":42,"end":62,"url":"http://t.co/eOEhqeHx","expanded_url":"http://bit.ly/HQFuac","display_url":"bit.ly/HQFuac"}],"annotations":[{"start":0,"end":10,"probability":0.9984,"type":"Person","normalized_text":"Eric Abadie"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187604515309092865","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @NHSlocal: This article explains the process from a medicine's concept to it being authorised and distributed http://t.co/9sjpgGol @m ...","id":"187558514623918081","created_at":"2012-04-04T15:13:29.000Z","entities":{"urls":[{"start":113,"end":133,"url":"http://t.co/9sjpgGol","expanded_url":"http://ow.ly/a4Cmh","display_url":"ow.ly/a4Cmh"}],"annotations":{},"mentions":[{"start":3,"end":12,"username":"NHSlocal","id":"2668730221"}],"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187558514623918081","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"187547599946006529"}]},{"text":"We're asking for feedback on our draft list of reference dates for periodic safety update reports: http://t.co/WrjotuWv","id":"187554953257164801","created_at":"2012-04-04T14:59:20.000Z","entities":{"urls":[{"start":99,"end":119,"url":"http://t.co/WrjotuWv","expanded_url":"http://bit.ly/HMmVY8","display_url":"bit.ly/HMmVY8"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187554953257164801","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're supporting World Health Day 2012 on Saturday 7 April: http://t.co/sWdWkOiO","id":"187540161226223616","created_at":"2012-04-04T14:00:33.000Z","entities":{"urls":[{"start":60,"end":80,"url":"http://t.co/sWdWkOiO","expanded_url":"http://bit.ly/HekgqI","display_url":"bit.ly/HekgqI"}],"annotations":[{"start":17,"end":32,"probability":0.8536,"type":"Other","normalized_text":"World Health Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187540161226223616","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @hcvresearchnews: GENFIT :GFT505: GENFIT VERY SATISFIED WITH THE SCIENTIFIC ADVICE OF THE EUROPEAN MEDICINES AGENCY (EMA) http://t.co ...","id":"187535753063043073","created_at":"2012-04-04T13:43:02.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":19,"username":"hcvresearchnews","id":"144906605"}],"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187535753063043073","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"187535284047585281"}]},{"text":"Yesterday we published updated policies on conflicts of interests and a new breach-of-trust procedure: http://t.co/xzY6MufI","id":"187534818232381440","created_at":"2012-04-04T13:39:19.000Z","entities":{"urls":[{"start":103,"end":123,"url":"http://t.co/xzY6MufI","expanded_url":"http://bit.ly/HPyk4p","display_url":"bit.ly/HPyk4p"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187534818232381440","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've published updated policies on conflicts of interests for experts, committee members and Management Board: http://t.co/xzY6MufI","id":"187480669109223424","created_at":"2012-04-04T10:04:09.000Z","entities":{"urls":[{"start":112,"end":132,"url":"http://t.co/xzY6MufI","expanded_url":"http://bit.ly/HPyk4p","display_url":"bit.ly/HPyk4p"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"187480669109223424","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Don't forget: our website will be down tomorrow afternoon from 1pm to 5.30pm UK time: http://t.co/qm7RJww6","id":"187480541656907778","created_at":"2012-04-04T10:03:39.000Z","entities":{"urls":[{"start":86,"end":106,"url":"http://t.co/qm7RJww6","expanded_url":"http://bit.ly/HchVgF","display_url":"bit.ly/HchVgF"}],"annotations":[{"start":77,"end":78,"probability":0.8745,"type":"Place","normalized_text":"UK"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187480541656907778","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're closed from this evening until Tuesday morning. Emergency telephone number for out-of-hours problems: http://t.co/ITc6FXxB","id":"187480434010095617","created_at":"2012-04-04T10:03:13.000Z","entities":{"urls":[{"start":108,"end":128,"url":"http://t.co/ITc6FXxB","expanded_url":"http://bit.ly/HhoHzu","display_url":"bit.ly/HhoHzu"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187480434010095617","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @WDD: 3 more days to @WHO World #Health Day! http://t.co/2KwLunDB","id":"187457148849098752","created_at":"2012-04-04T08:30:41.000Z","entities":{"urls":[{"start":48,"end":68,"url":"http://t.co/2KwLunDB","expanded_url":"http://youtu.be/LL-TJjCJPaI","display_url":"youtu.be/LL-TJjCJPaI"}],"annotations":{},"mentions":[{"start":3,"end":7,"username":"WDD","id":"15179874"},{"start":24,"end":28,"username":"WHO","id":"14499829"}],"hashtags":[{"start":35,"end":42,"tag":"Health"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187457148849098752","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"187455060454817792"}]},{"text":"We've published our updated policies on conflicts of interests: http://t.co/xzY6MufI","id":"187242928572350464","created_at":"2012-04-03T18:19:27.000Z","entities":{"urls":[{"start":64,"end":84,"url":"http://t.co/xzY6MufI","expanded_url":"http://bit.ly/HPyk4p","display_url":"bit.ly/HPyk4p"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187242928572350464","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Don't forget: our website will be down from 1pm to 5.30pm UK time on Thursday 5 April: http://t.co/qm7RJww6","id":"187199735520698369","created_at":"2012-04-03T15:27:49.000Z","entities":{"urls":[{"start":87,"end":107,"url":"http://t.co/qm7RJww6","expanded_url":"http://bit.ly/HchVgF","display_url":"bit.ly/HchVgF"}],"annotations":[{"start":58,"end":59,"probability":0.9061,"type":"Place","normalized_text":"UK"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187199735520698369","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Our website will be unavailable from 1pm to 5.30pm UK time on Thursday 5 April: http://t.co/qm7RJww6","id":"187178139879874561","created_at":"2012-04-03T14:02:00.000Z","entities":{"urls":[{"start":80,"end":100,"url":"http://t.co/qm7RJww6","expanded_url":"http://bit.ly/HchVgF","display_url":"bit.ly/HchVgF"}],"annotations":[{"start":51,"end":52,"probability":0.9088,"type":"Place","normalized_text":"UK"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187178139879874561","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We will be closed over Easter from 5 to 9 April. Emergency telephone number for out-of-hours problems: http://t.co/ITc6FXxB","id":"187177974594940928","created_at":"2012-04-03T14:01:21.000Z","entities":{"urls":[{"start":103,"end":123,"url":"http://t.co/ITc6FXxB","expanded_url":"http://bit.ly/HhoHzu","display_url":"bit.ly/HhoHzu"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187177974594940928","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Our website will be unavailable 13.00-17:30 on 5 Apri 2012: http://t.co/qm7RJww6","id":"187149264412086272","created_at":"2012-04-03T12:07:16.000Z","entities":{"urls":[{"start":60,"end":80,"url":"http://t.co/qm7RJww6","expanded_url":"http://bit.ly/HchVgF","display_url":"bit.ly/HchVgF"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187149264412086272","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're closed from 5 to 9 April: http://t.co/ITc6FXxB","id":"187136361281765376","created_at":"2012-04-03T11:16:00.000Z","entities":{"urls":[{"start":32,"end":52,"url":"http://t.co/ITc6FXxB","expanded_url":"http://bit.ly/HhoHzu","display_url":"bit.ly/HhoHzu"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"187136361281765376","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've increased our fees for applications by 3.1% in line with inflation: http://t.co/BjxSmGRg","id":"186784712038166528","created_at":"2012-04-02T11:58:40.000Z","entities":{"urls":[{"start":74,"end":94,"url":"http://t.co/BjxSmGRg","expanded_url":"http://bit.ly/Hxe9c2","display_url":"bit.ly/Hxe9c2"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"186784712038166528","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @TheLancet: The EMA champions pharmacometrics in the pursuit of accurate no-treatment effects in antimicrobial drug studies http://t. ...","id":"186511539384238080","created_at":"2012-04-01T17:53:10.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":13,"username":"TheLancet","id":"27013292"}],"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"186511539384238080","source":"Twitter for iPad","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"185842885864857601"}]},{"text":"RT @WHO_Europe: @WHO Join our #chat on active #ageing on Monday 2 April 09:00-10:00 CEST #AddHealth2Life","id":"185744050144546816","created_at":"2012-03-30T15:03:27.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"},{"start":16,"end":20,"username":"WHO","id":"14499829"}],"hashtags":[{"start":30,"end":35,"tag":"chat"},{"start":46,"end":53,"tag":"ageing"},{"start":89,"end":104,"tag":"AddHealth2Life"}]},"public_metrics":{"retweet_count":13,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"185744050144546816","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"185720996966301696"}]},{"text":"RT @WHO: 2 more days to @WHO World Health Day Twitter chat on 2 April! Get your questions ready and use hashtag #AddHealth2Life","id":"185729487588167680","created_at":"2012-03-30T14:05:35.000Z","entities":{"urls":{},"annotations":[{"start":29,"end":52,"probability":0.5767,"type":"Other","normalized_text":"World Health Day Twitter"}],"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"},{"start":24,"end":28,"username":"WHO","id":"14499829"}],"hashtags":[{"start":112,"end":127,"tag":"AddHealth2Life"}]},"public_metrics":{"retweet_count":72,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"185729487588167680","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"185729421322371072"}]},{"text":"Our fees are increasing by 3.1% in line with inflation on 1 April: http://t.co/BjxSmGRg","id":"185728956215992321","created_at":"2012-03-30T14:03:28.000Z","entities":{"urls":[{"start":67,"end":87,"url":"http://t.co/BjxSmGRg","expanded_url":"http://bit.ly/Hxe9c2","display_url":"bit.ly/Hxe9c2"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"185728956215992321","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've agreed a common approach with other EU regulators for identifying confidential information and personal data: http://t.co/FKpszoUa","id":"185728676707569664","created_at":"2012-03-30T14:02:21.000Z","entities":{"urls":[{"start":116,"end":136,"url":"http://t.co/FKpszoUa","expanded_url":"http://bit.ly/H7glfv","display_url":"bit.ly/H7glfv"}],"annotations":[{"start":42,"end":43,"probability":0.7369,"type":"Organization","normalized_text":"EU"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"185728676707569664","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @WHO_Europe: @ECDC_EU Join our #chat on active #ageing on Monday 2 April 09:00-10:00 CEST #AddHealth2Life","id":"185695589583962113","created_at":"2012-03-30T11:50:53.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"},{"start":16,"end":24,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":34,"end":39,"tag":"chat"},{"start":50,"end":57,"tag":"ageing"},{"start":93,"end":108,"tag":"AddHealth2Life"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"185695589583962113","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"185695332133380096"}]},{"text":"We're increasing our fees for applications on 1 April: http://t.co/BjxSmGRg","id":"185644298639900672","created_at":"2012-03-30T08:27:04.000Z","entities":{"urls":[{"start":55,"end":75,"url":"http://t.co/BjxSmGRg","expanded_url":"http://bit.ly/Hxe9c2","display_url":"bit.ly/Hxe9c2"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"185644298639900672","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EU medicines regulators agreed on a joined approach to identify commercially confidential information http://t.co/FKpszoUa","id":"184671301540134913","created_at":"2012-03-27T16:00:43.000Z","entities":{"urls":[{"start":102,"end":122,"url":"http://t.co/FKpszoUa","expanded_url":"http://bit.ly/H7glfv","display_url":"bit.ly/H7glfv"}],"annotations":[{"start":0,"end":1,"probability":0.7132,"type":"Organization","normalized_text":"EU"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"184671301540134913","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EU regulators agreed a common approach for the identification of commercially confidential information & personal data http://t.co/FKpszoUa","id":"184570532094685184","created_at":"2012-03-27T09:20:18.000Z","entities":{"urls":[{"start":119,"end":139,"url":"http://t.co/FKpszoUa","expanded_url":"http://bit.ly/H7glfv","display_url":"bit.ly/H7glfv"}],"annotations":[{"start":0,"end":1,"probability":0.7609,"type":"Organization","normalized_text":"EU"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"184570532094685184","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Management Board talked about Conflicts of interest policies and transparency http://t.co/rLksePVM","id":"184557485837926400","created_at":"2012-03-27T08:28:28.000Z","entities":{"urls":[{"start":78,"end":98,"url":"http://t.co/rLksePVM","expanded_url":"http://bit.ly/H2Dyjb","display_url":"bit.ly/H2Dyjb"}],"annotations":[{"start":0,"end":15,"probability":0.5191,"type":"Organization","normalized_text":"Management Board"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"184557485837926400","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EU Clinical Trials Register now feeds data to WHO’s International Clinical Trials Registry Platform http://t.co/PLBmRcfV","id":"184557243142905856","created_at":"2012-03-27T08:27:30.000Z","entities":{"urls":[{"start":100,"end":120,"url":"http://t.co/PLBmRcfV","expanded_url":"http://bit.ly/GQBGu5","display_url":"bit.ly/GQBGu5"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"184557243142905856","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"WHO’s International Clinical Trials Registry Platform now uses data from EU Clinical Trials Register http://t.co/PLBmRcfV","id":"184301058795896834","created_at":"2012-03-26T15:29:31.000Z","entities":{"urls":[{"start":101,"end":121,"url":"http://t.co/PLBmRcfV","expanded_url":"http://bit.ly/GQBGu5","display_url":"bit.ly/GQBGu5"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"184301058795896834","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Conflicts of interest policies and transparency strengthed by Management Board http://t.co/rLksePVM","id":"184300488328609792","created_at":"2012-03-26T15:27:15.000Z","entities":{"urls":[{"start":79,"end":99,"url":"http://t.co/rLksePVM","expanded_url":"http://bit.ly/H2Dyjb","display_url":"bit.ly/H2Dyjb"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"184300488328609792","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EU Clinical Trials Register information now available through WHO’s International Clinical Trials Registry Platform \nhttp://t.co/PLBmRcfV","id":"184271031672897536","created_at":"2012-03-26T13:30:12.000Z","entities":{"urls":[{"start":117,"end":137,"url":"http://t.co/PLBmRcfV","expanded_url":"http://bit.ly/GQBGu5","display_url":"bit.ly/GQBGu5"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":9,"reply_count":1,"like_count":1,"quote_count":0},"conversation_id":"184271031672897536","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Management Board strengthens conflicts of interest policies and transparency http://t.co/rLksePVM","id":"184223552264863744","created_at":"2012-03-26T10:21:32.000Z","entities":{"urls":[{"start":77,"end":97,"url":"http://t.co/rLksePVM","expanded_url":"http://bit.ly/H2Dyjb","display_url":"bit.ly/H2Dyjb"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"184223552264863744","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: #Influenza epidemic peak has passed in most European countries. Read the latest weekly #surveillance overview: http://t.co/ ...","id":"183190164514938880","created_at":"2012-03-23T13:55:13.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":23,"tag":"Influenza"},{"start":100,"end":113,"tag":"surveillance"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"183190164514938880","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"183189981018324992"}]},{"text":"Next month we're holding a workshop on vaccines against #Schmallenberg virus: http://t.co/bZ6JWDur","id":"183179611574763521","created_at":"2012-03-23T13:13:17.000Z","entities":{"urls":[{"start":78,"end":98,"url":"http://t.co/bZ6JWDur","expanded_url":"http://bit.ly/GI0kdk","display_url":"bit.ly/GI0kdk"}],"annotations":{},"mentions":{},"hashtags":[{"start":56,"end":70,"tag":"Schmallenberg"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"183179611574763521","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: Early estimates #influenza #vaccine effectiveness (VE) in #Spain: adjusted VE was 55%, Dec 2011- Feb 2012 http://t.co/EpSjNEew","id":"183161029935636480","created_at":"2012-03-23T11:59:27.000Z","entities":{"urls":[{"start":119,"end":139,"url":"http://t.co/EpSjNEew","expanded_url":"http://bit.ly/GIxfBp","display_url":"bit.ly/GIxfBp"}],"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":29,"end":39,"tag":"influenza"},{"start":40,"end":48,"tag":"vaccine"},{"start":71,"end":77,"tag":"Spain"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"183161029935636480","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"183109522905247744"}]},{"text":"RT @EFSA_EU: Understanding science - #EFSA’s new video explains #antimicrobial resistance and how it is related to food safety: http://t ...","id":"183160265431453697","created_at":"2012-03-23T11:56:24.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":[{"start":37,"end":42,"tag":"EFSA"},{"start":64,"end":78,"tag":"antimicrobial"}]},"public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"183160265431453697","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"183141139094831104"}]},{"text":"On 10 April, we're holding a workshop on vaccines against #Schmallenberg virus: http://t.co/bZ6JWDur","id":"182829329066098690","created_at":"2012-03-22T14:01:23.000Z","entities":{"urls":[{"start":80,"end":100,"url":"http://t.co/bZ6JWDur","expanded_url":"http://bit.ly/GI0kdk","display_url":"bit.ly/GI0kdk"}],"annotations":{},"mentions":{},"hashtags":[{"start":58,"end":72,"tag":"Schmallenberg"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182829329066098690","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're holding a workshop on #Schmallenberg virus in April: http://t.co/bZ6JWDur","id":"182776635328696320","created_at":"2012-03-22T10:32:00.000Z","entities":{"urls":[{"start":59,"end":79,"url":"http://t.co/bZ6JWDur","expanded_url":"http://bit.ly/GI0kdk","display_url":"bit.ly/GI0kdk"}],"annotations":{},"mentions":{},"hashtags":[{"start":28,"end":42,"tag":"Schmallenberg"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182776635328696320","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We are holding a workshop on medicines for older people today and tomorrow  http://t.co/UqbwVFvv","id":"182755983003631616","created_at":"2012-03-22T09:09:56.000Z","entities":{"urls":[{"start":76,"end":96,"url":"http://t.co/UqbwVFvv","expanded_url":"http://bit.ly/GGr1Q9","display_url":"bit.ly/GGr1Q9"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182755983003631616","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Application for an extension of the indication for #Qutenza (#capsaicin) was withdrawn by Astellas Pharma http://t.co/tBl9Lkbj","id":"182397315766697984","created_at":"2012-03-21T09:24:43.000Z","entities":{"urls":[{"start":106,"end":126,"url":"http://t.co/tBl9Lkbj","expanded_url":"http://bit.ly/GC4v8K","display_url":"bit.ly/GC4v8K"}],"annotations":[{"start":90,"end":104,"probability":0.7275,"type":"Organization","normalized_text":"Astellas Pharma"}],"mentions":{},"hashtags":[{"start":51,"end":59,"tag":"Qutenza"},{"start":61,"end":71,"tag":"capsaicin"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182397315766697984","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We were informed by Astellas Pharma of withdrawal of application for  extension of indication for #Qutenza (#capsaicin) http://t.co/tBl9Lkbj","id":"182143349942267904","created_at":"2012-03-20T16:35:33.000Z","entities":{"urls":[{"start":120,"end":140,"url":"http://t.co/tBl9Lkbj","expanded_url":"http://bit.ly/GC4v8K","display_url":"bit.ly/GC4v8K"}],"annotations":[{"start":20,"end":34,"probability":0.7395,"type":"Organization","normalized_text":"Astellas Pharma"}],"mentions":{},"hashtags":[{"start":98,"end":106,"tag":"Qutenza"},{"start":108,"end":118,"tag":"capsaicin"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182143349942267904","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: Om 15 minuter börjar en #twitterchat om #tuberkulos. Ställ dina frågor till @ECDC_EU eller @WHO_Europe använd #tbchat","id":"182116722088747008","created_at":"2012-03-20T14:49:44.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":89,"end":97,"username":"ECDC_EU","id":"204752573"},{"start":104,"end":115,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":37,"end":49,"tag":"twitterchat"},{"start":53,"end":64,"tag":"tuberkulos"},{"start":123,"end":130,"tag":"tbchat"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182116722088747008","source":"TweetDeck","lang":"sv","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"182116531080138752"}]},{"text":"RT @ECDC_EU: Fragen zum Thema #Tuberkulose? Stellt sie jetzt beim @ECDC_EU und @WHO_EURO live Twitter chat.  Ab 16.00 Uhr unter #TBchat","id":"182113702965809152","created_at":"2012-03-20T14:37:44.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":66,"end":74,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":30,"end":42,"tag":"Tuberkulose"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182113702965809152","source":"TweetDeck","lang":"de","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"182113449571131393"}]},{"text":"RT @ECDC_EU: Today 3pm UTC/GMT, WHO and ECDC experts will be answering questions on tuberculosis. Join the conversation! #TBchat @EUEnvi ...","id":"182057236359675906","created_at":"2012-03-20T10:53:22.000Z","entities":{"urls":{},"annotations":[{"start":40,"end":43,"probability":0.5636,"type":"Organization","normalized_text":"ECDC"}],"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":121,"end":128,"tag":"TBchat"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182057236359675906","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"182041458520498177"}]},{"text":"RT @WHO: World Health Day is celebrated 7 April to mark WHO anniversary. This year, we focus on ageing &amp; health http://t.co/6z13YyLP ...","id":"182055975400902656","created_at":"2012-03-20T10:48:21.000Z","entities":{"urls":[{"start":116,"end":136,"url":"http://t.co/6z13YyLP","expanded_url":"http://bit.ly/FOoUuA","display_url":"bit.ly/FOoUuA"}],"annotations":[{"start":9,"end":24,"probability":0.844,"type":"Other","normalized_text":"World Health Day"}],"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":{}},"public_metrics":{"retweet_count":111,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"182055975400902656","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"180862283759632384"}]},{"text":"Astellas Pharma Europe B.V. withdraws its application for an extension of the indication for Qutenza (capsaicin)\nhttp://t.co/tBl9Lkbj","id":"182037548225400832","created_at":"2012-03-20T09:35:08.000Z","entities":{"urls":[{"start":113,"end":133,"url":"http://t.co/tBl9Lkbj","expanded_url":"http://bit.ly/GC4v8K","display_url":"bit.ly/GC4v8K"}],"annotations":[{"start":0,"end":26,"probability":0.4663,"type":"Organization","normalized_text":"Astellas Pharma Europe B.V."}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"182037548225400832","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've recommended to transfer manufacturing sites for #Caelyx and #Ceplene from Ben Venue Laboratories: http://t.co/jt9E8oCR","id":"181661771751358464","created_at":"2012-03-19T08:41:56.000Z","entities":{"urls":[{"start":104,"end":124,"url":"http://t.co/jt9E8oCR","expanded_url":"http://bit.ly/Ay3IQi","display_url":"bit.ly/Ay3IQi"}],"annotations":[{"start":80,"end":101,"probability":0.5992,"type":"Organization","normalized_text":"Ben Venue Laboratories"}],"mentions":{},"hashtags":[{"start":54,"end":61,"tag":"Caelyx"},{"start":66,"end":74,"tag":"Ceplene"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"181661771751358464","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We said #Protelos/#Osseor have positive benefit-risk balance but we recommend new contraindications and warnings http://t.co/lKycyqmg","id":"181660912254582784","created_at":"2012-03-19T08:38:31.000Z","entities":{"urls":[{"start":113,"end":133,"url":"http://t.co/lKycyqmg","expanded_url":"http://bit.ly/FPdukm","display_url":"bit.ly/FPdukm"}],"annotations":{},"mentions":{},"hashtags":[{"start":8,"end":17,"tag":"Protelos"},{"start":18,"end":25,"tag":"Osseor"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"181660912254582784","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We published the strain recommendations for 2012/2013 seasonal flu vaccines: http://t.co/7lQrDT2j","id":"181659427944935424","created_at":"2012-03-19T08:32:37.000Z","entities":{"urls":[{"start":77,"end":97,"url":"http://t.co/7lQrDT2j","expanded_url":"http://bit.ly/FPlH7Y","display_url":"bit.ly/FPlH7Y"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"181659427944935424","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"The Committee for Medicinal Products for Human Use (#CHMP) met last week. Here is the outcome of the discussions: http://t.co/TUoL790n","id":"181658885717897216","created_at":"2012-03-19T08:30:28.000Z","entities":{"urls":[{"start":114,"end":134,"url":"http://t.co/TUoL790n","expanded_url":"http://bit.ly/FPm02L","display_url":"bit.ly/FPm02L"}],"annotations":{},"mentions":{},"hashtags":[{"start":52,"end":57,"tag":"CHMP"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"181658885717897216","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: Read the latest ECDC communicable disease threat report or #CDTR; http://t.co/BepFqt3J","id":"180687424559661056","created_at":"2012-03-16T16:10:13.000Z","entities":{"urls":[{"start":79,"end":99,"url":"http://t.co/BepFqt3J","expanded_url":"http://bit.ly/ynyPae","display_url":"bit.ly/ynyPae"}],"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":72,"end":77,"tag":"CDTR"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180687424559661056","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"180687293844168704"}]},{"text":"The highlights from this month's Committee for Medicinal Products for Human Use (CHMP) meeting are on our website: http://t.co/TUoL790n","id":"180687237925703680","created_at":"2012-03-16T16:09:29.000Z","entities":{"urls":[{"start":115,"end":135,"url":"http://t.co/TUoL790n","expanded_url":"http://bit.ly/FPm02L","display_url":"bit.ly/FPm02L"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"180687237925703680","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"This morning we published the strain recommendations for 2012/2013 seasonal flu vaccines: http://t.co/7lQrDT2j","id":"180687024670519296","created_at":"2012-03-16T16:08:38.000Z","entities":{"urls":[{"start":90,"end":110,"url":"http://t.co/7lQrDT2j","expanded_url":"http://bit.ly/FPlH7Y","display_url":"bit.ly/FPlH7Y"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"180687024670519296","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've recommended new contraindications and warnings for #Protelos/#Osseor, but benefits still outweigh risks: http://t.co/lKycyqmg","id":"180686856856412162","created_at":"2012-03-16T16:07:58.000Z","entities":{"urls":[{"start":111,"end":131,"url":"http://t.co/lKycyqmg","expanded_url":"http://bit.ly/FPdukm","display_url":"bit.ly/FPdukm"}],"annotations":{},"mentions":{},"hashtags":[{"start":57,"end":66,"tag":"Protelos"},{"start":67,"end":74,"tag":"Osseor"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180686856856412162","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We're recommending that manufacturing sites for #Caelyx and #Ceplene be transferred from Ben Venue Laboratories: http://t.co/jt9E8oCR","id":"180686509609975808","created_at":"2012-03-16T16:06:35.000Z","entities":{"urls":[{"start":113,"end":133,"url":"http://t.co/jt9E8oCR","expanded_url":"http://bit.ly/Ay3IQi","display_url":"bit.ly/Ay3IQi"}],"annotations":[{"start":89,"end":110,"probability":0.5937,"type":"Organization","normalized_text":"Ben Venue Laboratories"}],"mentions":{},"hashtags":[{"start":48,"end":55,"tag":"Caelyx"},{"start":60,"end":68,"tag":"Ceplene"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180686509609975808","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've announced withdrawal of applications for #Exelon and #Prometax (#rivastigmine) in Parkinson's dementia: http://t.co/144FVVvf","id":"180686152372731906","created_at":"2012-03-16T16:05:10.000Z","entities":{"urls":[{"start":110,"end":130,"url":"http://t.co/144FVVvf","expanded_url":"http://bit.ly/yH5l8Z","display_url":"bit.ly/yH5l8Z"}],"annotations":{},"mentions":{},"hashtags":[{"start":47,"end":54,"tag":"Exelon"},{"start":59,"end":68,"tag":"Prometax"},{"start":70,"end":83,"tag":"rivastigmine"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180686152372731906","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @WHO_Europe: Ask WHO and #ECDC experts about #TB in a #twitterchat - #tbchat - on Tuesday 20 March, 15:00-16:00 UTC @WHO","id":"180652084692135936","created_at":"2012-03-16T13:49:48.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"},{"start":119,"end":123,"username":"WHO","id":"14499829"}],"hashtags":[{"start":28,"end":33,"tag":"ECDC"},{"start":48,"end":51,"tag":"TB"},{"start":57,"end":69,"tag":"twitterchat"},{"start":72,"end":79,"tag":"tbchat"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180652084692135936","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"180651572374675456"}]},{"text":"We've published the highlights from the March meeting of the Committee for Medicinal Products for Human Use (CHMP): http://t.co/TUoL790n","id":"180626457335316480","created_at":"2012-03-16T12:07:57.000Z","entities":{"urls":[{"start":116,"end":136,"url":"http://t.co/TUoL790n","expanded_url":"http://bit.ly/FPm02L","display_url":"bit.ly/FPm02L"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"180626457335316480","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've issued the strain recommendations for 2012/2013 seasonal flu vaccines: http://t.co/7lQrDT2j","id":"180625494847406080","created_at":"2012-03-16T12:04:08.000Z","entities":{"urls":[{"start":77,"end":97,"url":"http://t.co/7lQrDT2j","expanded_url":"http://bit.ly/FPlH7Y","display_url":"bit.ly/FPlH7Y"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180625494847406080","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Novartis has withdrawn its applications for #Exelon and #Prometax (#rivastigmine) in Parkinson's dementia: http://t.co/144FVVvf","id":"180622518330204162","created_at":"2012-03-16T11:52:18.000Z","entities":{"urls":[{"start":107,"end":127,"url":"http://t.co/144FVVvf","expanded_url":"http://bit.ly/yH5l8Z","display_url":"bit.ly/yH5l8Z"}],"annotations":[{"start":0,"end":7,"probability":0.5791,"type":"Organization","normalized_text":"Novartis"},{"start":85,"end":93,"probability":0.3049,"type":"Person","normalized_text":"Parkinson"}],"mentions":{},"hashtags":[{"start":44,"end":51,"tag":"Exelon"},{"start":56,"end":65,"tag":"Prometax"},{"start":67,"end":80,"tag":"rivastigmine"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180622518330204162","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Yesterday we launched a public consultation on guidance on preventing #HIV with pre-exposure prophylaxis (PrEP): http://t.co/ouL4UoJU","id":"180622262012084224","created_at":"2012-03-16T11:51:17.000Z","entities":{"urls":[{"start":113,"end":133,"url":"http://t.co/ouL4UoJU","expanded_url":"http://bit.ly/yMjgwm","display_url":"bit.ly/yMjgwm"}],"annotations":{},"mentions":{},"hashtags":[{"start":70,"end":74,"tag":"HIV"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180622262012084224","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @WHO_Europe: Ask WHO and #ECDC experts about #tuberculosis in a #twitterchat - #tbchat - on Tuesday 20 March, 15:00-16:00 UCT","id":"180608953145765888","created_at":"2012-03-16T10:58:24.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":28,"end":33,"tag":"ECDC"},{"start":48,"end":61,"tag":"tuberculosis"},{"start":67,"end":79,"tag":"twitterchat"},{"start":82,"end":89,"tag":"tbchat"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180608953145765888","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"180365968869040128"}]},{"text":"We confirm positive benefit-risk balance of #Protelos/Osseor, but recommend new contraindications and revised warnings\nhttp://t.co/lKycyqmg","id":"180597541933559808","created_at":"2012-03-16T10:13:03.000Z","entities":{"urls":[{"start":119,"end":139,"url":"http://t.co/lKycyqmg","expanded_url":"http://bit.ly/FPdukm","display_url":"bit.ly/FPdukm"}],"annotations":{},"mentions":{},"hashtags":[{"start":44,"end":53,"tag":"Protelos"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"180597541933559808","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've recommend transfer of manufacturing sites for #Caelyx and #Ceplene http://t.co/jt9E8oCR","id":"180597312731623424","created_at":"2012-03-16T10:12:09.000Z","entities":{"urls":[{"start":73,"end":93,"url":"http://t.co/jt9E8oCR","expanded_url":"http://bit.ly/Ay3IQi","display_url":"bit.ly/Ay3IQi"}],"annotations":{},"mentions":{},"hashtags":[{"start":52,"end":59,"tag":"Caelyx"},{"start":64,"end":72,"tag":"Ceplene"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"180597312731623424","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Novartis has withdrawn its applications for an extension of the indication for #Exelon and #Prometax (#rivastigmine): http://t.co/144FVVvf","id":"180341758121619456","created_at":"2012-03-15T17:16:40.000Z","entities":{"urls":[{"start":118,"end":138,"url":"http://t.co/144FVVvf","expanded_url":"http://bit.ly/yH5l8Z","display_url":"bit.ly/yH5l8Z"}],"annotations":[{"start":0,"end":7,"probability":0.7522,"type":"Organization","normalized_text":"Novartis"}],"mentions":{},"hashtags":[{"start":79,"end":86,"tag":"Exelon"},{"start":91,"end":100,"tag":"Prometax"},{"start":102,"end":115,"tag":"rivastigmine"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180341758121619456","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Today we launched a public consultation on #HIV pre-exposure prophylaxis (PrEP): http://t.co/ouL4UoJU","id":"180307946863984640","created_at":"2012-03-15T15:02:19.000Z","entities":{"urls":[{"start":81,"end":101,"url":"http://t.co/ouL4UoJU","expanded_url":"http://bit.ly/yMjgwm","display_url":"bit.ly/yMjgwm"}],"annotations":{},"mentions":{},"hashtags":[{"start":43,"end":47,"tag":"HIV"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180307946863984640","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've launched a consultation on guidance on developing medicines to prevent #HIV transmission: http://t.co/ouL4UoJU","id":"180262835069272065","created_at":"2012-03-15T12:03:03.000Z","entities":{"urls":[{"start":96,"end":116,"url":"http://t.co/ouL4UoJU","expanded_url":"http://bit.ly/yMjgwm","display_url":"bit.ly/yMjgwm"}],"annotations":{},"mentions":{},"hashtags":[{"start":77,"end":81,"tag":"HIV"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180262835069272065","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @WHO_Europe: This year’s World Health Day is all about #activeageing. What can we do to stay fit for a long and satisfying life? Find ...","id":"180213713570234368","created_at":"2012-03-15T08:47:52.000Z","entities":{"urls":{},"annotations":[{"start":28,"end":43,"probability":0.8482,"type":"Other","normalized_text":"World Health Day"}],"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":58,"end":71,"tag":"activeageing"}]},"public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"180213713570234368","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"180209642683633664"}]},{"text":"RT @WHO: Read Dr Margaret Chan’s full keynote address on antimicrobial resistance here http://t.co/mcRBs55y #AMR #antibiotic","id":"179998509813084161","created_at":"2012-03-14T18:32:43.000Z","entities":{"urls":[{"start":87,"end":107,"url":"http://t.co/mcRBs55y","expanded_url":"http://bit.ly/ykNXpg","display_url":"bit.ly/ykNXpg"}],"annotations":[{"start":14,"end":29,"probability":0.9331,"type":"Person","normalized_text":"Dr Margaret Chan"}],"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":[{"start":108,"end":112,"tag":"AMR"},{"start":113,"end":124,"tag":"antibiotic"}]},"public_metrics":{"retweet_count":57,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179998509813084161","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179998345199230976"}]},{"text":"Most #advanced_therapies are developed by academics, charities and SMEs; we need to continue being proactive: http://t.co/5x8TqtzM","id":"179977407070085120","created_at":"2012-03-14T17:08:52.000Z","entities":{"urls":[{"start":110,"end":130,"url":"http://t.co/5x8TqtzM","expanded_url":"http://bit.ly/zpHfSl","display_url":"bit.ly/zpHfSl"}],"annotations":{},"mentions":{},"hashtags":[{"start":5,"end":24,"tag":"advanced_therapies"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179977407070085120","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @ECDC_EU: ECDC’s activities to fight #antimicrobial resistance: #surveillance data collection http://t.co/m3m1dqjK and #EAAD http://t ...","id":"179968870461874176","created_at":"2012-03-14T16:34:57.000Z","entities":{"urls":[{"start":97,"end":117,"url":"http://t.co/m3m1dqjK","expanded_url":"http://bit.ly/y4J7hY","display_url":"bit.ly/y4J7hY"}],"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":40,"end":54,"tag":"antimicrobial"},{"start":67,"end":80,"tag":"surveillance"},{"start":122,"end":127,"tag":"EAAD"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179968870461874176","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179968686864596992"}]},{"text":"RT @EFSA_EU: #EFSA and @ECDC_EU report says high proportion of #Campylobacter is resistant to a critically important #antimicrobial http ...","id":"179954627834429441","created_at":"2012-03-14T15:38:21.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"},{"start":23,"end":31,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":18,"tag":"EFSA"},{"start":63,"end":77,"tag":"Campylobacter"},{"start":117,"end":131,"tag":"antimicrobial"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179954627834429441","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179954486155034625"}]},{"text":"RT @ECDC_EU: Concerning high #antimicrobial resistance of #Campylobacter, most frequent cause of zoonoses in humans in EU: http://t.co/W ...","id":"179953465907351553","created_at":"2012-03-14T15:33:44.000Z","entities":{"urls":{},"annotations":[{"start":119,"end":120,"probability":0.5958,"type":"Place","normalized_text":"EU"}],"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":29,"end":43,"tag":"antimicrobial"},{"start":58,"end":72,"tag":"Campylobacter"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179953465907351553","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179952186367807488"}]},{"text":"RT @ECDC_EU: #Zoonotic bacteria resistant to #antimicrobials can be transmitted from animals to food and humans, compromising treatment  ...","id":"179939185480843266","created_at":"2012-03-14T14:36:59.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":22,"tag":"Zoonotic"},{"start":45,"end":60,"tag":"antimicrobials"}]},"public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179939185480843266","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179936060715962369"}]},{"text":"RT @EUinNL: Epidemiological update: #Schmallenberg #virus in the #EU, 13 March 2012 http://t.co/L95P6DgM #ECDC #cattle #sheep #goats #EC","id":"179915510442508290","created_at":"2012-03-14T13:02:55.000Z","entities":{"urls":[{"start":84,"end":104,"url":"http://t.co/L95P6DgM","expanded_url":"http://tinyurl.com/74zga5m","display_url":"tinyurl.com/74zga5m"}],"annotations":{},"mentions":[{"start":3,"end":10,"username":"EUinNL","id":"42368462"}],"hashtags":[{"start":36,"end":50,"tag":"Schmallenberg"},{"start":51,"end":57,"tag":"virus"},{"start":65,"end":68,"tag":"EU"},{"start":105,"end":110,"tag":"ECDC"},{"start":111,"end":118,"tag":"cattle"},{"start":119,"end":125,"tag":"sheep"},{"start":126,"end":132,"tag":"goats"},{"start":133,"end":136,"tag":"EC"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179915510442508290","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179913891244027905"}]},{"text":"RT @EFSA_EU: #EFSA and @ECDC_EU just published a report on #antimicrobial resistance in #zoonotic bacteria in the EU http://t.co/dTVKMgpK","id":"179892656019738624","created_at":"2012-03-14T11:32:06.000Z","entities":{"urls":[{"start":117,"end":137,"url":"http://t.co/dTVKMgpK","expanded_url":"http://www.efsa.europa.eu/en/press/news/120314.htm","display_url":"efsa.europa.eu/en/press/news/…"}],"annotations":{},"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"},{"start":23,"end":31,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":18,"tag":"EFSA"},{"start":59,"end":73,"tag":"antimicrobial"},{"start":88,"end":97,"tag":"zoonotic"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179892656019738624","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179892436854771712"}]},{"text":"RT @ECDC_EU: ECDC and @EFSA_EU publish joint annual report on #antimicrobial resistance in #zoonotic bacteria for 2010 in EU, http://t.c ...","id":"179886679023300608","created_at":"2012-03-14T11:08:21.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":22,"end":30,"username":"EFSA_EU","id":"84582815"}],"hashtags":[{"start":62,"end":76,"tag":"antimicrobial"},{"start":91,"end":100,"tag":"zoonotic"}]},"public_metrics":{"retweet_count":10,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179886679023300608","source":"TweetDeck","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"179886433140609024"}]},{"text":"We've published a paper showing that most #advanced_therapies are developed by academics, charities and SMEs: http://t.co/5x8TqtzM","id":"179871250720624640","created_at":"2012-03-14T10:07:02.000Z","entities":{"urls":[{"start":110,"end":130,"url":"http://t.co/5x8TqtzM","expanded_url":"http://bit.ly/zpHfSl","display_url":"bit.ly/zpHfSl"}],"annotations":{},"mentions":{},"hashtags":[{"start":42,"end":61,"tag":"advanced_therapies"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"179871250720624640","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"We've published a paper calling for continued support for development of advanced therapies: http://t.co/5x8TqtzM","id":"179593955338502146","created_at":"2012-03-13T15:45:10.000Z","entities":{"urls":[{"start":93,"end":113,"url":"http://t.co/5x8TqtzM","expanded_url":"http://bit.ly/zpHfSl","display_url":"bit.ly/zpHfSl"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179593955338502146","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Alkermes Pharma Ireland Limited withdraws its marketing authorisation application for #Megestrol #Alkermes (megestrol) http://t.co/9lbfXR0y","id":"179530359208288256","created_at":"2012-03-13T11:32:27.000Z","entities":{"urls":[{"start":119,"end":139,"url":"http://t.co/9lbfXR0y","expanded_url":"http://bit.ly/y2Atct","display_url":"bit.ly/y2Atct"}],"annotations":[{"start":0,"end":30,"probability":0.4447,"type":"Organization","normalized_text":"Alkermes Pharma Ireland Limited"}],"mentions":{},"hashtags":[{"start":86,"end":96,"tag":"Megestrol"},{"start":97,"end":106,"tag":"Alkermes"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179530359208288256","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Survey launched for veterinarians on prescribing habits for #antimicrobials   http://t.co/TFPxBM5M","id":"179510103198810112","created_at":"2012-03-13T10:11:58.000Z","entities":{"urls":[{"start":78,"end":98,"url":"http://t.co/TFPxBM5M","expanded_url":"http://bit.ly/yoBwuT","display_url":"bit.ly/yoBwuT"}],"annotations":{},"mentions":{},"hashtags":[{"start":60,"end":75,"tag":"antimicrobials"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179510103198810112","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches electronic application form pilot: http://t.co/s94yWsEM","id":"179132081073430528","created_at":"2012-03-12T09:09:50.000Z","entities":{"urls":[{"start":70,"end":90,"url":"http://t.co/s94yWsEM","expanded_url":"http://bit.ly/Ao20lp","display_url":"bit.ly/Ao20lp"}],"annotations":[{"start":0,"end":24,"probability":0.7436,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"179132081073430528","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Advanced Therapies re-elects Christian Schneider as chair: http://t.co/3Ge5KnoM","id":"178083886822203392","created_at":"2012-03-09T11:44:41.000Z","entities":{"urls":[{"start":73,"end":93,"url":"http://t.co/3Ge5KnoM","expanded_url":"http://bit.ly/AcWRIe","display_url":"bit.ly/AcWRIe"}],"annotations":[{"start":43,"end":61,"probability":0.9686,"type":"Person","normalized_text":"Christian Schneider"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"178083886822203392","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"World #Kidney Day: 8 March 2012: http://t.co/y3iZjK7a","id":"177441308242231296","created_at":"2012-03-07T17:11:19.000Z","entities":{"urls":[{"start":33,"end":53,"url":"http://t.co/y3iZjK7a","expanded_url":"http://bit.ly/zxO0cP","display_url":"bit.ly/zxO0cP"}],"annotations":{},"mentions":{},"hashtags":[{"start":6,"end":13,"tag":"Kidney"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"177441308242231296","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"International collaboration on good manufacturing practice #inspections expanded: http://t.co/xOowHEi3","id":"177095044426235904","created_at":"2012-03-06T18:15:23.000Z","entities":{"urls":[{"start":82,"end":102,"url":"http://t.co/xOowHEi3","expanded_url":"http://bit.ly/Azod5Y","display_url":"bit.ly/Azod5Y"}],"annotations":{},"mentions":{},"hashtags":[{"start":59,"end":71,"tag":"inspections"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"177095044426235904","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA publishes updated set of mandatory Article 57(2) requirements for marketing authorisation holders\nhttp://t.co/QyJ0ODyj","id":"176625998413045760","created_at":"2012-03-05T11:11:34.000Z","entities":{"urls":[{"start":102,"end":122,"url":"http://t.co/QyJ0ODyj","expanded_url":"http://bit.ly/yhD5gz","display_url":"bit.ly/yhD5gz"}],"annotations":[{"start":0,"end":2,"probability":0.6496,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"176625998413045760","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"@drug_czar Just published an hour ago. Technical problems but we managed to keep to our 1 March promise. Thanks","id":"175336211462881282","created_at":"2012-03-01T21:46:25.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":0,"end":10,"username":"drug_czar","id":"267894360"}],"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":1,"like_count":0,"quote_count":0},"conversation_id":"175253761432879104","source":"Twitter for iPad","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"replied_to","id":"175253761432879104"}],"in_reply_to_user_id":"267894360"},{"text":"European Medicines Agency publishes list of human medicines under evaluation: http://t.co/0OYeyn6i","id":"175303436332576768","created_at":"2012-03-01T19:36:10.000Z","entities":{"urls":[{"start":78,"end":98,"url":"http://t.co/0OYeyn6i","expanded_url":"http://bit.ly/yxrEXG","display_url":"bit.ly/yxrEXG"}],"annotations":[{"start":0,"end":24,"probability":0.62,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":9,"reply_count":0,"like_count":3,"quote_count":0},"conversation_id":"175303436332576768","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches call for expression of interest from healthcare professional organisations: http://t.co/1q2REWWG","id":"174895610959364096","created_at":"2012-02-29T16:35:37.000Z","entities":{"urls":[{"start":111,"end":131,"url":"http://t.co/1q2REWWG","expanded_url":"http://bit.ly/zuVn7T","display_url":"bit.ly/zuVn7T"}],"annotations":[{"start":0,"end":24,"probability":0.8635,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":1,"like_count":0,"quote_count":0},"conversation_id":"174895610959364096","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"@HelliumAtom Sorry we can't help with funding, patents or links with industry. Have a look at our FAQs for more info http://t.co/B4aTi02t","id":"174807648632442881","created_at":"2012-02-29T10:46:05.000Z","entities":{"urls":[{"start":117,"end":137,"url":"http://t.co/B4aTi02t","expanded_url":"http://bit.ly/wVTVnz","display_url":"bit.ly/wVTVnz"}],"annotations":{},"mentions":[{"start":0,"end":12,"username":"HelliumAtom","id":"246889415"}],"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170745729416036353","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"replied_to","id":"170745729416036353"}],"in_reply_to_user_id":"246889415"},{"text":"@Margaritus The EMA doesn't evaluate all medicines in Europe. Some info here http://t.co/bOwFePb7. Contact your national agency for more.","id":"174807063896141826","created_at":"2012-02-29T10:43:46.000Z","entities":{"urls":[{"start":77,"end":97,"url":"http://t.co/bOwFePb7","expanded_url":"http://bit.ly/zk5cr7","display_url":"bit.ly/zk5cr7"}],"annotations":[{"start":54,"end":59,"probability":0.9921,"type":"Place","normalized_text":"Europe"}],"mentions":[{"start":0,"end":11,"username":"Margaritus","id":"31437646"}],"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"174527363307151360","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"replied_to","id":"174527363307151360"}],"in_reply_to_user_id":"31437646"},{"text":"European Medicines Agency increases public information on conflicts of interest of experts and management: http://t.co/kaCIDbzj","id":"174793405761720320","created_at":"2012-02-29T09:49:30.000Z","entities":{"urls":[{"start":107,"end":127,"url":"http://t.co/kaCIDbzj","expanded_url":"http://bit.ly/wSP7cR","display_url":"bit.ly/wSP7cR"}],"annotations":[{"start":0,"end":24,"probability":0.6502,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"174793405761720320","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Rare Disease Day: 29 February 2012: http://t.co/ePP4FN6S","id":"174532696914132992","created_at":"2012-02-28T16:33:32.000Z","entities":{"urls":[{"start":36,"end":56,"url":"http://t.co/ePP4FN6S","expanded_url":"http://bit.ly/yuHBc6","display_url":"bit.ly/yuHBc6"}],"annotations":[{"start":0,"end":15,"probability":0.3858,"type":"Other","normalized_text":"Rare Disease Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":13,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"174532696914132992","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency website intermittently offline 25-26 February 2012: http://t.co/RTdVLy6h","id":"172718410080337921","created_at":"2012-02-23T16:24:12.000Z","entities":{"urls":[{"start":78,"end":98,"url":"http://t.co/RTdVLy6h","expanded_url":"http://bit.ly/wvylvW","display_url":"bit.ly/wvylvW"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"172718410080337921","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency releases good #pharmacovigilance practice modules for public consultation: http://t.co/wiCcR5ws","id":"172300899945938944","created_at":"2012-02-22T12:45:10.000Z","entities":{"urls":[{"start":101,"end":121,"url":"http://t.co/wiCcR5ws","expanded_url":"http://bit.ly/wPt5W1","display_url":"bit.ly/wPt5W1"}],"annotations":[{"start":0,"end":24,"probability":0.7346,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":40,"end":58,"tag":"pharmacovigilance"}]},"public_metrics":{"retweet_count":7,"reply_count":1,"like_count":2,"quote_count":0},"conversation_id":"172300899945938944","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Information on transitional arrangements for #pharmacovigilance legislation published\nhttp://t.co/xH0ypbA4","id":"171917423967084544","created_at":"2012-02-21T11:21:22.000Z","entities":{"urls":[{"start":86,"end":106,"url":"http://t.co/xH0ypbA4","expanded_url":"http://bit.ly/ymfiL6","display_url":"bit.ly/ymfiL6"}],"annotations":{},"mentions":{},"hashtags":[{"start":45,"end":63,"tag":"pharmacovigilance"}]},"public_metrics":{"retweet_count":10,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"171917423967084544","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency focuses on new legislation in 2012 work programme: http://t.co/x1nqwD3B","id":"171605611082022912","created_at":"2012-02-20T14:42:20.000Z","entities":{"urls":[{"start":77,"end":97,"url":"http://t.co/x1nqwD3B","expanded_url":"http://bit.ly/zFfCBJ","display_url":"bit.ly/zFfCBJ"}],"annotations":[{"start":0,"end":24,"probability":0.818,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":22,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"171605611082022912","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency to publish information on ongoing medicine evaluations: http://t.co/yS4o57Gy","id":"170526655343890433","created_at":"2012-02-17T15:14:57.000Z","entities":{"urls":[{"start":82,"end":102,"url":"http://t.co/yS4o57Gy","expanded_url":"http://bit.ly/AbWhD7","display_url":"bit.ly/AbWhD7"}],"annotations":[{"start":0,"end":24,"probability":0.6496,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"170526655343890433","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Adjusted fees for applications to European Medicines Agency from 1 April 2012: http://t.co/wM1Sk1K0","id":"170512201550004228","created_at":"2012-02-17T14:17:31.000Z","entities":{"urls":[{"start":79,"end":99,"url":"http://t.co/wM1Sk1K0","expanded_url":"http://bit.ly/zXa0FJ","display_url":"bit.ly/zXa0FJ"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170512201550004228","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Human Medicinal Products (#CHMP) 13-16 February 2012 \nhttp://t.co/SLPXo515","id":"170481947888467968","created_at":"2012-02-17T12:17:18.000Z","entities":{"urls":[{"start":96,"end":116,"url":"http://t.co/SLPXo515","expanded_url":"http://bit.ly/xyx3N1","display_url":"bit.ly/xyx3N1"}],"annotations":[{"start":42,"end":65,"probability":0.3425,"type":"Organization","normalized_text":"Human Medicinal Products"}],"mentions":{},"hashtags":[{"start":68,"end":73,"tag":"CHMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170481947888467968","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends approval of #Pixuvri (#pixantrone) for relapsed or refractory aggressive non-Hodgkin’s B-cell #lymphoma\nhttp://t.co/PaTWGTfM","id":"170478203775885312","created_at":"2012-02-17T12:02:25.000Z","entities":{"urls":[{"start":119,"end":139,"url":"http://t.co/PaTWGTfM","expanded_url":"http://bit.ly/w9HQBi","display_url":"bit.ly/w9HQBi"}],"annotations":{},"mentions":{},"hashtags":[{"start":27,"end":35,"tag":"Pixuvri"},{"start":37,"end":48,"tag":"pixantrone"},{"start":109,"end":118,"tag":"lymphoma"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170478203775885312","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends new anti-#malaria treatment for use outside the European Union\nhttp://t.co/jF13mNOt","id":"170477866260246528","created_at":"2012-02-17T12:01:05.000Z","entities":{"urls":[{"start":100,"end":120,"url":"http://t.co/jF13mNOt","expanded_url":"http://bit.ly/xlfc4p","display_url":"bit.ly/xlfc4p"}],"annotations":[{"start":0,"end":24,"probability":0.5464,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":46,"end":54,"tag":"malaria"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170477866260246528","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends lifting suspension of #aprotinin (#antifibrinolytic medicine)  http://t.co/9j5uqp5l","id":"170455661216407552","created_at":"2012-02-17T10:32:51.000Z","entities":{"urls":[{"start":78,"end":98,"url":"http://t.co/9j5uqp5l","expanded_url":"http://bit.ly/z0wcwp","display_url":"bit.ly/z0wcwp"}],"annotations":[{"start":0,"end":2,"probability":0.3465,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":[{"start":37,"end":47,"tag":"aprotinin"},{"start":49,"end":66,"tag":"antifibrinolytic"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170455661216407552","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency concludes review of dose recommendations for anti-#tuberculosis medicines used in children http://t.co/2rexuXGO","id":"170454845482995714","created_at":"2012-02-17T10:29:36.000Z","entities":{"urls":[{"start":117,"end":137,"url":"http://t.co/2rexuXGO","expanded_url":"http://bit.ly/z3pMIB","display_url":"bit.ly/z3pMIB"}],"annotations":[{"start":0,"end":24,"probability":0.663,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":76,"end":89,"tag":"tuberculosis"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170454845482995714","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends new contraindications and warnings for #aliskiren-containing medicines\nhttp://t.co/Z0wZLSvW","id":"170454545229553664","created_at":"2012-02-17T10:28:25.000Z","entities":{"urls":[{"start":108,"end":128,"url":"http://t.co/Z0wZLSvW","expanded_url":"http://bit.ly/wBSbcr","display_url":"bit.ly/wBSbcr"}],"annotations":[{"start":0,"end":24,"probability":0.5043,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":76,"end":86,"tag":"aliskiren"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170454545229553664","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA informs doctors & patients about drug interaction between #Victrelis and ritonavir-boosted HIV protease inhibitors http://t.co/iYIMOa5O","id":"170179228829093894","created_at":"2012-02-16T16:14:24.000Z","entities":{"urls":[{"start":119,"end":139,"url":"http://t.co/iYIMOa5O","expanded_url":"http://bit.ly/ygWrCU","display_url":"bit.ly/ygWrCU"}],"annotations":{},"mentions":{},"hashtags":[{"start":62,"end":72,"tag":"Victrelis"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170179228829093894","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Agency gives final recommendations for 12 centrally authorised medicines manufactured at #Ben_Venue Laboratories\nhttp://t.co/JPlknraP","id":"170178953238159360","created_at":"2012-02-16T16:13:18.000Z","entities":{"urls":[{"start":113,"end":133,"url":"http://t.co/JPlknraP","expanded_url":"http://bit.ly/z2Vqx2","display_url":"bit.ly/z2Vqx2"}],"annotations":{},"mentions":{},"hashtags":[{"start":89,"end":99,"tag":"Ben_Venue"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170178953238159360","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency confirms positive benefit-risk balance of #orlistat-containing medicines \nhttp://t.co/8I39AuWp","id":"170178408549060609","created_at":"2012-02-16T16:11:09.000Z","entities":{"urls":[{"start":100,"end":120,"url":"http://t.co/8I39AuWp","expanded_url":"http://bit.ly/Ap0JV2","display_url":"bit.ly/Ap0JV2"}],"annotations":[{"start":0,"end":24,"probability":0.7535,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":68,"end":77,"tag":"orlistat"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"170178408549060609","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Novartis withdraws application for paediatric-use marketing authorisation for #Fluad Paediatric (#influenza_vaccine) http://t.co/OObcGqgB","id":"170149218122604544","created_at":"2012-02-16T14:15:09.000Z","entities":{"urls":[{"start":117,"end":137,"url":"http://t.co/OObcGqgB","expanded_url":"http://bit.ly/xR1M3v","display_url":"bit.ly/xR1M3v"}],"annotations":[{"start":0,"end":7,"probability":0.7778,"type":"Organization","normalized_text":"Novartis"}],"mentions":{},"hashtags":[{"start":78,"end":84,"tag":"Fluad"},{"start":97,"end":115,"tag":"influenza_vaccine"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170149218122604544","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"GSK withdraws its application for an extension of the indication for #Tyverb (#lapatinib)  \nhttp://t.co/3G4yxHWx","id":"170148477295267843","created_at":"2012-02-16T14:12:12.000Z","entities":{"urls":[{"start":92,"end":112,"url":"http://t.co/3G4yxHWx","expanded_url":"http://bit.ly/zMkjeu","display_url":"bit.ly/zMkjeu"}],"annotations":[{"start":0,"end":2,"probability":0.8328,"type":"Organization","normalized_text":"GSK"}],"mentions":{},"hashtags":[{"start":69,"end":76,"tag":"Tyverb"},{"start":78,"end":88,"tag":"lapatinib"}]},"public_metrics":{"retweet_count":2,"reply_count":1,"like_count":0,"quote_count":0},"conversation_id":"170148477295267843","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"The Agency welcomes new Head of Information and Communications Technology  \nhttp://t.co/E8uW0VXR","id":"170101153432993792","created_at":"2012-02-16T11:04:09.000Z","entities":{"urls":[{"start":76,"end":96,"url":"http://t.co/E8uW0VXR","expanded_url":"http://bit.ly/xYfCjq","display_url":"bit.ly/xYfCjq"}],"annotations":[{"start":0,"end":9,"probability":0.6594,"type":"Organization","normalized_text":"The Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"170101153432993792","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency and European Commission extend confidentiality arrangement with Japan: http://t.co/9eOHXypd","id":"169444312445227008","created_at":"2012-02-14T15:34:06.000Z","entities":{"urls":[{"start":97,"end":117,"url":"http://t.co/9eOHXypd","expanded_url":"http://bit.ly/wQXA8Q","display_url":"bit.ly/wQXA8Q"}],"annotations":[{"start":0,"end":24,"probability":0.4579,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":90,"end":94,"probability":0.8359,"type":"Place","normalized_text":"Japan"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"169444312445227008","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"#CVMP meeting highlights from February 2012 plenary http://t.co/0qw9UvV7","id":"168005946646331392","created_at":"2012-02-10T16:18:33.000Z","entities":{"urls":[{"start":52,"end":72,"url":"http://t.co/0qw9UvV7","expanded_url":"http://bit.ly/yEgZaT","display_url":"bit.ly/yEgZaT"}],"annotations":{},"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"CVMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"168005946646331392","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency publishes guideline on use of #pharmacogenetics in evaluating #pharmacokinetics of medicines: http://t.co/BvTwBe3f","id":"167980366374780930","created_at":"2012-02-10T14:36:54.000Z","entities":{"urls":[{"start":120,"end":140,"url":"http://t.co/BvTwBe3f","expanded_url":"http://bit.ly/AqXjpK","display_url":"bit.ly/AqXjpK"}],"annotations":[{"start":0,"end":24,"probability":0.6359,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":56,"end":73,"tag":"pharmacogenetics"},{"start":88,"end":105,"tag":"pharmacokinetics"}]},"public_metrics":{"retweet_count":8,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"167980366374780930","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"World #Cancer Day: 4 February 2012: http://t.co/mcdk79av","id":"165454235855626241","created_at":"2012-02-03T15:18:58.000Z","entities":{"urls":[{"start":36,"end":56,"url":"http://t.co/mcdk79av","expanded_url":"http://bit.ly/x3jKx4","display_url":"bit.ly/x3jKx4"}],"annotations":{},"mentions":{},"hashtags":[{"start":6,"end":13,"tag":"Cancer"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"165454235855626241","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Better protection of public health: EMA counts down to introduction of new pharmacovigilance legislation\nhttp://t.co/r04Drjwl","id":"165008028909830145","created_at":"2012-02-02T09:45:54.000Z","entities":{"urls":[{"start":105,"end":125,"url":"http://t.co/r04Drjwl","expanded_url":"http://bit.ly/A5raR7","display_url":"bit.ly/A5raR7"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":13,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"165008028909830145","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"RT @EU_Commission: Health : #EC announces winners of the 3rd EU Prize for Journalists  http://t.co/OGLJWbYI","id":"164706382023634945","created_at":"2012-02-01T13:47:16.000Z","entities":{"urls":[{"start":87,"end":107,"url":"http://t.co/OGLJWbYI","expanded_url":"http://bit.ly/wJRp9L","display_url":"bit.ly/wJRp9L"}],"annotations":{},"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":28,"end":31,"tag":"EC"}]},"public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"164706382023634945","source":"Twitter for iPad","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"retweeted","id":"164669518839431168"}]},{"text":"European Medicines Agency and European Food Safety Authority commit to greater co-operation: http://t.co/UDxH9iVW","id":"162945686944489472","created_at":"2012-01-27T17:10:53.000Z","entities":{"urls":[{"start":93,"end":113,"url":"http://t.co/UDxH9iVW","expanded_url":"http://bit.ly/woGMet","display_url":"bit.ly/woGMet"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"162945686944489472","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Public consultation open on concept paper on #pharmacogenomics in evaluation of authorised medicines: http://t.co/HFJulUyu","id":"161487273496555522","created_at":"2012-01-23T16:35:40.000Z","entities":{"urls":[{"start":102,"end":122,"url":"http://t.co/HFJulUyu","expanded_url":"http://bit.ly/w6HKXM","display_url":"bit.ly/w6HKXM"}],"annotations":{},"mentions":{},"hashtags":[{"start":45,"end":62,"tag":"pharmacogenomics"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"161487273496555522","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends approval of new medicine for #Cushing’s disease\nhttp://t.co/LCL7SZtu","id":"160333290522423296","created_at":"2012-01-20T12:10:09.000Z","entities":{"urls":[{"start":85,"end":105,"url":"http://t.co/LCL7SZtu","expanded_url":"http://bit.ly/yL1DQR","display_url":"bit.ly/yL1DQR"}],"annotations":[{"start":0,"end":24,"probability":0.603,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":66,"end":74,"tag":"Cushing"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"160333290522423296","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends suspension of marketing authorisations for #meprobamate-containing medicines in the EU   http://t.co/E7oNGdzt","id":"160333149182758912","created_at":"2012-01-20T12:09:36.000Z","entities":{"urls":[{"start":104,"end":124,"url":"http://t.co/E7oNGdzt","expanded_url":"http://bit.ly/zqWl0c","display_url":"bit.ly/zqWl0c"}],"annotations":[{"start":0,"end":2,"probability":0.5315,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":[{"start":58,"end":70,"tag":"meprobamate"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"160333149182758912","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the #CHMP 16-19 January 2012\nhttp://t.co/8A4QEZc3","id":"160332854159613952","created_at":"2012-01-20T12:08:25.000Z","entities":{"urls":[{"start":53,"end":73,"url":"http://t.co/8A4QEZc3","expanded_url":"http://bit.ly/yUxFTj","display_url":"bit.ly/yUxFTj"}],"annotations":{},"mentions":{},"hashtags":[{"start":28,"end":33,"tag":"CHMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"160332854159613952","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency releases guideline on #biosimilar #interferon beta for public consultation: http://t.co/r1JMHGHx","id":"160315766024056832","created_at":"2012-01-20T11:00:31.000Z","entities":{"urls":[{"start":102,"end":122,"url":"http://t.co/r1JMHGHx","expanded_url":"http://bit.ly/whjo2e","display_url":"bit.ly/whjo2e"}],"annotations":[{"start":0,"end":24,"probability":0.5601,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":48,"end":59,"tag":"biosimilar"},{"start":60,"end":71,"tag":"interferon"}]},"public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"160315766024056832","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency starts review of #Gilenya (#fingolimod)  http://t.co/1mKLrgNY","id":"160300078244970496","created_at":"2012-01-20T09:58:11.000Z","entities":{"urls":[{"start":67,"end":87,"url":"http://t.co/1mKLrgNY","expanded_url":"http://bit.ly/yLUQj4","display_url":"bit.ly/yLUQj4"}],"annotations":[{"start":0,"end":24,"probability":0.4342,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":43,"end":51,"tag":"Gilenya"},{"start":53,"end":64,"tag":"fingolimod"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"160300078244970496","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Orphan Medicinal Products (COMP) January 2012 highlights: http://t.co/5L4stUFp","id":"158941002009292800","created_at":"2012-01-16T15:57:42.000Z","entities":{"urls":[{"start":72,"end":92,"url":"http://t.co/5L4stUFp","expanded_url":"http://bit.ly/Aj69i4","display_url":"bit.ly/Aj69i4"}],"annotations":[{"start":14,"end":38,"probability":0.222,"type":"Organization","normalized_text":"Orphan Medicinal Products"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"158941002009292800","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 January 2012: http://t.co/OszXp75K","id":"158870690899042304","created_at":"2012-01-16T11:18:19.000Z","entities":{"urls":[{"start":90,"end":110,"url":"http://t.co/OszXp75K","expanded_url":"http://bit.ly/zp105Q","display_url":"bit.ly/zp105Q"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"158870690899042304","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Public consultation opens on the revised guideline on the evaluation of human #anticancer medicines: http://t.co/nRnGNOUi","id":"157035906598051840","created_at":"2012-01-11T09:47:32.000Z","entities":{"urls":[{"start":101,"end":121,"url":"http://t.co/nRnGNOUi","expanded_url":"http://bit.ly/xYgqVC","display_url":"bit.ly/xYgqVC"}],"annotations":{},"mentions":{},"hashtags":[{"start":78,"end":89,"tag":"anticancer"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"157035906598051840","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA starts review of #aliskiren-containing medicines following termination of ALTITUDE study  http://t.co/qwYpAESt","id":"149883060685516801","created_at":"2011-12-22T16:04:41.000Z","entities":{"urls":[{"start":94,"end":114,"url":"http://t.co/qwYpAESt","expanded_url":"http://bit.ly/saCKBa","display_url":"bit.ly/saCKBa"}],"annotations":{},"mentions":{},"hashtags":[{"start":21,"end":31,"tag":"aliskiren"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"149883060685516801","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"New measures to facilitate conduct of #ENCePP studies  \nhttp://t.co/RXfRUqrL","id":"149782153205530624","created_at":"2011-12-22T09:23:42.000Z","entities":{"urls":[{"start":56,"end":76,"url":"http://t.co/RXfRUqrL","expanded_url":"http://bit.ly/snDjCx","display_url":"bit.ly/snDjCx"}],"annotations":{},"mentions":{},"hashtags":[{"start":38,"end":45,"tag":"ENCePP"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"149782153205530624","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee on #Herbal Medicinal Products approves four-year work programme   http://t.co/8BDpIFoJ","id":"149774653336989696","created_at":"2011-12-22T08:53:54.000Z","entities":{"urls":[{"start":76,"end":96,"url":"http://t.co/8BDpIFoJ","expanded_url":"http://bit.ly/tlWe2n","display_url":"bit.ly/tlWe2n"}],"annotations":{},"mentions":{},"hashtags":[{"start":13,"end":20,"tag":"Herbal"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"149774653336989696","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency formalises interaction with #healthcare professionals: http://t.co/VRenSoN2","id":"148798706228015106","created_at":"2011-12-19T16:15:50.000Z","entities":{"urls":[{"start":81,"end":101,"url":"http://t.co/VRenSoN2","expanded_url":"http://bit.ly/vrWaFt","display_url":"bit.ly/vrWaFt"}],"annotations":{},"mentions":{},"hashtags":[{"start":54,"end":65,"tag":"healthcare"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"148798706228015106","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency issues revised guidance on #genotoxicity testing of medicines: http://t.co/CzdDHtP4","id":"148795396074901504","created_at":"2011-12-19T16:02:41.000Z","entities":{"urls":[{"start":89,"end":109,"url":"http://t.co/CzdDHtP4","expanded_url":"http://bit.ly/u1Hvnk","display_url":"bit.ly/u1Hvnk"}],"annotations":[{"start":0,"end":24,"probability":0.5305,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":53,"end":66,"tag":"genotoxicity"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"148795396074901504","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency closed 23 December 2011 to 2 January 2012: http://t.co/UNOIhred","id":"148753377961054208","created_at":"2011-12-19T13:15:43.000Z","entities":{"urls":[{"start":69,"end":89,"url":"http://t.co/UNOIhred","expanded_url":"http://bit.ly/rypuAQ","display_url":"bit.ly/rypuAQ"}],"annotations":[{"start":0,"end":24,"probability":0.6773,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"148753377961054208","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA Management Board approves work programme 2012. Focus on implementing new pharmacovigilance legislation. http://t.co/PTZKwp2L","id":"147691902790139904","created_at":"2011-12-16T14:57:48.000Z","entities":{"urls":[{"start":108,"end":128,"url":"http://t.co/PTZKwp2L","expanded_url":"http://bit.ly/scniNW","display_url":"bit.ly/scniNW"}],"annotations":[{"start":0,"end":19,"probability":0.9199,"type":"Organization","normalized_text":"EMA Management Board"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"147691902790139904","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends authorisation of #Vimpat syrup for patients who cannot swallow tablets: http://t.co/kESZ8cxS","id":"147650620466282497","created_at":"2011-12-16T12:13:45.000Z","entities":{"urls":[{"start":109,"end":129,"url":"http://t.co/kESZ8cxS","expanded_url":"http://bit.ly/tTdvXq","display_url":"bit.ly/tTdvXq"}],"annotations":{},"mentions":{},"hashtags":[{"start":54,"end":61,"tag":"Vimpat"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"147650620466282497","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends approval of first-in-class treatment for metastatic or unresectable melanoma (#Zelboraf)\nhttp://t.co/lfZolX83","id":"147650078381842434","created_at":"2011-12-16T12:11:36.000Z","entities":{"urls":[{"start":104,"end":124,"url":"http://t.co/lfZolX83","expanded_url":"http://bit.ly/tGdZXg","display_url":"bit.ly/tGdZXg"}],"annotations":{},"mentions":{},"hashtags":[{"start":93,"end":102,"tag":"Zelboraf"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"147650078381842434","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (#CHMP) 12-15 December 2011 \nhttp://t.co/OijSI1h4","id":"147649753222623232","created_at":"2011-12-16T12:10:19.000Z","entities":{"urls":[{"start":104,"end":124,"url":"http://t.co/OijSI1h4","expanded_url":"http://bit.ly/ryglLo","display_url":"bit.ly/ryglLo"}],"annotations":{},"mentions":{},"hashtags":[{"start":76,"end":81,"tag":"CHMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"147649753222623232","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency to continue to involve #patients in #scientific discussions on human #medicines: http://t.co/pqBVhcvf","id":"147363470541725696","created_at":"2011-12-15T17:12:43.000Z","entities":{"urls":[{"start":107,"end":127,"url":"http://t.co/pqBVhcvf","expanded_url":"http://bit.ly/vO8wIk","display_url":"bit.ly/vO8wIk"}],"annotations":[{"start":0,"end":24,"probability":0.4675,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":49,"end":58,"tag":"patients"},{"start":62,"end":73,"tag":"scientific"},{"start":95,"end":105,"tag":"medicines"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"147363470541725696","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"General Court upholds European Medicines Agency decision to refuse #paediatric waiver for #perflubutane: http://t.co/I1KbetpX","id":"147335205663936513","created_at":"2011-12-15T15:20:25.000Z","entities":{"urls":[{"start":105,"end":125,"url":"http://t.co/I1KbetpX","expanded_url":"http://bit.ly/vBJvpS","display_url":"bit.ly/vBJvpS"}],"annotations":[{"start":0,"end":12,"probability":0.5554,"type":"Organization","normalized_text":"General Court"},{"start":22,"end":46,"probability":0.5574,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":67,"end":78,"tag":"paediatric"},{"start":90,"end":103,"tag":"perflubutane"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"147335205663936513","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Orphan Medicinal Products (COMP) December highlights: http://t.co/Q7zotUnM","id":"146655051061002241","created_at":"2011-12-13T18:17:43.000Z","entities":{"urls":[{"start":68,"end":88,"url":"http://t.co/Q7zotUnM","expanded_url":"http://bit.ly/vRa8qB","display_url":"bit.ly/vRa8qB"}],"annotations":[{"start":14,"end":38,"probability":0.2263,"type":"Organization","normalized_text":"Orphan Medicinal Products"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"146655051061002241","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories http://t.co/PZkmIEgr","id":"146621090301624321","created_at":"2011-12-13T16:02:46.000Z","entities":{"urls":[{"start":105,"end":125,"url":"http://t.co/PZkmIEgr","expanded_url":"http://bit.ly/uSHWO1","display_url":"bit.ly/uSHWO1"}],"annotations":[{"start":0,"end":2,"probability":0.4853,"type":"Organization","normalized_text":"EMA"},{"start":58,"end":64,"probability":0.3575,"type":"Place","normalized_text":"Vistide"},{"start":82,"end":103,"probability":0.612,"type":"Place","normalized_text":"Ben Venue Laboratories"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"146621090301624321","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 December 2011: http://t.co/5frlD3D9","id":"145188449203388416","created_at":"2011-12-09T17:09:58.000Z","entities":{"urls":[{"start":89,"end":109,"url":"http://t.co/5frlD3D9","expanded_url":"http://bit.ly/vF2aJj","display_url":"bit.ly/vF2aJj"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"145188449203388416","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories http://t.co/pZFUWO3W","id":"145171500780101632","created_at":"2011-12-09T16:02:37.000Z","entities":{"urls":[{"start":118,"end":138,"url":"http://t.co/pZFUWO3W","expanded_url":"http://bit.ly/t1CA7g","display_url":"bit.ly/t1CA7g"}],"annotations":[{"start":0,"end":2,"probability":0.4482,"type":"Organization","normalized_text":"EMA"},{"start":95,"end":116,"probability":0.7885,"type":"Organization","normalized_text":"Ben Venue Laboratories"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"145171500780101632","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency and United States Food and Drug Administration to share manufacturing site #inspections: http://t.co/GRj7OAuQ","id":"145140964825108481","created_at":"2011-12-09T14:01:17.000Z","entities":{"urls":[{"start":115,"end":135,"url":"http://t.co/GRj7OAuQ","expanded_url":"http://bit.ly/rKCWIF","display_url":"bit.ly/rKCWIF"}],"annotations":[{"start":0,"end":24,"probability":0.6295,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":30,"end":42,"probability":0.2773,"type":"Place","normalized_text":"United States"}],"mentions":{},"hashtags":[{"start":101,"end":113,"tag":"inspections"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"145140964825108481","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Experts and regulators discuss role of modelling and simulation in medicine development and regulatory assessment: http://t.co/GDqPs1h8","id":"144386908938711041","created_at":"2011-12-07T12:04:56.000Z","entities":{"urls":[{"start":115,"end":135,"url":"http://t.co/GDqPs1h8","expanded_url":"http://bit.ly/v7EPPj","display_url":"bit.ly/v7EPPj"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"144386908938711041","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Fees for type IA variations to be due at start of procedure: http://t.co/1WVc16jg","id":"142589790079033345","created_at":"2011-12-02T13:03:49.000Z","entities":{"urls":[{"start":61,"end":81,"url":"http://t.co/1WVc16jg","expanded_url":"http://bit.ly/tS8DHg","display_url":"bit.ly/tS8DHg"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"142589790079033345","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency hosts workshop on #ethics in #paediatric clinical trials: http://t.co/nsLwSWjS","id":"142572589838114816","created_at":"2011-12-02T11:55:28.000Z","entities":{"urls":[{"start":84,"end":104,"url":"http://t.co/nsLwSWjS","expanded_url":"http://bit.ly/tUS6ib","display_url":"bit.ly/tUS6ib"}],"annotations":[{"start":0,"end":24,"probability":0.4027,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":44,"end":51,"tag":"ethics"},{"start":55,"end":66,"tag":"paediatric"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"142572589838114816","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Registration open for Committee for Advanced Therapies stakeholders workshop: http://t.co/Ua20uIGY","id":"141929409820102656","created_at":"2011-11-30T17:19:42.000Z","entities":{"urls":[{"start":78,"end":98,"url":"http://t.co/Ua20uIGY","expanded_url":"http://bit.ly/tTdu2i","display_url":"bit.ly/tTdu2i"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"141929409820102656","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"World #AIDS Day: 1 December 2011: http://t.co/r0TWQLNr","id":"141920330871619584","created_at":"2011-11-30T16:43:38.000Z","entities":{"urls":[{"start":34,"end":54,"url":"http://t.co/r0TWQLNr","expanded_url":"http://bit.ly/vyevnp","display_url":"bit.ly/vyevnp"}],"annotations":{},"mentions":{},"hashtags":[{"start":6,"end":11,"tag":"AIDS"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"141920330871619584","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency hosts first workshop on subgroup analysis\nhttp://t.co/o0XLiwXI","id":"139739941205835776","created_at":"2011-11-24T16:19:32.000Z","entities":{"urls":[{"start":68,"end":88,"url":"http://t.co/o0XLiwXI","expanded_url":"http://bit.ly/v3JVaB","display_url":"bit.ly/v3JVaB"}],"annotations":[{"start":0,"end":24,"probability":0.7215,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"139739941205835776","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency invites registrations for eSubmission Gateway: http://t.co/LMPhS3wh","id":"139291805836517376","created_at":"2011-11-23T10:38:49.000Z","entities":{"urls":[{"start":73,"end":93,"url":"http://t.co/LMPhS3wh","expanded_url":"http://bit.ly/vzKv4w","display_url":"bit.ly/vzKv4w"}],"annotations":[{"start":0,"end":24,"probability":0.7792,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"139291805836517376","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA gives interim recommendations to deal with shortcomings in quality assurance at #Ben_Venue_Laboratories http://t.co/iioSwGor","id":"139012925024256000","created_at":"2011-11-22T16:10:38.000Z","entities":{"urls":[{"start":108,"end":128,"url":"http://t.co/iioSwGor","expanded_url":"http://bit.ly/sLzVet","display_url":"bit.ly/sLzVet"}],"annotations":[{"start":0,"end":2,"probability":0.5715,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":[{"start":84,"end":107,"tag":"Ben_Venue_Laboratories"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"139012925024256000","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Andreas Pott appointed Deputy Executive Director of European Medicines Agency: http://t.co/m401E6m2","id":"137560398558793729","created_at":"2011-11-18T15:58:49.000Z","entities":{"urls":[{"start":79,"end":99,"url":"http://t.co/m401E6m2","expanded_url":"http://bit.ly/uDWZKr","display_url":"bit.ly/uDWZKr"}],"annotations":[{"start":0,"end":11,"probability":0.9324,"type":"Person","normalized_text":"Andreas Pott"},{"start":52,"end":76,"probability":0.3241,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"137560398558793729","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from November 2001 #CHMP meeting http://t.co/whTpEfdJ","id":"137502546414665728","created_at":"2011-11-18T12:08:56.000Z","entities":{"urls":[{"start":52,"end":72,"url":"http://t.co/whTpEfdJ","expanded_url":"http://bit.ly/tUkQEf","display_url":"bit.ly/tUkQEf"}],"annotations":{},"mentions":{},"hashtags":[{"start":38,"end":43,"tag":"CHMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"137502546414665728","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency confirms positive benefit-risk balance of #pholcodine-containing cough medicines  http://t.co/SyqZAFF6","id":"137473283758100480","created_at":"2011-11-18T10:12:39.000Z","entities":{"urls":[{"start":108,"end":128,"url":"http://t.co/SyqZAFF6","expanded_url":"http://bit.ly/s8CN0G","display_url":"bit.ly/s8CN0G"}],"annotations":[{"start":0,"end":24,"probability":0.7931,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":68,"end":79,"tag":"pholcodine"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"137473283758100480","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency updates on safety of #Pradaxa  http://t.co/2sTwpzWl","id":"137472614150057984","created_at":"2011-11-18T10:09:59.000Z","entities":{"urls":[{"start":57,"end":77,"url":"http://t.co/2sTwpzWl","expanded_url":"http://bit.ly/rBi9Ap","display_url":"bit.ly/rBi9Ap"}],"annotations":[{"start":0,"end":24,"probability":0.6212,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":47,"end":55,"tag":"Pradaxa"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"137472614150057984","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends suspension of all #buflomedil-containing medicines\n http://t.co/r78RhCvW","id":"137198532049387520","created_at":"2011-11-17T16:00:53.000Z","entities":{"urls":[{"start":89,"end":109,"url":"http://t.co/r78RhCvW","expanded_url":"http://bit.ly/s4bZzp","display_url":"bit.ly/s4bZzp"}],"annotations":[{"start":0,"end":24,"probability":0.5728,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":55,"end":66,"tag":"buflomedil"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"137198532049387520","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European #Antibiotic Awareness Day: 18 November 2011: http://t.co/muXc4SC0","id":"137144907864342528","created_at":"2011-11-17T12:27:48.000Z","entities":{"urls":[{"start":54,"end":74,"url":"http://t.co/muXc4SC0","expanded_url":"http://bit.ly/tIdifh","display_url":"bit.ly/tIdifh"}],"annotations":{},"mentions":{},"hashtags":[{"start":9,"end":20,"tag":"Antibiotic"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"137144907864342528","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency welcomes new Head of Finance and Budget: http://t.co/QM0ymQ8c","id":"137137760996835328","created_at":"2011-11-17T11:59:24.000Z","entities":{"urls":[{"start":67,"end":87,"url":"http://t.co/QM0ymQ8c","expanded_url":"http://bit.ly/rPyC0r","display_url":"bit.ly/rPyC0r"}],"annotations":[{"start":0,"end":24,"probability":0.8682,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"137137760996835328","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Guido #Rasi begins as new head of European Medicines Agency   http://t.co/KrIQKjeo","id":"136843793864466433","created_at":"2011-11-16T16:31:17.000Z","entities":{"urls":[{"start":62,"end":82,"url":"http://t.co/KrIQKjeo","expanded_url":"http://bit.ly/sAChzT","display_url":"bit.ly/sAChzT"}],"annotations":[{"start":0,"end":4,"probability":0.9038,"type":"Person","normalized_text":"Guido"},{"start":34,"end":58,"probability":0.6949,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":6,"end":11,"tag":"Rasi"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"136843793864466433","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Dyax s.a. withdraws its marketing authorisation application for #Kalbitor (ecallantide)   http://t.co/YGitGS9M","id":"136368433108488192","created_at":"2011-11-15T09:02:22.000Z","entities":{"urls":[{"start":90,"end":110,"url":"http://t.co/YGitGS9M","expanded_url":"http://bit.ly/uhV6Ip","display_url":"bit.ly/uhV6Ip"}],"annotations":{},"mentions":{},"hashtags":[{"start":64,"end":73,"tag":"Kalbitor"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"136368433108488192","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Merck Sharp & Dohme (Europe), Inc. withdraws marketing authorisation application for #Janacti and related trade names http://t.co/wx3eW9HQ","id":"136030379952967680","created_at":"2011-11-14T10:39:04.000Z","entities":{"urls":[{"start":118,"end":138,"url":"http://t.co/wx3eW9HQ","expanded_url":"http://bit.ly/sIBDg1","display_url":"bit.ly/sIBDg1"}],"annotations":[{"start":0,"end":18,"probability":0.1558,"type":"Organization","normalized_text":"Merck Sharp & Dohme"},{"start":21,"end":26,"probability":0.471,"type":"Place","normalized_text":"Europe"}],"mentions":{},"hashtags":[{"start":85,"end":93,"tag":"Janacti"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"136030379952967680","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"#CVMP meeting highlights from 8-10 November 2011\nhttp://t.co/Oe3qGq0v","id":"136029356811223040","created_at":"2011-11-14T10:35:00.000Z","entities":{"urls":[{"start":49,"end":69,"url":"http://t.co/Oe3qGq0v","expanded_url":"http://bit.ly/uWGfCn","display_url":"bit.ly/uWGfCn"}],"annotations":{},"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"CVMP"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"136029356811223040","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"World Diabetes Day: 14 November 2011: http://t.co/MEzvdcS7","id":"134984938356350976","created_at":"2011-11-11T13:24:51.000Z","entities":{"urls":[{"start":38,"end":58,"url":"http://t.co/MEzvdcS7","expanded_url":"http://bit.ly/uFG1re","display_url":"bit.ly/uFG1re"}],"annotations":[{"start":0,"end":17,"probability":0.7007,"type":"Other","normalized_text":"World Diabetes Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"134984938356350976","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European and international experts discuss the way forward in developing #ophthalmology medicines\n http://t.co/Np1thT19","id":"132429569411129344","created_at":"2011-11-04T12:10:44.000Z","entities":{"urls":[{"start":99,"end":119,"url":"http://t.co/Np1thT19","expanded_url":"http://bit.ly/teiQQN","display_url":"bit.ly/teiQQN"}],"annotations":{},"mentions":{},"hashtags":[{"start":73,"end":87,"tag":"ophthalmology"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"132429569411129344","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency meetings to be held offsite during 2012 #Olympics: http://t.co/1fvi2Cci","id":"132396079298789376","created_at":"2011-11-04T09:57:39.000Z","entities":{"urls":[{"start":77,"end":97,"url":"http://t.co/1fvi2Cci","expanded_url":"http://bit.ly/urxw2Y","display_url":"bit.ly/urxw2Y"}],"annotations":[{"start":0,"end":24,"probability":0.5468,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":66,"end":75,"tag":"Olympics"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"132396079298789376","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Expressions of interest invited for workshop on medicines for older people: http://t.co/48kKLwyU","id":"132055656965480448","created_at":"2011-11-03T11:24:56.000Z","entities":{"urls":[{"start":76,"end":96,"url":"http://t.co/48kKLwyU","expanded_url":"http://bit.ly/sEKBK5","display_url":"bit.ly/sEKBK5"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"132055656965480448","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency simplifies SME assignment process: http://t.co/GyXbyhu5","id":"129929497884631041","created_at":"2011-10-28T14:36:20.000Z","entities":{"urls":[{"start":61,"end":81,"url":"http://t.co/GyXbyhu5","expanded_url":"http://bit.ly/soWhdI","display_url":"bit.ly/soWhdI"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"129929497884631041","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Assessment templates updated to include information on geriatric studies and new active substance claims: http://t.co/70k55el4","id":"129924369915973633","created_at":"2011-10-28T14:15:58.000Z","entities":{"urls":[{"start":106,"end":126,"url":"http://t.co/70k55el4","expanded_url":"http://bit.ly/uKq52p","display_url":"bit.ly/uKq52p"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"129924369915973633","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency closed 31 October to 2 November 2011   \nhttp://t.co/xJn4djr5","id":"129554444043038720","created_at":"2011-10-27T13:46:01.000Z","entities":{"urls":[{"start":66,"end":86,"url":"http://t.co/xJn4djr5","expanded_url":"http://bit.ly/uWYW1F","display_url":"bit.ly/uWYW1F"}],"annotations":[{"start":0,"end":24,"probability":0.7265,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"129554444043038720","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency reiterates support for staff member   http://t.co/jF9TinHd","id":"129151683581313024","created_at":"2011-10-26T11:05:35.000Z","entities":{"urls":[{"start":64,"end":84,"url":"http://t.co/jF9TinHd","expanded_url":"http://bit.ly/vqaDIm","display_url":"bit.ly/vqaDIm"}],"annotations":[{"start":0,"end":24,"probability":0.7863,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"129151683581313024","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency's 2009 budget approved: http://t.co/RQQZedaf","id":"128847902608080896","created_at":"2011-10-25T14:58:28.000Z","entities":{"urls":[{"start":50,"end":70,"url":"http://t.co/RQQZedaf","expanded_url":"http://bit.ly/urz9t2","display_url":"bit.ly/urz9t2"}],"annotations":[{"start":0,"end":24,"probability":0.4416,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"128847902608080896","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"#Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy   http://t.co/hsFk6JVe","id":"128803614817923072","created_at":"2011-10-25T12:02:29.000Z","entities":{"urls":[{"start":81,"end":101,"url":"http://t.co/hsFk6JVe","expanded_url":"http://bit.ly/t0ZZhq","display_url":"bit.ly/t0ZZhq"}],"annotations":{},"mentions":{},"hashtags":[{"start":0,"end":7,"tag":"Xigris"}]},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"128803614817923072","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the October 2011 #CHMP plenary http://t.co/y7mwgaR4","id":"127339930593665024","created_at":"2011-10-21T11:06:19.000Z","entities":{"urls":[{"start":55,"end":75,"url":"http://t.co/y7mwgaR4","expanded_url":"http://bit.ly/oy5u1d","display_url":"bit.ly/oy5u1d"}],"annotations":{},"mentions":{},"hashtags":[{"start":41,"end":46,"tag":"CHMP"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"127339930593665024","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency clarifies opinion on #pioglitazone and the risk of bladder cancer\n http://t.co/h3MlTHac","id":"127313554943651840","created_at":"2011-10-21T09:21:31.000Z","entities":{"urls":[{"start":93,"end":113,"url":"http://t.co/h3MlTHac","expanded_url":"http://bit.ly/nQiJcb","display_url":"bit.ly/nQiJcb"}],"annotations":{},"mentions":{},"hashtags":[{"start":47,"end":60,"tag":"pioglitazone"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"127313554943651840","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency starts new review of cardiovascular risks of non-selective #NSAIDs\nhttp://t.co/4EGydsDB","id":"127313372822777856","created_at":"2011-10-21T09:20:48.000Z","entities":{"urls":[{"start":93,"end":113,"url":"http://t.co/4EGydsDB","expanded_url":"http://bit.ly/pA7cGW","display_url":"bit.ly/pA7cGW"}],"annotations":[{"start":0,"end":24,"probability":0.6416,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":85,"end":92,"tag":"NSAIDs"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"127313372822777856","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA concludes that benefit-risk balance of #angiotensin II receptor antagonists remains positive: http://t.co/i1lqUSgm","id":"127075479722278912","created_at":"2011-10-20T17:35:29.000Z","entities":{"urls":[{"start":98,"end":118,"url":"http://t.co/i1lqUSgm","expanded_url":"http://bit.ly/oaBgdM","display_url":"bit.ly/oaBgdM"}],"annotations":{},"mentions":{},"hashtags":[{"start":43,"end":55,"tag":"angiotensin"}]},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"127075479722278912","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency agrees to precautionary recall of #Advagraf 0.5 mg capsule batches: http://t.co/zgAuA3Ig","id":"127075181997993984","created_at":"2011-10-20T17:34:18.000Z","entities":{"urls":[{"start":94,"end":114,"url":"http://t.co/zgAuA3Ig","expanded_url":"http://bit.ly/qqPGDZ","display_url":"bit.ly/qqPGDZ"}],"annotations":[{"start":0,"end":24,"probability":0.6856,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":60,"end":69,"tag":"Advagraf"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"127075181997993984","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency starts review of #Protelos / #Osseor: http://t.co/QiBR1tIp","id":"127074612801585152","created_at":"2011-10-20T17:32:03.000Z","entities":{"urls":[{"start":64,"end":84,"url":"http://t.co/QiBR1tIp","expanded_url":"http://bit.ly/oOItVB","display_url":"bit.ly/oOItVB"}],"annotations":[{"start":0,"end":24,"probability":0.4705,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":43,"end":52,"tag":"Protelos"},{"start":55,"end":62,"tag":"Osseor"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"127074612801585152","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Krka, d.d., Novo mesto withdraws its marketing authorisation application for #Desloratadine Krka (desloratadine)   http://t.co/sLfKjNMN","id":"126597795527397376","created_at":"2011-10-19T09:57:21.000Z","entities":{"urls":[{"start":115,"end":135,"url":"http://t.co/sLfKjNMN","expanded_url":"http://bit.ly/q2ajco","display_url":"bit.ly/q2ajco"}],"annotations":{},"mentions":{},"hashtags":[{"start":77,"end":91,"tag":"Desloratadine"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"126597795527397376","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Lux Biosciences GmbH withdraws its marketing authorisation application for #Luveniq (#voclosporin) \nhttp://t.co/YW2kUxA5","id":"126225292325961729","created_at":"2011-10-18T09:17:09.000Z","entities":{"urls":[{"start":100,"end":120,"url":"http://t.co/YW2kUxA5","expanded_url":"http://bit.ly/qRN68W","display_url":"bit.ly/qRN68W"}],"annotations":[{"start":0,"end":19,"probability":0.7179,"type":"Organization","normalized_text":"Lux Biosciences GmbH"}],"mentions":{},"hashtags":[{"start":75,"end":83,"tag":"Luveniq"},{"start":85,"end":97,"tag":"voclosporin"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"126225292325961729","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from October 2011 #CVMP plenary http://t.co/3QYi3mPy","id":"125904798590578688","created_at":"2011-10-17T12:03:37.000Z","entities":{"urls":[{"start":51,"end":71,"url":"http://t.co/3QYi3mPy","expanded_url":"http://bit.ly/q501fr","display_url":"bit.ly/q501fr"}],"annotations":{},"mentions":{},"hashtags":[{"start":37,"end":42,"tag":"CVMP"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"125904798590578688","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA releases qualification opinion on diagnosis of pre-dementia #Alzheimer's for public consultation: http://t.co/t5RTkPw4","id":"124137192581902336","created_at":"2011-10-12T14:59:47.000Z","entities":{"urls":[{"start":102,"end":122,"url":"http://t.co/t5RTkPw4","expanded_url":"http://bit.ly/q17sy3","display_url":"bit.ly/q17sy3"}],"annotations":[{"start":0,"end":2,"probability":0.5193,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":[{"start":64,"end":74,"tag":"Alzheimer"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"124137192581902336","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"World Arthritis Day: 12 October 2011: http://t.co/i2MWeoau","id":"123799312600793089","created_at":"2011-10-11T16:37:10.000Z","entities":{"urls":[{"start":38,"end":58,"url":"http://t.co/i2MWeoau","expanded_url":"http://bit.ly/oycqsD","display_url":"bit.ly/oycqsD"}],"annotations":[{"start":0,"end":18,"probability":0.6703,"type":"Other","normalized_text":"World Arthritis Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"123799312600793089","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches database of clinical studies in children completed before 2007: http://t.co/ZOjiBVXY","id":"123710587178979328","created_at":"2011-10-11T10:44:37.000Z","entities":{"urls":[{"start":99,"end":119,"url":"http://t.co/ZOjiBVXY","expanded_url":"http://bit.ly/rbsXcj","display_url":"bit.ly/rbsXcj"}],"annotations":[{"start":0,"end":24,"probability":0.81,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"123710587178979328","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Agency's Management Board officially appoints Guido Rasi as new Executive Director   http://t.co/UASrHdoX","id":"122302969134850049","created_at":"2011-10-07T13:31:14.000Z","entities":{"urls":[{"start":85,"end":105,"url":"http://t.co/UASrHdoX","expanded_url":"http://bit.ly/pwINcH","display_url":"bit.ly/pwINcH"}],"annotations":[{"start":46,"end":55,"probability":0.9747,"type":"Person","normalized_text":"Guido Rasi"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"122302969134850049","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA invites feedback on plans to revise existing #guidelines on #biosimilar medicines and #influenza #vaccines: http://t.co/DdasnPVo","id":"120885475627110400","created_at":"2011-10-03T15:38:37.000Z","entities":{"urls":[{"start":112,"end":132,"url":"http://t.co/DdasnPVo","expanded_url":"http://bit.ly/r50kGS","display_url":"bit.ly/r50kGS"}],"annotations":[{"start":0,"end":2,"probability":0.6106,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":[{"start":49,"end":60,"tag":"guidelines"},{"start":64,"end":75,"tag":"biosimilar"},{"start":90,"end":100,"tag":"influenza"},{"start":101,"end":110,"tag":"vaccines"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"120885475627110400","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Expressions of interest invited for membership of European Medicines Agency committees and Management Board: http://t.co/hlBrhGw8","id":"120820963192479744","created_at":"2011-10-03T11:22:17.000Z","entities":{"urls":[{"start":109,"end":129,"url":"http://t.co/hlBrhGw8","expanded_url":"http://bit.ly/mTd2UK","display_url":"bit.ly/mTd2UK"}],"annotations":[{"start":50,"end":74,"probability":0.5238,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"120820963192479744","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European SME Week: 3-9 October 2011: http://t.co/qY4Yc15I","id":"120783689083920384","created_at":"2011-10-03T08:54:10.000Z","entities":{"urls":[{"start":37,"end":57,"url":"http://t.co/qY4Yc15I","expanded_url":"http://bit.ly/ogbrKP","display_url":"bit.ly/ogbrKP"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"120783689083920384","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches new database of European experts: http://t.co/wAeepgIm","id":"119732660502409217","created_at":"2011-09-30T11:17:45.000Z","entities":{"urls":[{"start":69,"end":89,"url":"http://t.co/wAeepgIm","expanded_url":"http://bit.ly/nGPUkh","display_url":"bit.ly/nGPUkh"}],"annotations":[{"start":0,"end":24,"probability":0.8503,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"119732660502409217","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"World Heart Day: 29 September 2011: http://t.co/CzrqDKbW","id":"119111380409384960","created_at":"2011-09-28T18:09:00.000Z","entities":{"urls":[{"start":36,"end":56,"url":"http://t.co/CzrqDKbW","expanded_url":"http://bit.ly/qaCX6J","display_url":"bit.ly/qaCX6J"}],"annotations":[{"start":0,"end":14,"probability":0.6883,"type":"Other","normalized_text":"World Heart Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"119111380409384960","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency replies to concerns of Sane Vax Inc.: http://t.co/q0Hmtd7f","id":"117208918689714177","created_at":"2011-09-23T12:09:18.000Z","entities":{"urls":[{"start":64,"end":84,"url":"http://t.co/q0Hmtd7f","expanded_url":"http://bit.ly/qH4buI","display_url":"bit.ly/qH4buI"}],"annotations":[{"start":0,"end":24,"probability":0.4835,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":49,"end":61,"probability":0.8523,"type":"Organization","normalized_text":"Sane Vax Inc."}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"117208918689714177","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends authorisation of novel #antibiotic agent: http://t.co/9AfyK4On","id":"117196863672827905","created_at":"2011-09-23T11:21:24.000Z","entities":{"urls":[{"start":79,"end":99,"url":"http://t.co/9AfyK4On","expanded_url":"http://bit.ly/n3GfhZ","display_url":"bit.ly/n3GfhZ"}],"annotations":{},"mentions":{},"hashtags":[{"start":60,"end":71,"tag":"antibiotic"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"117196863672827905","source":"Twitter Web Client","lang":"fr","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 September 2011: http://t.co/Mi5yqMLN","id":"117194862385840128","created_at":"2011-09-23T11:13:27.000Z","entities":{"urls":[{"start":104,"end":124,"url":"http://t.co/Mi5yqMLN","expanded_url":"http://bit.ly/nVy5Xb","display_url":"bit.ly/nVy5Xb"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"117194862385840128","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends contraindications for suppositories containing #terpenic derivatives: http://t.co/hCloaCSZ","id":"117164948215435264","created_at":"2011-09-23T09:14:35.000Z","entities":{"urls":[{"start":107,"end":127,"url":"http://t.co/hCloaCSZ","expanded_url":"http://bit.ly/opnxWD","display_url":"bit.ly/opnxWD"}],"annotations":[{"start":0,"end":24,"probability":0.4796,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":84,"end":93,"tag":"terpenic"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"117164948215435264","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency concludes that benefit-risk balance of #Revlimid remains positive: http://t.co/rwMr6jZe","id":"117164467116195841","created_at":"2011-09-23T09:12:40.000Z","entities":{"urls":[{"start":93,"end":113,"url":"http://t.co/rwMr6jZe","expanded_url":"http://bit.ly/npCdvJ","display_url":"bit.ly/npCdvJ"}],"annotations":[{"start":0,"end":24,"probability":0.6715,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":65,"end":74,"tag":"Revlimid"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"117164467116195841","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency finalises review of #Baxter's #dialysis solutions: http://t.co/jEDagDYA","id":"117164217785778176","created_at":"2011-09-23T09:11:40.000Z","entities":{"urls":[{"start":77,"end":97,"url":"http://t.co/jEDagDYA","expanded_url":"http://bit.ly/r5yMJ9","display_url":"bit.ly/r5yMJ9"}],"annotations":{},"mentions":{},"hashtags":[{"start":46,"end":53,"tag":"Baxter"},{"start":56,"end":65,"tag":"dialysis"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"117164217785778176","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency website unavailable 23-25 September 2011: http://t.co/XX70mMOV","id":"117141255816871936","created_at":"2011-09-23T07:40:26.000Z","entities":{"urls":[{"start":68,"end":88,"url":"http://t.co/XX70mMOV","expanded_url":"http://bit.ly/nJ8snx","display_url":"bit.ly/nJ8snx"}],"annotations":[{"start":0,"end":24,"probability":0.5053,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"117141255816871936","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends discontinuation of #Vimpat 15mg/ml syrup: http://t.co/HY0KpcFh","id":"116894632058699776","created_at":"2011-09-22T15:20:26.000Z","entities":{"urls":[{"start":79,"end":99,"url":"http://t.co/HY0KpcFh","expanded_url":"http://bit.ly/pIbJ0H","display_url":"bit.ly/pIbJ0H"}],"annotations":{},"mentions":{},"hashtags":[{"start":56,"end":63,"tag":"Vimpat"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"116894632058699776","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency starts review of #orlistat-containing medicines\n: http://t.co/6QYyNNPB","id":"116894320375758848","created_at":"2011-09-22T15:19:12.000Z","entities":{"urls":[{"start":76,"end":96,"url":"http://t.co/6QYyNNPB","expanded_url":"http://bit.ly/pACTrO","display_url":"bit.ly/pACTrO"}],"annotations":[{"start":0,"end":24,"probability":0.47,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":43,"end":52,"tag":"orlistat"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"116894320375758848","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends restricting use of #Multaq\n: http://t.co/YcLB22Gw","id":"116892263971426304","created_at":"2011-09-22T15:11:02.000Z","entities":{"urls":[{"start":66,"end":86,"url":"http://t.co/YcLB22Gw","expanded_url":"http://bit.ly/refQr1","display_url":"bit.ly/refQr1"}],"annotations":[{"start":0,"end":24,"probability":0.633,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":56,"end":63,"tag":"Multaq"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"116892263971426304","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"The European Medicines Agency supports World Alzheimer's Day: 21 September 2011: http://t.co/yh8MEUkZ","id":"116170285895532544","created_at":"2011-09-20T15:22:09.000Z","entities":{"urls":[{"start":81,"end":101,"url":"http://t.co/yh8MEUkZ","expanded_url":"http://bit.ly/nfljIK","display_url":"bit.ly/nfljIK"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"116170285895532544","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency publishes first report on sales of veterinary antimicrobial agents: http://t.co/y7g4G8Gf","id":"115729442126565376","created_at":"2011-09-19T10:10:23.000Z","entities":{"urls":[{"start":94,"end":114,"url":"http://t.co/y7g4G8Gf","expanded_url":"http://bit.ly/qN6kNM","display_url":"bit.ly/qN6kNM"}],"annotations":[{"start":0,"end":24,"probability":0.6647,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"115729442126565376","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 13-15 September 2011: http://t.co/T06mZpSD","id":"114704232204075008","created_at":"2011-09-16T14:16:34.000Z","entities":{"urls":[{"start":92,"end":112,"url":"http://t.co/T06mZpSD","expanded_url":"http://bit.ly/p9Xxhg","display_url":"bit.ly/p9Xxhg"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"114704232204075008","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EU #Clinical #Trials Register recognised as 'primary registry' of #WHO International Clinical Trials Registry Platform: http://t.co/LZHIxx2","id":"113960991162777601","created_at":"2011-09-14T13:03:12.000Z","entities":{"urls":[{"start":120,"end":139,"url":"http://t.co/LZHIxx2","expanded_url":"http://bit.ly/qTqhWO","display_url":"bit.ly/qTqhWO"}],"annotations":{},"mentions":{},"hashtags":[{"start":3,"end":12,"tag":"Clinical"},{"start":13,"end":20,"tag":"Trials"},{"start":66,"end":70,"tag":"WHO"}]},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"113960991162777601","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Concept paper on pharmacovigilance implementing measures released for consultation: http://t.co/auJDvYC","id":"111850761939451904","created_at":"2011-09-08T17:17:54.000Z","entities":{"urls":[{"start":84,"end":103,"url":"http://t.co/auJDvYC","expanded_url":"http://bit.ly/n8WODJ","display_url":"bit.ly/n8WODJ"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"111850761939451904","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"CHMP meets to discuss #Multaq: http://t.co/bBJSBUG","id":"109634946464874496","created_at":"2011-09-02T14:33:02.000Z","entities":{"urls":[{"start":31,"end":50,"url":"http://t.co/bBJSBUG","expanded_url":"http://bit.ly/o2A07G","display_url":"bit.ly/o2A07G"}],"annotations":{},"mentions":{},"hashtags":[{"start":22,"end":29,"tag":"Multaq"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"109634946464874496","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency provides update on electronic submission of information on medicines: http://t.co/xxOBawD","id":"109331251802025984","created_at":"2011-09-01T18:26:16.000Z","entities":{"urls":[{"start":96,"end":115,"url":"http://t.co/xxOBawD","expanded_url":"http://bit.ly/pNNFGp","display_url":"bit.ly/pNNFGp"}],"annotations":[{"start":0,"end":24,"probability":0.7479,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"109331251802025984","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"CHMP meeting to discuss #Multaq on Friday 2 September: http://t.co/9EGk3cz","id":"109210301882310656","created_at":"2011-09-01T10:25:39.000Z","entities":{"urls":[{"start":55,"end":74,"url":"http://t.co/9EGk3cz","expanded_url":"http://bit.ly/pbfVGe","display_url":"bit.ly/pbfVGe"}],"annotations":{},"mentions":{},"hashtags":[{"start":24,"end":31,"tag":"Multaq"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"109210301882310656","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency closed 29 August 2011: http://t.co/A3LM47M","id":"107018607262842880","created_at":"2011-08-26T09:16:38.000Z","entities":{"urls":[{"start":49,"end":68,"url":"http://t.co/A3LM47M","expanded_url":"http://bit.ly/p0bzp6","display_url":"bit.ly/p0bzp6"}],"annotations":[{"start":0,"end":24,"probability":0.6685,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"107018607262842880","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"New validation criteria for electronic submissions from 1 September 2011: http://t.co/tLIKpKY","id":"104456747363733505","created_at":"2011-08-19T07:36:43.000Z","entities":{"urls":[{"start":74,"end":93,"url":"http://t.co/tLIKpKY","expanded_url":"http://bit.ly/qRYfzj","display_url":"bit.ly/qRYfzj"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"104456747363733505","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency website unavailable Saturday 13 August: http://t.co/cdUipvH","id":"101240841665912833","created_at":"2011-08-10T10:37:52.000Z","entities":{"urls":[{"start":66,"end":85,"url":"http://t.co/cdUipvH","expanded_url":"http://bit.ly/reXiHY","display_url":"bit.ly/reXiHY"}],"annotations":[{"start":0,"end":24,"probability":0.6309,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"101240841665912833","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency signs lease for new office space \nhttp://t.co/HVurUuH","id":"100472916189249536","created_at":"2011-08-08T07:46:24.000Z","entities":{"urls":[{"start":60,"end":79,"url":"http://t.co/HVurUuH","expanded_url":"http://bit.ly/oUBisM","display_url":"bit.ly/oUBisM"}],"annotations":[{"start":0,"end":24,"probability":0.6197,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"100472916189249536","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency and its international partners complete successful inspection pilots   http://t.co/bI0o1ay","id":"98407682880454656","created_at":"2011-08-02T14:59:54.000Z","entities":{"urls":[{"start":97,"end":116,"url":"http://t.co/bI0o1ay","expanded_url":"http://bit.ly/nzEI6o","display_url":"bit.ly/nzEI6o"}],"annotations":[{"start":0,"end":24,"probability":0.6051,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"98407682880454656","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Identifying research priorities for the study of drug-related progressive multifocal leukoencephalopathy (PML)\nhttp://t.co/vTWOeUm","id":"96598081243578370","created_at":"2011-07-28T15:09:11.000Z","entities":{"urls":[{"start":111,"end":130,"url":"http://t.co/vTWOeUm","expanded_url":"http://bit.ly/qwaZvz","display_url":"bit.ly/qwaZvz"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"96598081243578370","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Software development companies invited to express interest in workshop on electronic prescribing: http://t.co/RBg7kWM","id":"96252588034490368","created_at":"2011-07-27T16:16:19.000Z","entities":{"urls":[{"start":98,"end":117,"url":"http://t.co/RBg7kWM","expanded_url":"http://bit.ly/nbhsnd","display_url":"bit.ly/nbhsnd"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"96252588034490368","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Hexal AG withdraws its marketing authorisation application for Ibandronic acid Hexal (ibandronic acid) \nhttp://t.co/zzPz8w4","id":"96161648900976640","created_at":"2011-07-27T10:14:58.000Z","entities":{"urls":[{"start":104,"end":123,"url":"http://t.co/zzPz8w4","expanded_url":"http://bit.ly/p8whrH","display_url":"bit.ly/p8whrH"}],"annotations":[{"start":0,"end":7,"probability":0.3793,"type":"Organization","normalized_text":"Hexal AG"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"96161648900976640","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Expressions of interest invited for workshop on ethics of clinical trials in children: http://t.co/586ciRz","id":"95833733181095936","created_at":"2011-07-26T12:31:57.000Z","entities":{"urls":[{"start":87,"end":106,"url":"http://t.co/586ciRz","expanded_url":"http://bit.ly/oHPWio","display_url":"bit.ly/oHPWio"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"95833733181095936","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA publishes new strategy on combating antimicrobial resistance: http://t.co/r2cF9tv","id":"95504320589598720","created_at":"2011-07-25T14:42:59.000Z","entities":{"urls":[{"start":66,"end":85,"url":"http://t.co/r2cF9tv","expanded_url":"http://bit.ly/nhPHgK","display_url":"bit.ly/nhPHgK"}],"annotations":[{"start":0,"end":2,"probability":0.5729,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"95504320589598720","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency improves package leaflets: http://t.co/LyzNxDH","id":"94460509717409792","created_at":"2011-07-22T17:35:15.000Z","entities":{"urls":[{"start":53,"end":72,"url":"http://t.co/LyzNxDH","expanded_url":"http://bit.ly/mRRwUq","display_url":"bit.ly/mRRwUq"}],"annotations":[{"start":0,"end":24,"probability":0.6485,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"94460509717409792","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the #CHMP 18-21 July 2011 \nhttp://t.co/e3mv4Ow","id":"94394845564633088","created_at":"2011-07-22T13:14:19.000Z","entities":{"urls":[{"start":51,"end":70,"url":"http://t.co/e3mv4Ow","expanded_url":"http://bit.ly/pFUnNF","display_url":"bit.ly/pFUnNF"}],"annotations":{},"mentions":{},"hashtags":[{"start":28,"end":33,"tag":"CHMP"}]},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"94394845564633088","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA agrees to recall of #Vimpat 15-mg/ml syrup/Doctors advised to switch patients to an alternative formulation \nhttp://t.co/lTYGgea","id":"94394478474956801","created_at":"2011-07-22T13:12:52.000Z","entities":{"urls":[{"start":113,"end":132,"url":"http://t.co/lTYGgea","expanded_url":"http://bit.ly/paUzem","display_url":"bit.ly/paUzem"}],"annotations":{},"mentions":{},"hashtags":[{"start":24,"end":31,"tag":"Vimpat"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"94394478474956801","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends restricting use of #Pandemrix\nhttp://t.co/VrcvRzP","id":"94059973541236736","created_at":"2011-07-21T15:03:39.000Z","entities":{"urls":[{"start":67,"end":86,"url":"http://t.co/VrcvRzP","expanded_url":"http://bit.ly/oQyPRt","display_url":"bit.ly/oQyPRt"}],"annotations":[{"start":0,"end":24,"probability":0.6372,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":[{"start":56,"end":66,"tag":"Pandemrix"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"94059973541236736","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends new contra-indications and warnings for #pioglitazone to reduce small increased risk of bladder cancer\nhttp://t.co/4cHTTOh","id":"94059821904560129","created_at":"2011-07-21T15:03:03.000Z","entities":{"urls":[{"start":118,"end":137,"url":"http://t.co/4cHTTOh","expanded_url":"http://bit.ly/pNIWr9","display_url":"bit.ly/pNIWr9"}],"annotations":{},"mentions":{},"hashtags":[{"start":55,"end":68,"tag":"pioglitazone"}]},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"94059821904560129","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA confirms positive benefit-risk balance for #Champix \nhttp://t.co/t5Tppf7","id":"94059505805037568","created_at":"2011-07-21T15:01:48.000Z","entities":{"urls":[{"start":57,"end":76,"url":"http://t.co/t5Tppf7","expanded_url":"http://bit.ly/ogE8mn","display_url":"bit.ly/ogE8mn"}],"annotations":[{"start":0,"end":2,"probability":0.5042,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":[{"start":47,"end":55,"tag":"Champix"}]},"public_metrics":{"retweet_count":1,"reply_count":1,"like_count":0,"quote_count":0},"conversation_id":"94059505805037568","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA updates on ongoing benefit-risk review of #Multaq. \nFurther advice expected in September\nhttp://t.co/I4D6lCQ","id":"94059076257988608","created_at":"2011-07-21T15:00:05.000Z","entities":{"urls":[{"start":93,"end":112,"url":"http://t.co/I4D6lCQ","expanded_url":"http://bit.ly/pb5UAC","display_url":"bit.ly/pb5UAC"}],"annotations":{},"mentions":{},"hashtags":[{"start":46,"end":53,"tag":"Multaq"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"94059076257988608","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Sun Pharmaceutical Industries Europe B.V. withdraws its marketing authorisation aplication for #Doxorubicin SUN\nhttp://t.co/0J94trs","id":"94055604234092544","created_at":"2011-07-21T14:46:18.000Z","entities":{"urls":[{"start":112,"end":131,"url":"http://t.co/0J94trs","expanded_url":"http://bit.ly/nN0tCk","display_url":"bit.ly/nN0tCk"}],"annotations":[{"start":0,"end":40,"probability":0.2771,"type":"Organization","normalized_text":"Sun Pharmaceutical Industries Europe B.V."}],"mentions":{},"hashtags":[{"start":95,"end":107,"tag":"Doxorubicin"}]},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"94055604234092544","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Pfizer Limited withdraws its application for an extension of the indication for #Macugen (pegaptanib sodium)  http://t.co/Xfw50th","id":"93261342957518848","created_at":"2011-07-19T10:10:11.000Z","entities":{"urls":[{"start":110,"end":129,"url":"http://t.co/Xfw50th","expanded_url":"http://bit.ly/o594Et","display_url":"bit.ly/o594Et"}],"annotations":[{"start":0,"end":5,"probability":0.7473,"type":"Organization","normalized_text":"Pfizer"}],"mentions":{},"hashtags":[{"start":80,"end":88,"tag":"Macugen"}]},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"93261342957518848","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Public consultation opens on the revised guideline on good distribution practice of medicinal products for human use\nhttp://t.co/FDKrDxU","id":"92929461753880576","created_at":"2011-07-18T12:11:24.000Z","entities":{"urls":[{"start":117,"end":136,"url":"http://t.co/FDKrDxU","expanded_url":"http://bit.ly/plHCof","display_url":"bit.ly/plHCof"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"92929461753880576","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency responds to criticism of staff member  \nhttp://t.co/Dsm0oHI","id":"91131073395830784","created_at":"2011-07-13T13:05:15.000Z","entities":{"urls":[{"start":66,"end":85,"url":"http://t.co/Dsm0oHI","expanded_url":"http://bit.ly/n7tTMu","display_url":"bit.ly/n7tTMu"}],"annotations":[{"start":0,"end":24,"probability":0.8213,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"91131073395830784","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency seeks views on genomic markers in medicine development\nhttp://t.co/h9GDAVC","id":"90776576328871936","created_at":"2011-07-12T13:36:37.000Z","entities":{"urls":[{"start":81,"end":100,"url":"http://t.co/h9GDAVC","expanded_url":"http://bit.ly/rrmVo3","display_url":"bit.ly/rrmVo3"}],"annotations":[{"start":0,"end":24,"probability":0.6979,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"90776576328871936","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA reviews cardiovascular risk of Multaq - Ongoing benefit-risk assessment broadened\nhttp://t.co/JAnXOJO","id":"90421535743029248","created_at":"2011-07-11T14:05:48.000Z","entities":{"urls":[{"start":86,"end":105,"url":"http://t.co/JAnXOJO","expanded_url":"http://bit.ly/r4lXut","display_url":"bit.ly/r4lXut"}],"annotations":[{"start":0,"end":2,"probability":0.4071,"type":"Organization","normalized_text":"EMA"},{"start":35,"end":40,"probability":0.4161,"type":"Organization","normalized_text":"Multaq"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"90421535743029248","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Registration open for conference on advanced therapies: http://t.co/WXqihDi","id":"89377009146413060","created_at":"2011-07-08T16:55:14.000Z","entities":{"urls":[{"start":56,"end":75,"url":"http://t.co/WXqihDi","expanded_url":"http://bit.ly/p8E4MA","display_url":"bit.ly/p8E4MA"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"89377009146413060","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency plans public access to information on side effects: http://t.co/8Bv0tEI","id":"89348331867873280","created_at":"2011-07-08T15:01:16.000Z","entities":{"urls":[{"start":78,"end":97,"url":"http://t.co/8Bv0tEI","expanded_url":"http://bit.ly/o35sR2","display_url":"bit.ly/o35sR2"}],"annotations":[{"start":0,"end":24,"probability":0.6586,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"89348331867873280","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency invites expressions of interest for ophthalmology workshop: http://t.co/sIh0u66","id":"88665978153615361","created_at":"2011-07-06T17:49:51.000Z","entities":{"urls":[{"start":86,"end":105,"url":"http://t.co/sIh0u66","expanded_url":"http://bit.ly/o5QIWW","display_url":"bit.ly/o5QIWW"}],"annotations":[{"start":0,"end":24,"probability":0.6606,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"88665978153615361","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency welcomes new rules on falsified medicines: http://t.co/r6YKH6o","id":"87850101082570752","created_at":"2011-07-04T11:47:50.000Z","entities":{"urls":[{"start":69,"end":88,"url":"http://t.co/r6YKH6o","expanded_url":"http://bit.ly/iLxqSc","display_url":"bit.ly/iLxqSc"}],"annotations":[{"start":0,"end":24,"probability":0.8889,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"87850101082570752","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency hosts meeting with European Parliament representatives: http://t.co/y68UjaS","id":"86860340175978497","created_at":"2011-07-01T18:14:53.000Z","entities":{"urls":[{"start":82,"end":101,"url":"http://t.co/y68UjaS","expanded_url":"http://bit.ly/llLMWf","display_url":"bit.ly/llLMWf"}],"annotations":[{"start":0,"end":24,"probability":0.6509,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":45,"end":63,"probability":0.6086,"type":"Organization","normalized_text":"European Parliament"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"86860340175978497","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency publishes format for submission of information on medicines: http://t.co/2xULqj2","id":"86842673666859008","created_at":"2011-07-01T17:04:41.000Z","entities":{"urls":[{"start":87,"end":106,"url":"http://t.co/2xULqj2","expanded_url":"http://bit.ly/lDAKyI","display_url":"bit.ly/lDAKyI"}],"annotations":[{"start":0,"end":24,"probability":0.6088,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"86842673666859008","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) sees rapid growth: http://t.co/vhefHH3","id":"86514943494590464","created_at":"2011-06-30T19:22:24.000Z","entities":{"urls":[{"start":103,"end":122,"url":"http://t.co/vhefHH3","expanded_url":"http://bit.ly/jgZvDT","display_url":"bit.ly/jgZvDT"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"86514943494590464","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency's 2010 annual report shows increase in activities: http://t.co/C1tMV4O","id":"86388096903548928","created_at":"2011-06-30T10:58:21.000Z","entities":{"urls":[{"start":77,"end":96,"url":"http://t.co/C1tMV4O","expanded_url":"http://bit.ly/ki6mOx","display_url":"bit.ly/ki6mOx"}],"annotations":[{"start":0,"end":24,"probability":0.6157,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"86388096903548928","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency listens to stakeholder expectations for pharmacovigilance reforms: http://t.co/PpDr09B","id":"84339675376005121","created_at":"2011-06-24T19:18:40.000Z","entities":{"urls":[{"start":93,"end":112,"url":"http://t.co/PpDr09B","expanded_url":"http://bit.ly/kaXhfo","display_url":"bit.ly/kaXhfo"}],"annotations":[{"start":0,"end":24,"probability":0.8391,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"84339675376005121","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from June 2011 CHMP plenary\nhttp://t.co/8ieOeTK","id":"84231671393697793","created_at":"2011-06-24T12:09:30.000Z","entities":{"urls":[{"start":47,"end":66,"url":"http://t.co/8ieOeTK","expanded_url":"http://bit.ly/mHC8Oy","display_url":"bit.ly/mHC8Oy"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"84231671393697793","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends new malaria treatment for approval \nhttp://t.co/CMmFeo4","id":"84231333953548288","created_at":"2011-06-24T12:08:09.000Z","entities":{"urls":[{"start":73,"end":92,"url":"http://t.co/CMmFeo4","expanded_url":"http://bit.ly/kVVPpA","display_url":"bit.ly/kVVPpA"}],"annotations":[{"start":0,"end":24,"probability":0.5423,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"84231333953548288","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends restricting the use of dexrazoxane-containing medicines\nhttp://t.co/BIP1V4y","id":"84216803039002624","created_at":"2011-06-24T11:10:25.000Z","entities":{"urls":[{"start":71,"end":90,"url":"http://t.co/BIP1V4y","expanded_url":"http://bit.ly/kat6x4","display_url":"bit.ly/kat6x4"}],"annotations":[{"start":0,"end":2,"probability":0.5503,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"84216803039002624","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA gives first positive opinion for paediatric-use marketing authorisation\nhttp://t.co/kaAtPY5","id":"84205897441742848","created_at":"2011-06-24T10:27:05.000Z","entities":{"urls":[{"start":76,"end":95,"url":"http://t.co/kaAtPY5","expanded_url":"http://bit.ly/lXeSi2","display_url":"bit.ly/lXeSi2"}],"annotations":[{"start":0,"end":2,"probability":0.4898,"type":"Person","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"84205897441742848","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA concludes review of systemic nimesulide-containing medicines. \nhttp://t.co/nz1loS2","id":"83926370924756992","created_at":"2011-06-23T15:56:20.000Z","entities":{"urls":[{"start":67,"end":86,"url":"http://t.co/nz1loS2","expanded_url":"http://bit.ly/ltqV0z","display_url":"bit.ly/ltqV0z"}],"annotations":[{"start":0,"end":2,"probability":0.4088,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"83926370924756992","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA updates on ongoing benefit-risk review of pioglitazone–containing medicines. Recommendations expected in July. \nhttp://t.co/fokYpse","id":"83920155742179328","created_at":"2011-06-23T15:31:38.000Z","entities":{"urls":[{"start":116,"end":135,"url":"http://t.co/fokYpse","expanded_url":"http://bit.ly/ldq3fm","display_url":"bit.ly/ldq3fm"}],"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"83920155742179328","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and US Food and Drug Administration set up biosimilar 'cluster' and publish first report on interactions: http://t.co/SW3zUGM","id":"83899353613344768","created_at":"2011-06-23T14:08:59.000Z","entities":{"urls":[{"start":110,"end":129,"url":"http://t.co/SW3zUGM","expanded_url":"http://bit.ly/iLdiUR","display_url":"bit.ly/iLdiUR"}],"annotations":[{"start":0,"end":2,"probability":0.5639,"type":"Organization","normalized_text":"EMA"},{"start":8,"end":38,"probability":0.4672,"type":"Organization","normalized_text":"US Food and Drug Administration"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":2,"quote_count":0},"conversation_id":"83899353613344768","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA holds first meeting of expert group on the replacement, reduction and refinement of the use of animals: http://t.co/2ye2Nb2","id":"83604797684592640","created_at":"2011-06-22T18:38:31.000Z","entities":{"urls":[{"start":108,"end":127,"url":"http://t.co/2ye2Nb2","expanded_url":"http://bit.ly/meLoev","display_url":"bit.ly/meLoev"}],"annotations":[{"start":0,"end":2,"probability":0.4482,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"83604797684592640","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency and US Food and Drug Administration receive first parallel quality-by-design application: http://t.co/SShsLAX","id":"81755979406000128","created_at":"2011-06-17T16:11:59.000Z","entities":{"urls":[{"start":116,"end":135,"url":"http://t.co/SShsLAX","expanded_url":"http://bit.ly/ij6TAB","display_url":"bit.ly/ij6TAB"}],"annotations":[{"start":0,"end":24,"probability":0.5797,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"81755979406000128","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 7-9 June 2011: http://bit.ly/lqnMrL","id":"79228357144883200","created_at":"2011-06-10T16:48:06.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"79228357144883200","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency Management Board elects Kent Woods as new chair\nhttp://bit.ly/kBE4jO","id":"79145380922654720","created_at":"2011-06-10T11:18:23.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":41,"probability":0.3743,"type":"Organization","normalized_text":"European Medicines Agency Management Board"},{"start":50,"end":59,"probability":0.6641,"type":"Person","normalized_text":"Kent Woods"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"79145380922654720","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Suspension of use of pioglitazone–containing medicines in France while Europe-wide review continues \nhttp://bit.ly/is0rSN","id":"78865929257222145","created_at":"2011-06-09T16:47:57.000Z","entities":{"urls":{},"annotations":[{"start":58,"end":63,"probability":0.9874,"type":"Place","normalized_text":"France"},{"start":71,"end":76,"probability":0.8914,"type":"Place","normalized_text":"Europe"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":8,"reply_count":0,"like_count":3,"quote_count":0},"conversation_id":"78865929257222145","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency’s Management Board nominates Guido Rasi as new Executive Director  http://bit.ly/kHEHuN","id":"78502320303898624","created_at":"2011-06-08T16:43:06.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.538,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":55,"end":64,"probability":0.9858,"type":"Person","normalized_text":"Guido Rasi"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"78502320303898624","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency establishes Geriatric Expert Group\nhttp://bit.ly/jP6dGz","id":"78096535547674624","created_at":"2011-06-07T13:50:39.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"78096535547674624","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency responds to criticism over clinical trial reporting: http://bit.ly/kr9lAt","id":"77739586423504898","created_at":"2011-06-06T14:12:16.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8341,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"77739586423504898","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"ENCePP publishes the ‘guide on methodological standards in pharmacoepidemiology’: http://bit.ly/kPW31l","id":"75982244241608704","created_at":"2011-06-01T17:49:13.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":5,"probability":0.3414,"type":"Organization","normalized_text":"ENCePP"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":1},"conversation_id":"75982244241608704","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and Heads of Medicines Agencies propose measures to make information in application dossiers more transparent  http://bit.ly/m9MctT","id":"75929468862087168","created_at":"2011-06-01T14:19:30.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4809,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"75929468862087168","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency marks 40th anniversary of PIC/S: http://bit.ly/kI3nqh","id":"75583594566926336","created_at":"2011-05-31T15:25:07.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.3875,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"75583594566926336","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Study provides recommendations on European Medicines Agency's communication on medicines: http://bit.ly/jWo4jZ","id":"75529282075635712","created_at":"2011-05-31T11:49:18.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"75529282075635712","source":"Twitter Web Client","lang":"fr","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency website updated with new pages http://bit.ly/iTZFst","id":"75153124708466688","created_at":"2011-05-30T10:54:35.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5128,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"75153124708466688","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Report and videos available from Enpr-EMA launch: http://bit.ly/kAQn87","id":"74094243718766592","created_at":"2011-05-27T12:46:58.000Z","entities":{"urls":{},"annotations":[{"start":33,"end":40,"probability":0.6138,"type":"Organization","normalized_text":"Enpr-EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"74094243718766592","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends revaccination for some travellers in need of protection with Ixiaro  http://bit.ly/ksissX","id":"74022322843037696","created_at":"2011-05-27T08:01:11.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.557,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"74022322843037696","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency responds to criticism over transparency in British Medical Journal: http://bit.ly/kkkuRa","id":"72688600046772224","created_at":"2011-05-23T15:41:27.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8259,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":69,"end":91,"probability":0.6637,"type":"Organization","normalized_text":"British Medical Journal"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"72688600046772224","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends suspension of oral buflomedil-containing medicines: http://bit.ly/lxupQe","id":"71539148196032512","created_at":"2011-05-20T11:33:56.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.4387,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"71539148196032512","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency concludes on use of celecoxib in familial adenomatous polyposis: http://bit.ly/mRTMnd","id":"71538999893823488","created_at":"2011-05-20T11:33:21.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5742,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"71538999893823488","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2011: http://bit.ly/jFEtTQ","id":"71538878720389120","created_at":"2011-05-20T11:32:52.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"71538878720389120","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency discusses pharmacovigilance with French General Inspectorate of Social Affairs: http://bit.ly/lGBQKf","id":"71248076748234752","created_at":"2011-05-19T16:17:19.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"71248076748234752","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Report published from workshop on ethics and GCP in clinical trials outside the European Union: http://bit.ly/iuRYCy","id":"70784990807470080","created_at":"2011-05-18T09:37:11.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"70784990807470080","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 3-5 May 2011: http://bit.ly/j6w2GF","id":"66505411645292544","created_at":"2011-05-06T14:11:40.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"66505411645292544","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency closed 9 May 2011: http://bit.ly/kWkGzh","id":"66430657273937920","created_at":"2011-05-06T09:14:37.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5489,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"66430657273937920","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Monitoring of products originating from Japan for the possibility of radioactivity: http://bit.ly/kfMzjw","id":"65356524284936192","created_at":"2011-05-03T10:06:24.000Z","entities":{"urls":{},"annotations":[{"start":40,"end":44,"probability":0.9293,"type":"Place","normalized_text":"Japan"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"65356524284936192","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency addresses development of new antibacterials:      http://bit.ly/e7prtS","id":"63167659017109504","created_at":"2011-04-27T09:08:38.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.7446,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"63167659017109504","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"NicOx S.A. withdraws its marketing authorisation application for Beprana (naproxcinod)\n http://bit.ly/dSCSXS","id":"60659328776019969","created_at":"2011-04-20T11:01:25.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":9,"probability":0.5884,"type":"Organization","normalized_text":"NicOx S.A."}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"60659328776019969","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency holds first stakeholder forum on the implementation of the new pharmacovigilance legislation: http://bit.ly/fRtAlE","id":"60358154302660608","created_at":"2011-04-19T15:04:40.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8805,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"60358154302660608","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Novartis withdraws its marketing authorisation application for Joicela (lumiracoxib) \n http://bit.ly/fjMZRW","id":"60267464696659968","created_at":"2011-04-19T09:04:17.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":7,"probability":0.79,"type":"Organization","normalized_text":"Novartis"},{"start":63,"end":69,"probability":0.317,"type":"Organization","normalized_text":"Joicela"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"60267464696659968","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 April 2011: http://bit.ly/glPkpE","id":"58841683462340608","created_at":"2011-04-15T10:38:45.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"58841683462340608","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency concludes class review of bisphosphonates and atypical fractures: http://bit.ly/gI0hC8","id":"58841564360884224","created_at":"2011-04-15T10:38:16.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.4951,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"58841564360884224","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends interim measures for Pandemrix: http://bit.ly/i9uqHP","id":"58841241957306368","created_at":"2011-04-15T10:36:59.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.6495,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"58841241957306368","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends lifting of suspension of Octagam: \nhttp://bit.ly/igni8R","id":"58546103754305536","created_at":"2011-04-14T15:04:13.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.6232,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"58546103754305536","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency issues reminder on PIP deferral obligations: http://bit.ly/g1O2KO","id":"58203609518706688","created_at":"2011-04-13T16:23:16.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.566,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"58203609518706688","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches consultation on its position on replacement of animal studies: http://bit.ly/dXS4jb","id":"57823290240143360","created_at":"2011-04-12T15:12:01.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8047,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"57823290240143360","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 5-7 April 2011: http://bit.ly/dF0Blf","id":"56373343795941377","created_at":"2011-04-08T15:10:27.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"56373343795941377","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Registration open for EMA/EFPIA Info Day 23 May 2011: http://bit.ly/gVyHvC","id":"55980831000363008","created_at":"2011-04-07T13:10:44.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"55980831000363008","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Reliance GeneMedix Plc. withdraws its marketing authorisation application for Epostim (erythropoietin): http://bit.ly/emII6R","id":"55555490171715584","created_at":"2011-04-06T09:00:35.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":21,"probability":0.3794,"type":"Organization","normalized_text":"Reliance GeneMedix Plc"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"55555490171715584","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Recommendations on labelling and packaging for non-prescription medicines released for consultation: http://bit.ly/eff9e5","id":"53751567496654848","created_at":"2011-04-01T09:32:27.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"53751567496654848","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Increased fees coming into effect on 1 April 2011: http://bit.ly/gigGfN","id":"52763208259354624","created_at":"2011-03-29T16:05:03.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"52763208259354624","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency closes PIM project : http://bit.ly/h73yby","id":"52372573530501120","created_at":"2011-03-28T14:12:49.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5686,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"52372573530501120","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Second phase of public SME register goes live: http://bit.ly/gNvaVz","id":"51206860279250944","created_at":"2011-03-25T09:00:41.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"51206860279250944","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches survey to gather feedback on SME programme: http://bit.ly/fgCktU","id":"50980839445630976","created_at":"2011-03-24T18:02:33.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.789,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"50980839445630976","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EU Clinical Trials Register goes live: http://bit.ly/guwUbr","id":"50134535005929472","created_at":"2011-03-22T09:59:39.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":5,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"50134535005929472","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Activities of former EMA Executive Director Thomas Lönngren: http://bit.ly/fWdkR8","id":"49803068937736192","created_at":"2011-03-21T12:02:31.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"49803068937736192","source":"Twitter Web Client","lang":"ca","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency announces start of process improvement of core business procedures: http://bit.ly/dHQXHW","id":"48745148011659264","created_at":"2011-03-18T13:58:43.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8784,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"48745148011659264","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 March 2011: http://bit.ly/eNydVP","id":"48714767560482817","created_at":"2011-03-18T11:58:00.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"48714767560482817","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Recommendations issued for 2011/2012 seasonal flu vaccine composition: http://bit.ly/eNhoGA","id":"48422005237751808","created_at":"2011-03-17T16:34:40.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"48422005237751808","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Registration open for PDA/EMA 2011 Conference: 3-5 May 2011: http://bit.ly/hdQ3x6","id":"48364950149799936","created_at":"2011-03-17T12:47:57.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"48364950149799936","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and U.S. FDA announce pilot program for parallel assessment of Quality by Design applications: http://bit.ly/epCWRn","id":"48023014603890688","created_at":"2011-03-16T14:09:13.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5513,"type":"Organization","normalized_text":"EMA"},{"start":8,"end":11,"probability":0.461,"type":"Place","normalized_text":"U.S."},{"start":13,"end":15,"probability":0.5552,"type":"Organization","normalized_text":"FDA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"48023014603890688","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 March 2011: http://bit.ly/dLzGaB","id":"46254324074029056","created_at":"2011-03-11T17:01:04.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"46254324074029056","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Network of Paediatric Research at the European Medicines Agency introduced to wider audience: http://bit.ly/fwLT9j","id":"46248986650226688","created_at":"2011-03-11T16:39:52.000Z","entities":{"urls":{},"annotations":[{"start":47,"end":71,"probability":0.7523,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"46248986650226688","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency hosts training course for GCP inspectors from countries across the world: http://bit.ly/eCZayD","id":"43709686838607872","created_at":"2011-03-04T16:29:36.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5862,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"43709686838607872","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Public statement on Thelin: Withdrawal of the marketing authorisation in the European Union http://bit.ly/dZA7FZ","id":"43248128257826816","created_at":"2011-03-03T09:55:31.000Z","entities":{"urls":{},"annotations":[{"start":20,"end":25,"probability":0.4181,"type":"Place","normalized_text":"Thelin"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"43248128257826816","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency releases updated guidance on insomnia treatments: http://bit.ly/fE3yNG","id":"41162049119715328","created_at":"2011-02-25T15:46:11.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.7632,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"41162049119715328","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Rare Disease Day: 28 February 2011: Phttp://bit.ly/g0yAly","id":"41105567737061376","created_at":"2011-02-25T12:01:45.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"41105567737061376","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Concept paper on medicines to prevent HIV infection released for public consultation: http://bit.ly/g9LZHq","id":"40803679665795072","created_at":"2011-02-24T16:02:09.000Z","entities":{"urls":{},"annotations":[{"start":38,"end":40,"probability":0.7683,"type":"Other","normalized_text":"HIV"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"40803679665795072","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Adjusted fees for applications to European Medicines Agency on 1 April 2011: http://bit.ly/ff1rap","id":"40747870890106880","created_at":"2011-02-24T12:20:24.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"40747870890106880","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches strategy on medicines for older people: http://bit.ly/hSYqEG","id":"40357648230645760","created_at":"2011-02-23T10:29:47.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8224,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"40357648230645760","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Registration open for EMA/IFAH-Europe Info Day: 10-11 March 2011: http://bit.ly/e3sCjA","id":"38652391695978496","created_at":"2011-02-18T17:33:42.000Z","entities":{"urls":{},"annotations":[{"start":31,"end":45,"probability":0.4339,"type":"Other","normalized_text":"Europe Info Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38652391695978496","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"@regaffairs: The technical problem has been resolved and the link is working now: http://bit.ly/gxWOyh","id":"38592815101378560","created_at":"2011-02-18T13:36:58.000Z","entities":{"urls":{},"annotations":{},"mentions":[{"start":0,"end":11,"username":"regaffairs","id":"118116598"}],"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38560502737014784","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":[{"type":"replied_to","id":"38560502737014784"}],"in_reply_to_user_id":"118116598"},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 February 2011: http://bit.ly/eSm8nl","id":"38578620758753280","created_at":"2011-02-18T12:40:34.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38578620758753280","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA reviews further data on narcolepsy and possible association with Pandemrix (PDF version): http://bit.ly/hDaB3u","id":"38577036532527104","created_at":"2011-02-18T12:34:16.000Z","entities":{"urls":{},"annotations":[{"start":69,"end":77,"probability":0.2614,"type":"Organization","normalized_text":"Pandemrix"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38577036532527104","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"There seems to be a technical glitch with the EMA web server, we are working to remedy this as quickly as we can.","id":"38561613267222528","created_at":"2011-02-18T11:32:59.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38561613267222528","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix: http://bit.ly/gxWOyh","id":"38555028419514368","created_at":"2011-02-18T11:06:49.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5255,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38555028419514368","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Sun Pharmaceutical Industries Europe B.V. withdraws its marketing authorisation application for Topotecan SUN: http://bit.ly/g52kQt","id":"38267283738464256","created_at":"2011-02-17T16:03:26.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":40,"probability":0.348,"type":"Organization","normalized_text":"Sun Pharmaceutical Industries Europe B.V."}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38267283738464256","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro (cladribine): http://bit.ly/fvtzr1","id":"38208560441593856","created_at":"2011-02-17T12:10:05.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":26,"probability":0.2517,"type":"Organization","normalized_text":"Merck Serono Europe Limited"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38208560441593856","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"First clinical biomarker qualification released for public consultation: http://bit.ly/h2SGRV","id":"38193872668463104","created_at":"2011-02-17T11:11:43.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"38193872668463104","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency website updated with new searching and sharing features: http://bit.ly/eIyPRY","id":"37826178584682496","created_at":"2011-02-16T10:50:38.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5351,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"37826178584682496","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency and Swissmedic extend confidentiality arrangement: http://bit.ly/hU8Rni","id":"37174425321209857","created_at":"2011-02-14T15:40:48.000Z","entities":{"urls":{},"annotations":[{"start":30,"end":39,"probability":0.3245,"type":"Organization","normalized_text":"Swissmedic"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"37174425321209857","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency launches web survey to gather feedback on online user experience : http://bit.ly/i49b11","id":"37092249955209216","created_at":"2011-02-14T10:14:16.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.7766,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"37092249955209216","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"CVMP February 2011 meeting highlights: http://bit.ly/hjtbsr","id":"36103785801584640","created_at":"2011-02-11T16:46:27.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"36103785801584640","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Agency sets out work priorities for 2011: http://bit.ly/f7LxZ1","id":"36005915681366016","created_at":"2011-02-11T10:17:33.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"36005915681366016","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency hosts global animal health conference on availability of veterinary medicines: http://bit.ly/gvvNgO","id":"34975990404882433","created_at":"2011-02-08T14:05:00.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.607,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"34975990404882433","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"New version of EudraGMP allows access to information from all Member States: http://bit.ly/eBrw62","id":"34573997899259904","created_at":"2011-02-07T11:27:38.000Z","entities":{"urls":{},"annotations":[{"start":15,"end":22,"probability":0.4985,"type":"Organization","normalized_text":"EudraGMP"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"34573997899259904","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Expressions of interest invited for the transatlantic workshop on drug-related PML, London 25-26 July 2011: http://bit.ly/hHxY25","id":"33536759719534592","created_at":"2011-02-04T14:46:01.000Z","entities":{"urls":{},"annotations":[{"start":79,"end":81,"probability":0.5003,"type":"Organization","normalized_text":"PML"},{"start":84,"end":89,"probability":0.7533,"type":"Place","normalized_text":"London"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"33536759719534592","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Agency releases new guidance on medicines based on stem cells: http://bit.ly/fpT0xx","id":"33527978205908993","created_at":"2011-02-04T14:11:07.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"33527978205908993","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA is supporting World Cancer Day: http://bit.ly/gb09oD","id":"33212547255504899","created_at":"2011-02-03T17:17:42.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.3678,"type":"Person","normalized_text":"EMA"},{"start":18,"end":33,"probability":0.8587,"type":"Other","normalized_text":"World Cancer Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"33212547255504899","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) adopts work plan for 2011-2012: http://bit.ly/fq95RF","id":"32817860426334208","created_at":"2011-02-02T15:09:22.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"32817860426334208","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Pre-accession linguistic check for Croatian underway: http://bit.ly/frWJab","id":"32072329416671232","created_at":"2011-01-31T13:46:53.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"32072329416671232","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency publishes final ‘Road map to 2015’: http://bit.ly/fKfb2k","id":"30203905186988033","created_at":"2011-01-26T10:02:26.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5957,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"30203905186988033","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Benefit-risk review of Multaq started: http://bit.ly/dWDwo8","id":"28461502860099584","created_at":"2011-01-21T14:38:45.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":4,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"28461502860099584","source":"Twitter Web Client","lang":"da","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 January 2011: http://bit.ly/h96ENK","id":"28415162780229632","created_at":"2011-01-21T11:34:37.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":3,"quote_count":0},"conversation_id":"28415162780229632","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Review of manufacture of Baxter’s peritoneal dialysis solutions initiated: http://bit.ly/dO7QEV","id":"28410380027957248","created_at":"2011-01-21T11:15:37.000Z","entities":{"urls":{},"annotations":[{"start":25,"end":30,"probability":0.4592,"type":"Person","normalized_text":"Baxter"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"28410380027957248","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Report published on the uses of medicines for children in the European Union: http://bit.ly/eni3KM","id":"28127756910862336","created_at":"2011-01-20T16:32:34.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"28127756910862336","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Launch of public consultation to start discussion on clinical studies of herbal medicines in children: http://bit.ly/i2vdhl","id":"27401592508522496","created_at":"2011-01-18T16:27:03.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"27401592508522496","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Abbott Laboratories Limited withdraws its marketing authorisation application for Ozespa (briakinumab): http://bit.ly/fcHPUM","id":"26968091590131712","created_at":"2011-01-17T11:44:28.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":26,"probability":0.5447,"type":"Organization","normalized_text":"Abbott Laboratories Limited"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"26968091590131712","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 11-13 January 2011: http://bit.ly/eJO0VJ","id":"25943538550181888","created_at":"2011-01-14T15:53:16.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25943538550181888","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"ChemGenex Europe SAS withdraws its marketing authorisation application for Tekinex (omacetaxine mepesuccinate): http://bit.ly/fN3xAc","id":"25241482457780224","created_at":"2011-01-12T17:23:33.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":19,"probability":0.3801,"type":"Organization","normalized_text":"ChemGenex Europe SAS"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25241482457780224","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency opens public discussion on need for active control in clinical trials: http://bit.ly/dVeBTG","id":"24871717100855296","created_at":"2011-01-11T16:54:14.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.7803,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"24871717100855296","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use publishes new draft strategy on combating antimicrobial resistance:http://bit.ly/f1UTHo","id":"24418577696161792","created_at":"2011-01-10T10:53:37.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"24418577696161792","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"New membership list published for the European Network of Paediatric Research at the EMA (Enpr-EMA) : http://bit.ly/hQzX3r","id":"23037446295916544","created_at":"2011-01-06T15:25:29.000Z","entities":{"urls":{},"annotations":[{"start":38,"end":76,"probability":0.4199,"type":"Other","normalized_text":"European Network of Paediatric Research"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"23037446295916544","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and European Centre for Disease Prevention and Control agree to enhance co-operation: http://bit.ly/eO5AEj","id":"17604660974059521","created_at":"2010-12-22T15:37:32.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4079,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"17604660974059521","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency’s Management Board endorses work programme 2011 and launches new Road Map to 2015: http://bit.ly/f1v1nc","id":"17242379513765888","created_at":"2010-12-21T15:37:58.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.6035,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"17242379513765888","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency facilitates interaction between small and medium-sized enterprises: http://bit.ly/hou8C4","id":"16807697278050304","created_at":"2010-12-20T10:50:41.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5138,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"16807697278050304","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2010: http://bit.ly/hv8D82","id":"15724582384181248","created_at":"2010-12-17T11:06:47.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15724582384181248","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends action plan to deal with possible presence of endotoxins in Baxter peritoneal dialysis solutions: http://bit.ly/fhrJcb","id":"15724401056030721","created_at":"2010-12-17T11:06:04.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.6141,"type":"Organization","normalized_text":"EMA"},{"start":75,"end":80,"probability":0.799,"type":"Place","normalized_text":"Baxter"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15724401056030721","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Update on somatropin-containing medicines: http://bit.ly/ewmoaL","id":"15438603903565826","created_at":"2010-12-16T16:10:24.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15438603903565826","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Update on the withdrawal of Thelin: http://bit.ly/eFCbdh","id":"15437796462305280","created_at":"2010-12-16T16:07:12.000Z","entities":{"urls":{},"annotations":[{"start":28,"end":33,"probability":0.4468,"type":"Place","normalized_text":"Thelin"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15437796462305280","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency completes its review of Avastin used in breast cancer: http://bit.ly/hJ8ckf","id":"15437577267970048","created_at":"2010-12-16T16:06:19.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5856,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15437577267970048","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Novartis Europharm Ltd. withdraws its application for an extension of indication for Zometa (zoledronic acid): http://bit.ly/ihIquI","id":"15010277267349504","created_at":"2010-12-15T11:48:23.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":22,"probability":0.8092,"type":"Organization","normalized_text":"Novartis Europharm Ltd."}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15010277267349504","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 7-9 December 2010: http://bit.ly/dQ1CQB","id":"13286114815119360","created_at":"2010-12-10T17:37:11.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13286114815119360","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury: http://bit.ly/fQdtRy","id":"13225342835630080","created_at":"2010-12-10T13:35:42.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":5,"probability":0.4919,"type":"Person","normalized_text":"Thelin"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13225342835630080","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency to review the safety of somatropin-containing medicines: http://bit.ly/fCHaNE","id":"13203853952421888","created_at":"2010-12-10T12:10:18.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5243,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13203853952421888","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Sanofi Pasteur withdraws its marketing authorisation application for Emerflu, pandemic influenza vaccine (H5N1) : http://bit.ly/fNUvEf","id":"11731464567660545","created_at":"2010-12-06T10:39:33.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"11731464567660545","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"The EMA supports World AIDS Day 1 December 2010: http://bit.ly/htPg1i","id":"9657686735978496","created_at":"2010-11-30T17:19:06.000Z","entities":{"urls":{},"annotations":[{"start":4,"end":30,"probability":0.308,"type":"Other","normalized_text":"EMA supports World AIDS Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"9657686735978496","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency widens public access to documents: http://bit.ly/eJVQv5","id":"9592234320076801","created_at":"2010-11-30T12:59:01.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.698,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"9592234320076801","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA has published a new 'special topic' page dedicated to biosimilars: http://bit.ly/dYk8Az","id":"8125336336211968","created_at":"2010-11-26T11:50:05.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.3466,"type":"Person","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"8125336336211968","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Guideline on biosimilar medicines containing monoclonal antibodies released for consultation: http://bit.ly/e2L8JU","id":"8123943588204544","created_at":"2010-11-26T11:44:33.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"8123943588204544","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and European Network of Centres for Pharmacoepidemiology and Pharmacovigilance launch E-Register of Studies: http://bit.ly/ga8YmB","id":"7801924598370304","created_at":"2010-11-25T14:24:58.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4299,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"7801924598370304","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee on Herbal Medicinal Products elects new chair and vice-chair: http://bit.ly/hVzHoH","id":"7451672930418689","created_at":"2010-11-24T15:13:11.000Z","entities":{"urls":{},"annotations":[{"start":13,"end":37,"probability":0.517,"type":"Organization","normalized_text":"Herbal Medicinal Products"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"7451672930418689","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 15-18 November 2010: http://bit.ly/cMuZtH","id":"5570806541189120","created_at":"2010-11-19T10:39:18.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"5570806541189120","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA confirms that presence of unexpected viral DNA in live attenuated vaccines does not raise public health concerns: http://bit.ly/981fTY","id":"5290964348313601","created_at":"2010-11-18T16:07:18.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.2997,"type":"Person","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"5290964348313601","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Advanced Therapies adopts five-year work programme to foster development of advanced therapies: http://bit.ly/alUFmC","id":"5214457005350912","created_at":"2010-11-18T11:03:18.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"5214457005350912","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"The EMA supports the European Antibiotic Awareness Day 18 November 2010: http://bit.ly/cstjE7","id":"4953115287625728","created_at":"2010-11-17T17:44:49.000Z","entities":{"urls":{},"annotations":[{"start":4,"end":6,"probability":0.3227,"type":"Organization","normalized_text":"EMA"},{"start":21,"end":53,"probability":0.6668,"type":"Other","normalized_text":"European Antibiotic Awareness Day"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"4953115287625728","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and Massachusetts Institute of Technology launch joint project on regulatory science: http://bit.ly/9jXszP","id":"2712127907303425","created_at":"2010-11-11T13:19:56.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5656,"type":"Organization","normalized_text":"EMA"},{"start":8,"end":44,"probability":0.8357,"type":"Organization","normalized_text":"Massachusetts Institute of Technology"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"conversation_id":"2712127907303425","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Schering-Plough Europe withdraws its marketing authorisation application for Zenhale: http://bit.ly/celNQS","id":"2047593462894592","created_at":"2010-11-09T17:19:18.000Z","entities":{"urls":{},"annotations":[{"start":9,"end":21,"probability":0.2589,"type":"Organization","normalized_text":"Plough Europe"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"2047593462894592","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends use of fibrates as second-line treatment: http://bit.ly/aH2gJa","id":"28391166916","created_at":"2010-10-22T10:24:41.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5855,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"28391166916","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency reviews treatment recommendations for Fabrazyme: http://bit.ly/cYqNbY","id":"28391130104","created_at":"2010-10-22T10:24:02.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.4901,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"28391130104","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"CHMP October 2010 meeting highlights: http://bit.ly/clPXtY","id":"28391074917","created_at":"2010-10-22T10:23:02.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"28391074917","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency concludes that benefit-risk balance of Invirase remains positive: http://bit.ly/dx1VFW","id":"28037036642","created_at":"2010-10-21T15:31:53.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.6768,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"28037036642","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency strengthens rules on conflicts of interests of its scientific experts: http://bit.ly/awK6jd","id":"27348226139","created_at":"2010-10-14T14:55:49.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5306,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"27348226139","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA Management Board adopt new policies on handling of conflicts of interests and on access to documents: http://bit.ly/ahvC6X","id":"26733516100","created_at":"2010-10-08T09:45:01.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":19,"probability":0.818,"type":"Organization","normalized_text":"EMA Management Board"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"26733516100","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency awards first ‘ENCePP study’ seal for post-marketing study: http://bit.ly/byZB7X","id":"26064214171","created_at":"2010-10-01T09:27:49.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"26064214171","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Warner Chilcott UK Ltd withdraws its application for an extension of indication for Intrinsa: http://bit.ly/chDWiC","id":"25882438024","created_at":"2010-09-29T13:27:03.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":21,"probability":0.3941,"type":"Organization","normalized_text":"Warner Chilcott UK Ltd"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25882438024","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 20-23 September 2010: http://bit.ly/bQvy5A","id":"25398048321","created_at":"2010-09-24T12:13:10.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25398048321","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends suspension of Octagam in all EU Member States: http://bit.ly/b5WskX","id":"25397999584","created_at":"2010-09-24T12:12:26.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5379,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25397999584","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim: http://bit.ly/cwOIxG","id":"25348470605","created_at":"2010-09-23T22:34:57.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25348470605","source":"Twitter Web Client","lang":"fr","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency confirms positive benefit-risk balance of RotaTeq: http://bit.ly/cAHmOB","id":"25348406718","created_at":"2010-09-23T22:34:06.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8081,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25348406718","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy: http://bit.ly/bL4fVj","id":"25348307798","created_at":"2010-09-23T22:32:43.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5704,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"25348307798","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Novartis Europharm Ltd withdraws its marketing authorisation application for Rasival (aliskiren/valsartan): http://bit.ly/aZN1Ur","id":"24759844028","created_at":"2010-09-17T13:56:25.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":21,"probability":0.7356,"type":"Organization","normalized_text":"Novartis Europharm Ltd"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"24759844028","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency and U.S. Food and Drug Administration extend confidentiality arrangements indefinitely: http://bit.ly/aAd4gq","id":"24575484978","created_at":"2010-09-15T14:40:06.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5825,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":30,"end":33,"probability":0.6173,"type":"Place","normalized_text":"U.S."}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"24575484978","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA holds international workshop on clinical trials in the context of global medicines development: http://bit.ly/byTny9","id":"24019272335","created_at":"2010-09-09T15:27:05.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5951,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"24019272335","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency holds first scientific workshop on nanomedicines: http://bit.ly/b3GuMc","id":"23158713695","created_at":"2010-09-06T16:25:17.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.7936,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"23158713695","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"CHMP meeting on 8 September 2010 to discuss Avandia and Pandemrix: http://bit.ly/aJQuI3","id":"22872855309","created_at":"2010-09-03T09:11:20.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"22872855309","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)\n19-22 July 2010: http://bit.ly/aJi2KS","id":"19331540694","created_at":"2010-07-23T11:25:16.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"19331540694","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency recommends restricting the use of modafinil: http://bit.ly/bNx1Mu","id":"19262051245","created_at":"2010-07-22T15:15:26.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.6328,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"19262051245","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency confirms positive benefit-risk balance of topical formulations of ketoprofen: http://bit.ly/bfvGYl","id":"19261955693","created_at":"2010-07-22T15:14:07.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8083,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"19261955693","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency confirms positive benefit-risk balance of Rotarix: http://bit.ly/afdBMl","id":"19261826175","created_at":"2010-07-22T15:12:18.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.8081,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"19261826175","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim: http://bit.ly/bSNX6v","id":"19261727089","created_at":"2010-07-22T15:10:57.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5265,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":67,"end":73,"probability":0.3627,"type":"Place","normalized_text":"Avandia"},{"start":76,"end":84,"probability":0.3656,"type":"Place","normalized_text":"Avandamet"},{"start":90,"end":96,"probability":0.4685,"type":"Place","normalized_text":"Avaglim"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"19261727089","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA launches a new web site: \nhttp://www.ema.europa.eu","id":"18690762326","created_at":"2010-07-16T14:41:39.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5409,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"18690762326","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency starts review of rosiglitazone-containing medicines: http://bit.ly/cFu1Fd","id":"18104538703","created_at":"2010-07-09T09:06:34.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.5315,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"18104538703","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and European Commission start reflection process on way forward for the Agency and the network\nhttp://bit.ly/cSIaz1","id":"18024978881","created_at":"2010-07-08T10:28:11.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.536,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"18024978881","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency updates Fabrazyme treatment recommendations:\nhttp://bit.ly/cVGOBv","id":"17867879453","created_at":"2010-07-06T13:40:30.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"17867879453","source":"bitly bitlink","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the EMA CHMP Meeting June 21 - 24: http://www.ema.europa.eu/pdfs/human/press/pr/27209310en.pdf","id":"17580251345","created_at":"2010-07-02T15:20:07.000Z","entities":{"urls":{},"annotations":[{"start":28,"end":43,"probability":0.6493,"type":"Other","normalized_text":"EMA CHMP Meeting"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"17580251345","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA and European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP) launch ‘ENCePP studies’  http://bit.ly/duGwKG","id":"15926998893","created_at":"2010-06-11T13:15:00.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15926998893","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Check this video out -- Workshop on stem-cell based therapies http://youtu.be/SvwlXjyPaYo","id":"15707863586","created_at":"2010-06-08T13:56:41.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"15707863586","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Public consultation on ethical and good clinical practice (GCP) aspects of clinical trials conducted in third countries http://bit.ly/dbbN2J","id":"14915387582","created_at":"2010-05-28T15:58:32.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14915387582","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Wyeth Europa Limited withdraws its marketing authorisation application for Brilence  http://bit.ly/92KksK","id":"14912671940","created_at":"2010-05-28T15:16:11.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":19,"probability":0.6332,"type":"Organization","normalized_text":"Wyeth Europa Limited"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14912671940","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Committee for Advanced Therapies gives first certification opinion for advanced therapies medicinal product - http://bit.ly/czwDmq","id":"14768442065","created_at":"2010-05-26T14:57:35.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14768442065","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EudraVigilance signal detection methods help detect drug safety issues earlier - http://bit.ly/apcVFN","id":"14699588281","created_at":"2010-05-25T15:22:28.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14699588281","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Veterinary Use\n(CVMP) - May 2010  http://bit.ly/cArXtU","id":"14699541405","created_at":"2010-05-25T15:21:42.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14699541405","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the Committee for Medicinal Products for Human Use - May 2010 meeting  http://bit.ly/9wVuyn","id":"14420788654","created_at":"2010-05-21T11:01:59.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14420788654","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Ten years of orphan medicines legislation in Europe – European Medicines Agency reviews success and looks ahead   http://bit.ly/bw4SZu","id":"14366917994","created_at":"2010-05-20T15:06:45.000Z","entities":{"urls":{},"annotations":[{"start":45,"end":50,"probability":0.9868,"type":"Place","normalized_text":"Europe"},{"start":54,"end":78,"probability":0.5925,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14366917994","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency publishes its 2009 annual report. http://bit.ly/c5vkEY","id":"14302633244","created_at":"2010-05-19T16:08:42.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.6763,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"14302633244","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European paediatric research network ready to start   http://bit.ly/dcZegX","id":"13857679476","created_at":"2010-05-12T15:44:32.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13857679476","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European and international experts discuss the way forward in stem-cell research and development   http://bit.ly/b8LH2f","id":"13842956961","created_at":"2010-05-12T10:14:16.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13842956961","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA notes European Ombudsman’s recommendation to increase transparency  http://www.ema.europa.eu/","id":"13730686203","created_at":"2010-05-10T14:53:18.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4637,"type":"Organization","normalized_text":"EMA"},{"start":10,"end":27,"probability":0.432,"type":"Organization","normalized_text":"European Ombudsman"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13730686203","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Seventeenth pandemic pharmacovigilance update  http://bit.ly/daJkg5","id":"13491726250","created_at":"2010-05-06T14:58:03.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13491726250","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"New Head of Sector appointments at the Agency.  http://www.ema.europa.eu/","id":"13491527299","created_at":"2010-05-06T14:53:52.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"13491527299","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"First report on the Agency's Benefit-Risk Methodology Project published   http://bit.ly/bhwfmA","id":"12934125354","created_at":"2010-04-27T08:25:04.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"12934125354","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the April 2010 CHMP plenary   http://bit.ly/9OMhpI","id":"12812979980","created_at":"2010-04-25T09:10:11.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"12812979980","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"European Medicines Agency gives new temporary treatment recommendations for Fabrazyme   http://bit.ly/bXT6C3","id":"12812949865","created_at":"2010-04-25T09:09:08.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":24,"probability":0.78,"type":"Organization","normalized_text":"European Medicines Agency"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"12812949865","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"EMA recommends revocation of marketing authorisations for bufexamac http://bit.ly/aNmX6K. See also Q&A document http://bit.ly/cdhqvy","id":"12647028543","created_at":"2010-04-22T16:03:57.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5167,"type":"Organization","normalized_text":"EMA"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"12647028543","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Novartis Europharm Ltd withdraws its marketing authorisation application for Joulferon (albinterferon alfa-2b)  http://bit.ly/aRJWa3","id":"12524992535","created_at":"2010-04-20T16:24:34.000Z","entities":{"urls":{},"annotations":[{"start":0,"end":21,"probability":0.7599,"type":"Organization","normalized_text":"Novartis Europharm Ltd"}],"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"12524992535","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}},{"text":"Meeting highlights from the April 2010 CVMP plenary  http://bit.ly/cHeqVH","id":"12292334260","created_at":"2010-04-16T16:34:47.000Z","entities":{"urls":{},"annotations":{},"mentions":{},"hashtags":{}},"public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"conversation_id":"12292334260","source":"Twitter Web Client","lang":"en","possibly_sensitive":false,"author_id":"116716199","referenced_tweets":{}}]
